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Keratoconjunctivitis  sicca: Also  known  as  dry  eye  syndrome  and  is  a multifactorial  disease that affects the tear film production and/or stability.  
 



























1.1 Introduction  Human  serum  albumin  is  an  important  plasma  protein.  It  is  present  in  higher  concentrations than any other plasma protein and performs a vast array of different functions. Albumin has also been  identified  in  tears,  as  a  product  of  plasma  leakage  through  the  blood‐tear  barrier  that separates the blood vessels from the ocular environment. Increased levels of albumin in the tear film  have  been  reported  in  ocular  disease  or  insult  (Sen  and  Sarin,  1986a;  Gupta  et  al,  1988; Versura et al, 2010) and during problematic contact  lens wear (Lundh et al, 1984; Nichols and Green‐Church,  2009).  Ocular  insults  that  lead  to  inflammation  and  activation  of  the  immune response  produce  gaps  between  cells  in  the  blood‐tear  endothelium.  This  promotes  plasma leakage and may be responsible for some of the reported albumin influx. Albumin has, however, also  been  detected  in  atopic  subjects  and  it  has  been  impossible  to  verify  whether  albumin leakage  is  passive  or  if  albumin  is  purposely  recruited.  Additionally,  the  in  situ  effects  of increases  in  tear albumin concentration have yet  to be determined. A possible scenario  is  that albumin,  and  potentially  other  serum  products,  are  recruited  into  the  tear  film  as  part  of  an active process to create a dynamic adaptable ocular environment. The determination of albumin concentrations  in  the  tear  film  could  provide  information  on  the  integrity  of  the  blood‐tear barrier  and  on  how  a  subject  is  able  to  withstand  deviations  from  the  ocular  norm,  such  as contact lens wear. There exist presently no comprehensive evaluation of albumin concentrations in  the  tear  film.  The  aim  of  the  research  presented  in  this  thesis  was  therefore  to  provide  a foundation for the investigation of whether albumin in the tear film is responsive and recruited, or passively leaked.   The objectives were  fourfold:  firstly,  it was vital  to characterise and develop methods suitable for  sampling  and  determining  albumin  concentration  in  tears.  Secondly,  it  was  important  to compile  and  critically  assess  the  conflicting  data  presented  in  the  literature,  where  albumin concentrations vary significantly between studies. Thirdly, it was imperative to identify factors that significantly impact the measurement of albumin concentrations in tears. This information is necessary  for  the determination of  tear albumin baseline concentration and  investigation of subject‐to‐subject  variation.  Fourthly,  a  more  commercial  aspect  of  albumin  analysis  was investigated.  This  involved  the  development  and  evaluation  of  existing  urinary  point‐of‐care analysis equipment for the measurement of tear albumin concentrations.   This  introductory  chapter  provides  background  information  for  the  conducted  research.  The sections  discuss  the  anterior  surface  of  the  eye,  with  focus  on  the  tear  film  function  and  its 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constituents.  Human  serum  albumin  is  also  evaluated with  respect  to  physical  characteristics and functions, the defined plasma role and the less defined presence in tears.  
 
1.2 The anterior surface of the eye 
 The  anterior  surface  of  the  eye  is  compromised  of  the  anterior  portions  of  the  cornea,  the conjunctiva and the tear film. The cornea and the conjunctiva (Fig 1.1) will be described briefly, whilst a more detailed overview of the tear film will be given. The structure and function of the tear film is integral to the understanding and characterisation of tear albumin.  








 Fig  1.2.  Histology  of  the  cornea  showing  the  different  layers.  (New  York  University, www.med.nyu.edu)  The outermost layer, the corneal epithelium, provides a smooth refractive and protective barrier towards foreign material. Corneal epithelium represents roughly one tenth of the cornea and is penetrated  by  nerve  endings  providing  sensitivity  and  pain  upon  touch  and/or  insult.  The subsequent Bowman’s layer is a transparent sheet of tissue consisting of collagen. Whilst quick to  repair,  damage  to  bowman’s  layer  can  result  in  scar  tissue  affecting  vision.  The  corneal stroma represents the remaining nine tenths of the corneal thickness and its major constituents are  water  (78%)  and  collagen  (16%).  Descemet’s  membrane  is  another  strong  thin  collagen layer  providing  an  additional  barrier  towards  injuries  and  infection.  Endothelial  cells  provide the  collagen  in  this  layer  and  Descemet’s  membrane  is  easily  repaired  after  injury.    The innermost layer, the corneal endothelium, is also the thinnest and performs the vital function of keeping the fluid balance in the stroma. Damage to endothelial cells can lead to corneal oedema and blindness, as the cells cannot be replaced once destroyed. 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• The  tear  film  reduces  the  friction  of  the  eye‐lid  on  the  cornea  and  keeps  the  blinking action  smooth  and  comfortable.  Tear  fluid  also  aids  refraction  by  providing  an  even surface that appears smoother to incoming light.   Historically, the tear film has been described as a three‐layered structure (Fig 1.3) consisting of an  outer  lipid  layer,  an  aqueous  layer  in  the middle,  and  a mucin  layer  closest  to  the  cornea (Wolff, 1946, 1954).   A more complex six‐layer structure has since been suggested  taking  into account  the  internal  structures  of  the  lipid  layer  and  the  mucin  layer  (Tiffany,  1988).  The thickness  of  the  tear  film  has  been  under  dispute  with  several  reported  conflicting  values. Minimum and maximum values (3µm vs. 40µm) have both been produced using interferometry (King‐Smith et al, 2000; Prydal et al 1992; Prydal and Campbell, 1992) and show great disparity. A  compilation of  thickness data made by Bron et  al,  (2004),  showed  that  the most  frequently reported values were within the range of 6‐11µm. The relative sizes of the individual tear film layers  are  represented  in  Fig  1.3.,  where  the  aqueous  layer  is  the  dominant  entity  with  an 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estimated thickness of 7 µm. The interference between the aqueous layer and the mucin layer is diffuse and is better described as a gradation of mucin with a decrease in concentration towards the  lipid  layer. This diffuse  transition makes  it difficult  to estimate  the  thickness of  the mucin layer, as there are no defined reference points of where the aqueous layer begins.   
 Fig 1.3. Diagram representing the structure of the tear film.  Adapted from Craig, (2002).  1.3.2 The lipid layer 
 The  lipid  layer  is  composed  of  a  mixture  of  polar  and  non‐polar  lipids,  which  are  secreted primarily by the meibomian glands (Bron and Tiffany, 1998) and released during blinking. The Meibomian glands  are  tubulo‐acinar holocrine  glands  located  in  the  tarsal  plates  in  the upper eyelids  (30‐40  glands)  and  lower  eyelids  (20‐30  glands)  (Wolff,  1954)  (Fig  1.4).    Non‐polar lipids,  such  as  wax  esters,  cholesterol  and  cholesterol  esters,  make  up  60‐70%  of  the  lipid composition.  The  remainder  consists  of  polar  phospholipids  and  glycolipids,  as well  as minor amounts of alcohols, free fatty acids, mono‐ and di‐glycerides and neutral fats (Nicolaides et al, 1981). The three most prevalent free fatty acids in meibomian gland secretions, or meibum, are palmitic, stearic and oleic acids. Reported concentrations of the individual meibum components are varied, and have been shown to differ significantly between studies (Wojtowicz et al, 2009). Similarly,  meibum  composition  has  been  shown  to  vary  between  individuals,  with  respect  to cholesterol  and  unsaturated  fatty  acid  esters  (Shine  and  McCulley,  1991).  Both  these observations  add  to  the  contentions  regarding  the  lipid  composition of  the  tear  film, which  is still a large research area of interest. 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Fig 1.4. The position of the lacrimal gland and the meibomian glands.  The internal structure of the lipid layer has been described as a complex structure, exhibiting a non‐polar phase at the air  interface, and a polar phase at the aqueous layer interface (Fig 1.5), (McCulley and Shine, 2002).  A review on the lipid layer thickness by Bron et al (2004) showed that  early measurements  reported  100  nm  and more  recent  studies  reported  lesser  numbers between  13‐70  nm.  The  difference  between  these  values may  be  related  to  technique,  as  the former  data  is  based  on  specular  microscopy  and  the  latter  derived  from  reflectometry measurements. 
 Fig  1.5.  Diagram  showing  the  division  and  interaction  between  the  polar  and  the  non‐polar components of the lipid layer. Adapted from McCulley and Shine, (2002)   The lipid layer has important functions, both in the lid margin reservoirs, where it prevents tear over‐spill and resists sebum contamination, and as the outermost barrier of the tear film. One of the most  important  functions of  the  lipid  layer  is  as a  lubricant  for  the eyelids when blinking. 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During the blinking action, the lipid layer can conveniently be thought of as a concertina being compressed and stretched out when it is played (Bron et al, 2004). During eye closure, the lipid layer  is  compressed  and  rests  between  the  lid  edges  during  eye  closure. When  the  eye  opens again, it exhibits rapid spreading to cover the conjunctiva and promote stability of the tear film. The  lipids  protect  against  evaporation  of  the  aqueous  portion  of  the  tear  film  and  provide  a smooth optical surface for the cornea. In the case of a non‐confluent lipid layer or the absence of a  lipid  layer, evaporation of  the aqueous  tear has been shown to  increase  four‐fold  (Craig and Tomlinson, 1997). The same study also  found a  relationship between  the  lipid  layer  thickness and tear break up time, which emphasises the important link between a healthy lipid layer and ocular  disorders  such  as  dry  eye.  The  lipid  layer  also  provides  a  protective  physical  barrier against  foreign  particles  and  contributes  towards  the  immunological  defence with  some  anti‐microbial activity.   1.3.3 The aqueous layer 
 1.3.3.1 The lacrimal gland 
 The  lacrimal  gland  is  responsible  for  the  main  secretion  of  the  aqueous  component  of  tears (water,  proteins,  glyco‐proteins  and  electrolytes)  and  is  situated  in  the  lacrimal  gland  fossa, under the superolateral orbital rim (Fig 1.4).  There are also the accessory glands of Krause (20‐40 glands situated in the superior conjunctival fornix) and of Wolfring (along the superior tarsal border  in  the upper  eyelid), which  contribute  to  the  aqueous  secretions  (Milder,  1987).   New aqueous fluid from the lacrimal gland is expelled during every blink to refresh the tear film. The production of  tear  fluid  is under central nervous system control and the  lacrimal gland can be stimulated  by  ocular  irritation  or  emotional  experiences  to  increase  tear  flow  (Milder,  1987). Normal tear flow has been estimated with the help of fluorescein instillations, to be 1.2 µl/min (Mischima et al, 1966). Tear volume was similarly estimated to have a value around 7µl where 3 µl  is  thought  to  be present  in  the marginal  strip  of  the  eye,  forming  the  tear meniscus, which leaves 3‐4 µl to cover the conjunctiva and a further 1 µl to cover the cornea. Tears are drained through the upper and lower eyelid puncta. The physical forces provided by the eyelids during blinking aid the drainage and presses tear fluid into the puncta (Doane, 1984).    Electrolytes  determined  in  the  tear  film  include:  sodium,  potassium,  calcium,  magnesium, chloride  and  bicarbonate  ions.    These  are  responsible  for  the  tear  film  osmolarity  (Bothelo, 1964). Tear  film composition has been shown  to vary between  individuals and can be  further altered depending on ocular health and disease. The identification of tear protein biomarkers is therefore an important tool in investigating ocular disorders. 491 proteins have been identified 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to date in the tear film using various analytical techniques (De Souza et al, 2006). Lacrimal gland proteins are secreted by one of two pathways: regulated secretion or constitutive secretion.  In the  constitutive  secretion  pathway,  proteins  are  secreted  directly  after  being  assembled whereas  in  the  regulated  pathway  they  are  stored  until  sensory  stimulus  promotes  release (Lucarelli et al 2003).  The regulated pathway is the predominant protein secretion mechanism. Plasma  derived  proteins  also  occur  in  the  tear  film  and  these  originate  from  serum  leakage through the ocular blood‐tear barrier.   Levels of plasma proteins  in  the tear  film are therefore varied,  as  they  are  dependent  on  the  integrity  of  the  blood‐tear  barrier.  Albumin  is  the main protein originating from plasma leakage.   1.3.3.2 Proteins present in the tear film at high concentrations 
 The  five  most  concentrated  proteins  in  the  tear  film  are:  lysozyme,  lactoferrin,  lipocalin, secretory immunoglobulin A (sIgA) and albumin. Albumin will be discussed in more detail at the end of this chapter, as it is the main focus of this thesis. Other substances identified in the tear film  but  present  to  a  lesser  extent  include:  complement  factors,  transferrin,  matrix metalloproteinases, histamine, prostaglandins and other immunoglobulins such as IgG, IgE and IgM.   1.3.3.2.1 Lysozyme  Lysozyme is a 14.6 kDa positively charged protein that originates from the lacrimal gland and is secreted  simultaneously  with  lactoferrin  and  lipocalin.  It  is  one  of  the  most  concentrated proteins in the tear film, making up almost a third of the total protein. Reported concentrations vary between 1.0 and 3.1 mg/ml (Fullard and Snyder, 1990). Lysozyme is also present in saliva, serum, nasal secretions and urine.   Alexander Fleming, who detected the presence of a protein with  antiseptic  and  antibacterial  qualities,  first  reported  lysozyme  in  tears  in  1922.    It  is  the most important antibacterial enzyme in tears and functions by hydrolysing the ß‐1,4‐glycosidic bond in the polysaccharide walls of microorganisms. It has also been suggested to be present at the  tear  film  surface,  mixing  and  adsorbing  to  the  lipid  layer,  where  it  potentially  fulfils  a stabilising function (Mudgil et al, 2006). Several studies have reported a reduction in lysozyme concentration  during  ocular  disorders,  and  concentrations  have  also  been  shown  to  decrease with age. Some variation over the day has been reported (Sen and Sarin, 1986b; Horwitz et al, 1974)  although  earlier  reports  found  no  diurnal  variation  (Pietsch  and  Pearlman,  1973).  No significant differences have been found for samples obtained over the course of a year (Sen and Sarin, 1986b). 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Lysozyme  has  been  implicated  in  contact  lens  complications  due  to  its  heavy  deposits  on conventional hydrogels during wear (Bilbaut et al, 1984; Lin et al, 1991).  Interactions are likely to be due to electrostatic attraction between the positively charged lysozyme and conventional anionic  lens  materials  (Soltys‐Robitaille  et  al,  2001).  More  attention  to  the  nature  and consequence of the deposits are needed to establish whether deposited or denatured lysozyme on the contact lens is a significant factor of complications and discomfort or not.   1.3.3.2.2 Lactoferrin  Lactoferrin is a positively charged 82 kDa protein produced and secreted by the lacrimal gland. It  was  first  described  by  Masson  et  al  in  1966  and  tear  concentrations  have  been  reported ranging between 0.63‐2.9 mg/ml with an average of 1.42 mg/ml (Flanagan et al, 2009).  Bovine ocular surface epithelial cells have been shown to independently produce lactoferrin (Santagati 
et al, 2005) and the presence of lactoferrin precursors in mouse meibomian glands suggest that these might also be involved in secretion (Tsai et al, 2006), although, this is yet to be determined in human subjects.   Lactoferrin  is an  important part of  the ocular defense mechanism where  it has been shown to have  both  antimicrobial  and  anti‐inflammatory  properties.  It  has  a  high  affinity  for  iron  and, through binding, depletes the tear film of this component required for bacterial growth (Kiljstra (1990).  Consequently  lactoferrin  is  able  to  inhibit  the  growth  of  several  bacterial  species damaging  to  ocular  health  including  Escheria  coli.,  Staphylococcus  spp.  and  Pseudomonas  spp. (Flanagan et al,  2009). The positive  charge of  lactoferrin  also  attracts  it  to negatively  charged surfaces  of  bacteria,  where  it  interacts  with  the  lipopolysaccharide  components  of  the  cell membranes and increases the permeability, with damaging effects for the bacteria. Recent data have suggested the presence of an up‐regulation of lactoferrin secretion in females compared to males (Ananthi et al, 2011; Mii et al, 1992).  1.3.3.2.3 Lipocalin  Tear  lipocalin  is a 17.4 kDa protein  that has previously been referred  to  in  literature as a von Ebner’s  gland  protein    (Schmale  et  al,  1990)  and  tear  specific  pre‐albumin  (Bonavida  et  al, 1969). It is the second most concentrated protein in the tear film and approximately 15‐33 % of the total protein consists of lipocalin under normal ocular conditions (Redl, 2000). Lipocalin is a lacrimal  gland  protein, which  is  secreted  accompanied  by  lysozyme  and  lactoferrin.    There  is strong  evidence  that  lipocalin  interacts  with  both  lysozyme  and  lactoferrin,  based  on electromagnetic  resonance  spectroscopy,  and  possibly  works  in  cohort  with  these  proteins 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(Gasymov et al, 1999). The same experiment showed no  interaction between  lipocalin and the focus of this thesis, albumin.   The main function of lipocalin is as a carrier protein able to bind a broad range of ligands. It can bind  and  transport  vitamin  E,  vitamin  A  and  steroid  hormones  but  most  significantly  ocular lipids. Lipocalin has been shown to have a protective function by binding and removing ocular lipids  attached  to  dehydrated  or  other  abnormal  corneal  surfaces  exposed  through  ocular disorder (Glasgow et al, 2010). Lipocalin can also integrate with the meibomian lipids at the air‐lipid interface through a very complex mechanism to potentially promote its integrity and retard evaporation (Millar et al, 2009). Other functions of lipocalin include contribution to the viscosity of  tears  and  reducing  surface  tension  of  the  tear  film.  It  is  also  the  primary  endonuclease  in tears.  Alongside  lactoferrin,  lipocalin  has  also  been  found  to  be  up‐regulated  in  female  tears compared to male (Ananthi et al, 2011).  1.3.3.2.4 Secretory immunoglobulin A 
 Immunoglobulins  are  glycoproteins  produced  by  B‐lymphocytes  and  are  part  of  the  adaptive immune  system.  They  are  present  in  all  types  of  bodily  fluids  from  serum,  saliva,  urine  and breast milk  to  tears.  Secretory  immunoglobulin A  (sIgA)  is  the main  immunoglobulin  in  tears. Other  immunoglobulins  sometimes  present  in  the  tear  film,  although  in  much  smaller concentrations,  are  IgG  and  IgE,  IgD  and  IgM.  IgG  is  serum  derived  and  IgE  will  rarely  be detectable outside of  allergic  responses.  Secretory  Immunoglobin A has a molecular weight of 385 kDa,  as  it  is  the dimeric  form of  IgA  (160 kDa),  and  is  essential  for  immunity  at mucosal surfaces. Whilst  lactoferrin,  lipocalin  and  lysozyme  are  part  of  the  regulated  pathway,  sIgA  is part of the constitutive secretory pathway of the lacrimal gland and is continuously secreted into the  tear  film  (Lucarelli et al,  2003).  Localised production of  sIgA  in  conjunctival  cells has  also been verified (Knop et al 2008). As part of  the adaptive  immune system, sIgA has a protective role  against  disturbance  of  the  corneal  surface  by  foreign  pathogens  and  also  has  reported antiviral  properties  (Mazanec  et  al,  1993).    A  possible  SigA mediated  excretory  pathway  has been suggested (Mazanec et al, 1993; Robinson et al, 2001) where sIgA clears antibody/antigen complexes from the tear film.   Reported  sIgA  concentrations  are  varied  and  range  between  71  µg/ml  and  2.4 mg/ml  in  the open  eye  tear  film  (Sullivan,  1994).  Concentrations  of  sIgA  are  dramatically  increased  during prolonged  eye  closure  from  0.85 mg/ml  to  8.40 mg/ml  (Sack  et  al,  1992).  The  closed  eye  is described as a static environment with ongoing sub‐clinical inflammation suggesting a possible vital  protective  role  of  sIgA  during  the  night.  In  contrast  to  the  closed  eye  environment,  sIgA 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concentrations  have  shown  to  be  reduced  in  keratoconus.  and  during  contact  lens  wear (Balasubramanian et al, 2012; Willcox and Lan, 1999; Pearce et al, 1999). Although Stapleton et 
al (1998) found no difference in sIgA concentrations between samples taken from contact lens wearers and non lens‐wearing baseline samples.  1.3.4 The mucin layer  Mucins  are  extensively  glycosylated  protein  cores  with  varying  oligosaccaride  side  chain lengths. This has given rise to a large heterogeneity in mucin molecular mass from 500–40,000 kDa.  The  different  types  of  mucins  are  collectively  known  as  MUCs  and  19  types  of  mucin protein cores have been identified in humans, numbered in order of discovery.   The  mucin  component  of  the  tear  film  can  be  described  as  a  two‐layer  model  of  membrane bound and gel  forming mucins  (Lemp et al, 1992; Gipson et al, 2004). MUC1, MUC3A, MUC3B, MUC4 and MUC 16 are membrane bound mucins attached  to  the  stratisfied  squamous cells of the conjunctival and corneal epithelia. This membrane‐attached  layer  is covered  in soluble gel forming mucins  (MUC2, MUC5AC, MUC5B, MUC6, MUC7 and MUC9). Membrane bound mucins can also be found in soluble form in the tear film, most likely because of detachment by epithelial shedding  (Dartt, 2004).   The majority of mucin  in  the  tear  film  is  secreted by  the conjunctival goblet cells and the stratisfied squamous cells of  the cornea and conjunctiva.   Origins of MUC7 and MUC5B are more uncertain and have been identified in human lacrimal tissue but not in tear samples (Jumblatt, et al, 2003; Spurr‐Michaud et al, 2007).  The ocular  surface mucin  layer  is  a  prolific  area of  research,  especially with  respect  to  ocular disorders  and  contact  lens wear. Mucin  is  a  vital defence barrier of  the eye and  fulfils  several complex  functions.  Because  of  the  extensive  glycosylation,  mucins  are  highly  resistant  to proteolytic  degradation  and  have  a  hydrophilic  nature,  able  to  retain  water  on  the  ocular surface.   The retaining of water  is an  important barrier against desiccation and the mucin also anchors,  and  facilitates  even  spread  of  the  aqueous  tear  film  to  the  ocular  surface  (Tiffany, 1990).  The  mucin  layer  provides  a  smooth  lubricating  surface  protecting  the  corneal  and conjunctival  surfaces  from  kinetic  friction  damage  by  blinking.    MUC5AC  is  the  largest  gel forming  protein  and  has  an  anionic  nature.  Because  of  this  it  moves  easily  across  the  ocular surface  and performs  a  scavenger  function by  the  trapping  and  the  removal  of  cellular debris and  pathogens.  Mucins  have  also  been  suggested  to  be  partially  responsible  for  the  surface tension  of  tears. Millar  et  al  (2006) was,  however,  only  able  to  find  surface  activity  of mucin when mixed with meibomian  gland  lipids,  suggesting  a  supportive  role  in  stabilising  the  lipid layer rather than a direct influence on surface tension. 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Mucin  concentration  is  regulated  by  mucin  production,  mucin  release,  and  mucin  cell proliferation  (Dartt,  2002),  where  secretion  is  under  parasympathetic  nervous  control. Overproduction  or  deficiency  of  mucin  is  associated  with  ocular  disorders  including  dry  eye (Lemp et al, 1971; Danjo et al, 1998) and Sjögren’s Syndrome (Pflugfelder et al, 1997; Argueso et 





 Fig. 1.6. Heart shaped structure of albumin in the solid state (Carter and He, 1992)  However,  these  experiments  have  only  been  performed  on  fatty  acid  free  albumin  and  it  is known that the binding of long chain fatty acid ligands (C16‐C20) alters the shape of the molecule, making  it more compact and more resistant  to heat denaturation and proteolytic degradation. 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(Peters,  1996).  The  shape  of  albumin  in  solution  might  therefore  be  slightly  altered  in comparison.  An  ellipsoid,  or  cigar  shaped,  structure  in  solution  has  long  been  the  general concensus based on theoretical viscosity models using BSA (Squire et al, 1968; Bendedouch and Chen 1983). This view has however  lately been challenged by Ferrer et al  (2001) who studied the motions  of  a  dye‐bovine  albumin  complex  in  solution  using  phosphorescence.  The  results from  that  experiment,  and  experiments  on BSA  and  albumin  using  bead modelling,  suggested that  BSA  and  albumin  in  solution  in  all  likelihood would  appear  rigid  and  very  similar  to  the heart shaped structure.  The albumin molecule itself is made up of nine loops grouped into three homogenous domains (Fig 1.7) (Brown, 1976; Carter and He, 1992). Loops 1‐2, 4‐5, 7‐8, are the longer loops and these are  labelled AI,  AII  and AIII.  Conversely  loops 3,  6,  9  are  labelled BI,  BII  and BIII.  Two  longer loops separated by a shorter  loop constitutes a domain,  labelled  I,  II or  III. These domains are similar in structure but appear to have vastly different ligand binding properties.  
  Fig 1.7.  The loops and domains of the albumin molecule, showing the 17 di‐sulphide bridges. Adapted from (Peters, 1996)  Albumin contains 35 half‐cystins, which form 17 disulphide bridges (Dugaiczyk, 1982) (Fig 1.7). This  disulphide‐bonding  pattern  is  a  prominent  structural  feature  of  the  albumin molecule  as the positioning of  the cystins enables  short‐range coupling, which  leads  to both  flexibility and increased  resistance  to  extreme  conditions.  Both  these  characteristics  are  defining  for  the functions of the albumin molecule. Albumin also has a high total charge (185 ions per molecule 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at pH 7) due to a large number of ionised residues, which aid solubility (Peters, 1996). Because a high  proportion  of  the  amino  acids  are  acidic  (i.e.  aspartate  and  glutamate),  albumin  has  a negative net charge at physiological pH.   Due to the structural similarities of human serum albumin to bovine serum albumin, the latter is commonly  used  as  a  cheaper  substitute  for  the  human  version  in  research.  This  is  perhaps favourable  in  terms of  cost  and potentially  useful  as  a  tool  for  the  early  stages  of  designing  a model or method where a  large amount of waste  is  to be expected.   The proteins are however not  identical  and  it  is  not  advisable  to  ascribe  results  using BSA  to  be  directly  comparable  to human serum albumin.  Use of BSA as a substitute for human serum albumin is more prominent in older reports, when the human version was less accessible.   1.4.2 Albumin metabolism  Albumin  is  synthesised  in  the  liver  daily  and  is  not  stored  (Redman,  1968).  The  plasma concentration  of  albumin  lies  in  the  range  of  35‐50  g/L  and  between  1  fifth  and  1  third  of hepatocytes are designated to albumin production with an average synthesis of 9‐25 g per day.  Total albumin in the body amounts to around 250 ‐300 g for a 70 kg adult. Albumin is present to some degree in every bodily fluid, although the extent varies significantly between sites. Ca 42% is  present  in  the  plasma  compartment,  some  is  tissue‐bound  and  the  rest  is  situated  in  the extravascular compartment (Nicholson et al, 2000).  Both these compartments are normally in a state  of  dynamic  equilibrium.  The  rate  of  albumin  production  is  controlled  by  changes  in  the colloid  osmotic  pressure,  osmolality  of  the  extravascular  liver  space  and  substances  such  as insulin  (De Feo et al, 1991) and hormones  (Johnson et al, 1991;  John and Miller, 1969). Acute phase trauma, burns or infections can impede albumin production at the transcriptional level by slowing down the rate of mRNA transcription from the gene (Cairo et al, 1982; Liao et al, 1986). Similarly, direct deprivation of amino acids results  in depression of albumin synthesis (Pain et 
al, 1978; Sakuma et al, 1987). Albumin catabolism is less understood than albumin synthesis but they  generally  operate  at  similar  rates  in  healthy  subjects  and  keep  albumin  concentrations stable. Degradation of  albumin  (on average 14 g/day) occurs  in most organs of  the body. The liver is only responsible for 15% of the breakdown whereas muscle and skin degrade 40 ‐ 60 % (Nicholson et al, 2000; Yedgar et al, 1983). The rest is broken down by the kidneys or lost to the gastrointestinal  tract  through  the stomach wall. As mentioned  in section 1.3.1, binding of  long chain  fatty  acids  on  albumin  appear  to  have  a  protective  function  preventing  degradation. Albumin  half‐life  is  long  (>20  days),  compared  to  other  plasma  proteins.  This  longevity  is utilised by drug manufacturers, who use albumin as a carrier  to  improve  the pharmacokinetic profile of circulating drug components (Krantz, 2008). 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Oncotic  pressure  (the  osmotic  pressure  exerted  by  colloidal  blood  proteins)  is  vital  for maintenance of fluid balance in tissues and to stop osmotic flow e.g. preventing blood pressure to force water through capillaries and into tissue. Proteins in the blood counteract this flow by attracting water into the circulatory system. Albumin accounts for around 50% of total plasma protein  but  contributes  up  to  80% of  the  normal  oncotic  pressure  in  capillaries  at  25 mmHg. This is due partially to its high concentration in plasma and high molecular weight, which makes 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it unable to diffuse across the semi‐permeable membrane separating the blood from the lymph.  The other contributor is the negative charge of albumin, which attracts positively charged solute particles  and  keeps  them  in  the  intravascular  compartment  (the  Gibbs‐Donnan  effect).    E.g. albumin attracts positive sodium  ions, which  in  turn brings water with  them, and changes  the colloid oncotic pressure. The effect of changes in albumin concentration, and resultant changes in  oncotic  pressure,  in  critical  illness  is  a  much‐debated  issue  and  was  recently  reviewed  by Nicholson  et  al  (2000).  Low  serum  albumin  in  the  critically  ill  is  associated  with  negative outcome and increased mortality.  Conversely, the apparent correction of this using intravenous injection  of  albumin  is  not  necessarily  correlated  with  an  improvement  in  condition  or preferential  to  other  colloidal  therapies.  Results  are  unclear  as  to  why  this  adjustment  of albumin concentration does not live up to its theoretical promise. Furthermore, humans who are suffering  from  genetically  related  analbuminemia  (plasma  concentration  of  less  than  1g/L) present with  some pathological  features,  but  the  condition  is  not directly  fatal  (Peters,  1996). Potentially,  prolonged  albumin  deprivation  allows  the  body  to  adapt  accordingly  whereas sudden fall in concentrations have more severe consequences, which are difficult to resolve.    1.4.3.2 Coagulation effects 
 Albumin appears to exhibit heparin‐like anti‐coagulant activity on blood clotting and enhances the inhibition of factor Xa by anti‐thrombin III. It also inhibits the aggregation of blood platelets (Jorgensen and Stoffersen, 1979, 1980). This  is particularly valuable with respect to  implanted biomaterials.  The  laws  of  thermodynamics  show  that  interfaces will  adapt  to  reach  a  system with as little interfacial energy as possible. For a blood vessel replacement, high surface energy amongst  other  unwanted  properties  may  result  in  unwanted  clotting  and  eventually  plaque formation  and  blockage.    By  attracting  albumin  to  the  surface,  the  formation  of  clotting  and other detrimental interactions are bypassed. For a solid implant the best scenario for this kind of interaction results in a thin fibrous encapsulation produced by the adsorption of other proteins, primarily albumin, shielding it from further interaction (Hench and Jones, 2005). Goncalves et al, (2009)  tried  to  increase  the  beneficial  albumin  binding  by  attaching  C‐18  ligands  to  poly‐hydroxyethylmethacrylate. The aim of the ligands was to attract albumin by mimicking the long chain  fatty  acid  (C16‐C20)  binding  site  of  albumin.    The  amount  of  poly‐hydroxyethylmethacrylate‐albumin  binding  increased  at  high  concentrations  of  C‐18  (>  5%). However, when albumin was present in competition with other proteins, high concentrations of C‐18 were found not to have a significant effect on binding. 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1.4.3.3 Anti‐oxidant 
 Albumin has been  implicated  in more  than 70% of  the scavenging of oxygen  free radicals  that occurs  in  serum  (Bourdon  and  Blache,  2001).  The  free  reduced  cysteine  residue  (Cys34)  on albumin is a potent scavenger of oxidising agents (Gutteridge, 1986).   Amongst other functions Cys34 enables the removal of the powerful oxidant hypochlorous acid, which is a by‐product of enzymes  released  by  activated  phagocytes  and  neutrophils  (Weiss,  1989;  Winterbourn  et  al, 2000). Albumin also performs a protective anti‐oxidant function by binding detrimental plasma components and removing them from circulation.  Plasma copper and iron ions in the free form are  liable  to  interact  with  hydrogen  peroxide  leading  to  the  formation  of  damaging  hydroxyl radicals. When bound to albumin, products created by the metal ion interactions (if they interact at all) are diverted towards albumin and less likely to affect more important tissue target (Roche 
et al, 2008). Albumin also provides  indirect protection by gathering bilirubin, which has some anti‐oxidant properties,  from sites of haemoglobin breakdown. Bilirubin bound to albumin has been shown to be an  inhibitor of  lipid peroxidation (Neuzil and Stocker 1993, 1994) and  thus albumin might also play a role in protecting polyunsaturated fatty acids from oxidation.  









   Richieri et al 1993 Bilirubin  9.5 x 107   Brodersen, 1980 Hematin  1.1 x 108   Adams and Berman, 1980 Copper (II)  1.5 x 1016   Masouka et al, 1993 Zinc (II)  3.4 x 107   Masouka et al, 1993  
Pharmaceutical  Salicylate  1.9 x 105 
   Kragh‐Hansen, 1988  Benzylpenicillin  1.2 x 103   Joos and Hall, 1969  Diazepam  3.8 x 105   Kragh‐Hansen, 1991  Ibuprofen  2.7 x 106   Kragh‐Hansen, 1981       It  is  estimated  that more  than  99.9% of  all  ‘free’  long  chain  fatty  acids  (C16‐C20)  in  serum  are transported  on  albumin  molecules.  Statistically  with  long  chain  fatty  acid  concentrations  in plasma  reaching  1mM  and  circulating  albumin  levels  reaching  only  0.6mM,  each  albumin molecule would  carry 1‐2 LCFA molecules.  Ligand binding  alters  the  structure of  the  albumin molecule  and  can  in  the  instance  of  fatty  acid  binding  lead  to  increased  stability  and  better resistance  towards  degradation  (Peters,  1996).  Medium‐chain  fatty  acids  (C6‐C14)  have  less affinity for the albumin binding sites, although binding might occur at long chain fatty acid sites if medium  chain  fatty  acids  are  present  in  excess  in  the  plasma.  As  these medium  chain  fatty acids are rarely present outside cells this has little practical influence (Peters, 1996).     Six sites for  long  chain  fatty  acid  binding  have  been  detected  on  albumin  but  only  three  have  been properly  characterised.  These  are  the  three  strongest  ones  and  they  each  lie  in  different domains. The binding of very long‐chain saturated fatty acids (>C20) has been demonstrated on bovine serum albumin (Choi et al, 2002) and was shown to decrease in affinity with increase in chain  length.  The  transport  of  fatty  acids  is  vital  for  the  functions  of  a  variety  of  tissue  cells: adipocytes  for  storage,  Leydig  cells  for  hormonal  production  and  myocytes  for  energy production. 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1.5 Albumin in tears 
 1.5.1 Albumin in the pre‐corneal tear film and anterior eye  Albumin  is  not  an  indigenous  lacrimal  gland  protein  and  is  present  in  tears  as  a  result  of vascular  leakage  from  serum  through  the  blood‐tear  barrier.  Due  to  its  high  concentration  in plasma  and  relatively  low molecular  weight  (66  kDa)  it  can  easily  transverse  the  blood‐tear capillary layer and is an effective marker for vascular leakage and the integrity of the blood‐tear barrier. Whilst  albumin  in  serum has been extensively  researched,  tear albumin  levels  remain poorly  defined.  The  available  data  are  not  completely  understood  and  a  distinct  lack  of authoritative information concerning the presence and role of albumin in tears is noticeable.  It is  well  recognised  that  tear  albumin  concentrations  vary  significantly  from  study  to  study compared  to  other  major  lacrimal  gland  proteins  such  as  lysozyme  and  lactoferrin.  This variability makes it difficult to establish a range even in asymptomatic subjects, where minimum and  maximum  determined  values  are  8.41  µg/ml  and  1830  µg/ml  respectively  (Fullard  and Tucker,  1991;  Farris,  1985).  The  evaluation  and  characterisation  of  published  tear  albumin concentrations was key for this research. Literature tear albumin concentrations and factors for variations are therefore extensively discussed in chapter 3.   1.5.2 Albumin in the cornea  Albumin  is  present  in  the  cornea,  although  reports  differ  with  respect  to  abundance  and location.  Studies  carried  out  in  rabbits  suggest  that  albumin  originates  from peripheral  blood vessels  and  diffuses  towards  the  center  of  the  cornea,  exhibiting  a  concentration  gradient  of albumin  (Maurice  and Watson,  1965;  Wiig,  1990).  In  mouse  and  bovine  corneas,  albumin  is present almost exclusively  in  the  stroma with  localised  staining  in  cells next  to  the Bowman’s and Descemet’s membranes (Nees et al, 2003). Gong et al (1997), using similar techniques, also reported albumin staining in both bovine and human stroma but found a difference between the anterior and the posterior portion; the anterior one third of the stroma staining more intensely.    1.5.3 Albumin transport across the blood tear barrier  Mechanisms of transcapillary transport of albumin across the blood‐tear barrier have yet to be determined  and  may  be  a  combination  of  receptor‐mediated  pathways  and  other  pathways including:  intercellular  junctions,  vesicular  transcytosis  and  transendothelial  channels.  In plasma,  transport  of  albumin  into  the  extravascular  compartment  is  across  capillaries. Historically,  trans‐capillary  transport  has  been  attributed  to  the  four  Starling  forces  (osmotic 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• Chemokines – macrophage inflammatory protein 1alpha  These  identified mediators may also be responsible  for  the  leakiness of  the blood‐tear barrier, and may have a role in the control and augmentation of albumin concentrations in the tear film.  
  38 
Although the precise modality of albumin  leakage  into the tear  film is not yet understood,  it  is recognised  that  ocular  disorders  such  as  giant  papillary  conjunctivitis  or  dry  eye,  amongst others, result  in  increased albumin concentrations. Contact  lens wear has also been implicated in increased albumin concentrations in the tear film (Lundh et al, 1984; Choy et al, 2004).   1.5.4 Albumin in the closed eye tear film  The  closed  eye  tear  film  became  a  research  area  of  growing  interest  in  the  early  1990s,  as researchers and clinicians were trying to determine factors that have an impact on contact lens wear.  The  safety  of  overnight wear  of  contact  lenses was  a  disputed  issue,  as  there was  little information  on  risk  factors  associated with  lens wear  during  prolonged  eye  closure.  Previous studies  had  shown  that  overnight  eye  closure  is  associated  with  corneal  swelling  and vasodilation (Smelser and Ozanics, 1952; Holden et al, 1983). Increased risk of infection, ulcers and corneal hypoxia were therefore major concerns (Weissman et al, 1984; Poggio et al, 1989; Holden and Mertz, 1984). Studies on the closed eye showed that the tear film composition was significantly different from the open eye state (Sack et al, 1992; Tan et al, 1993; Sack et al, 1993; Choy  et  al,  2004).  The  seminal  study  by  Sack  et  al,  (1992)  compared  tear  samples  collected immediately upon waking (closed eye tears) with samples taken during the daytime (open eye tears).  They  found  that  total  protein  concentration  in  the  closed  eye  tears  was  double  the concentration  in  the  open  eye  (9.0  mg/ml  to  18  mg/ml)  and  that  SigA  concentrations  were increased by tenfold (0.85 mg/ml to 8.40 mg/ml) in the closed eye tear film. More significantly for the present study, albumin concentrations exhibited a twenty‐fold increase from 0.06 mg/ml in  the  open  eye  to  1.10mg/ml  in  the  closed  eye  tear  film.  Complement  factors  and polymorphonuclear neutrophils were also increased in the closed eye (Sack et al, 1992; Wilson 








 The overall aim of the research is to try to gain a greater understanding of the role and nature of tear albumin and of factors that affect tear albumin concentrations. It is clear that in order to do this,  the previously uncharacterised published  tear albumin data needs  to be  collated. Factors that affect tear albumin needs to be taken into account to interpret the significance of reported concentrations  and  to  provide  a  foundation  for  further  work.  The  choice  of  sampling  and analysis  technique  for  the  determination  of  tear  albumin  is  also  of  great  importance.  Another aim  is  therefore  to  create  and  evaluate  an  in‐house  enzyme‐linked  immunosorbent  assay  for tear albumin analysis.  
 Having characterised the tear albumin literature, a second aim of the work is to investigate the possible occurrence of systematic variation in tear albumin. Although, a great effort has been put into  characterising  the  closed  eye,  diurnal  variation  of  tear  albumin  has  not  been  studied  ‐ despite the fact that variation of albumin has been identified at other body sites.  
 A major driving force for the present investigation is that tear albumin levels may produce some information into the responses of the eye to insult. Therefore tear albumin may be a predictive factor  in the determination of contact  lens wear success  in a subject (50% of potential contact lens‐wearers drop out for unknown reasons). It was intended from the outset to investigate the possibilities  of  adapting  existing  point  of  care  techniques,  currently  used  to measure  urinary albumin, for tear analysis in the contact lens clinic. The potential benefits of this are: 
 
• Means of gaining additional data related to the investigation into albumin as a biomarker 

















 Tears were collected from all subjects in line with the ethical guidelines of Aston University. No signs of ocular disease or discomfort were found during any of the sampling periods and contact lens wear was  restricted with  respect  to  the  relevant  studies.  This  research  project  used  two different techniques to evaluate albumin concentration in tears:  
• Microcapillary pipette with positive displacement  
• Schirmer strip   The use of both microcapillary pipettes and Schirmer strips to collect tears for albumin analysis has been previously reported in the literature (Stuchell, 1984; Farris, 1985; Fullard and Tucker, 1990). Whilst Schirmer strip is considered a more invasive technique out of the two, the use of it was  necessary  to  evaluate  external  factors  that  affect  albumin  concentration.  The  use  of Schirmer strip for tear protein analysis is also beneficial in subjects with low tear volume, where microcapillary  collection  is  more  difficult.  Effects  of  tear  sampling  technique  on  measured albumin concentration are discussed in detail in chapter 3.  
2.3 Microcapillary sampling  Microcapillary sampling was the main technique employed for the collection of tear samples in the  research  presented  in  this  thesis.    This  method  of  collection  uses  narrow‐bore  glass microcapillaries  and was  carried  out  in  line with  protocols  described  by  Bjerrum  and  Prause (1994), Fullard and Snyder (1990), and Mann and Tighe (2007). Capillaries have a volume range of 1‐10µl and are provided with a separate stainless steel plunger wire used to express the tear sample. The use of  the plunger  to  express  the  tear  fluid  eliminates  the need  for  an  extraction step,  which  is  often  needed  for  absorbable  collection  techniques.  Gradation  on  the  capillary makes  it  simple  to  assess  the  volume  collected,  depending  on  the  accuracy  and  precision 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• Tweezers   2.4.2 Schirmer strip sampling protocol  The rounded end of the Schirmer strip was bent to form a lip over the lower eyelid, which keeps the strip in place during sampling.  Subjects were asked to face the researcher and look up. The filter paper strip was then placed in the lower conjunctival sac, one third of the palpebral width from  the  temporal  canthus,  to  absorb  the  tear  fluid  (Fig  2.2.).  Subjects  were  told  to  blink normally or close their eyes during sampling and also to report if any significant discomfort was experienced. Wetting  length  and  time  of  wetting were  recorded  during  the  experiments.  The Schirmer strip was removed with tweezers after 5 minutes or when the full 35 mm of the strip had been wetted. Tweezers were used to avoid contamination of the Schirmer strip by excessive handling. If a subject wet the full strip before 5 minutes, the time at which full wetting occurred was recorded. The Schirmer strip was then subjected to extraction as discussed below. 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Fig 2.2. Schirmer strip sampling (Legarreta Eye Center and MedNet Technologies, Inc).  2.4.3 Schirmer strip extraction protocol  The method  for  Schirmer  strip  extraction  described  below was  designed  by  the  Biomaterials Research  Group.  Other  protocols  of  Schirmer  strip  extraction  exist  and  are  discussed  more thoroughly  in  section  3.6.  The  removed  Schirmer  strip  was  placed  in  a  microcentrifuge  tube (650 µl), which had a hole punctured in the bottom. This 650 µl tube was then positioned in a larger microcentrifuge tube (1.7 ml) and centrifuged for 5 minutes at 10, 000 rpm (Fig 2.3).  









 Protein analysis of individual tear samples is dependent upon the availability of systems able to quantify proteins  in small sample volumes (2‐5 µl). Sensitivity  is also a key  issue, especially  in terms  of  albumin  analysis,  where  reported  concentrations  are  in  the  µg/ml  range.  Tear quantification  in  the present study was performed using enzyme‐linked  immunosorbent assay (ELISA) and two point‐of‐care kits (POC): the HemoCue® 201 albumin analyser (Hemocue AB) and the AfinionTM AS100 Analyser (Axis‐Shield).   
2.6. Enzyme­linked immunosorbent assay   A review on clinical application of tear proteomics identified ELISA as the most commonly used assay  method  for  the  quantification  of  tear  proteins  (Wu  et  al,  2007).  The  method  has  four features, which makes it advantageous for a wide range of applications (Crowther, 2009):   
• It is versatile with many different combinations of systems available and easy separation of bound and unbound reactants is possible. 
• It  is  simple  to  use  with  the  ability  to  do  a  high  capacity  of  samples  whilst  remaining relatively cheap.  
• It is sensitive due to the enzyme‐catalyst amplification. 
• It is quantifiable, either by eye or by spectrophotometry.  One  disadvantage  of  using  ELISA  is  that  commercially  available  kits  are  relatively  expensive compared  to  the  individual  components.  Preliminary  investigations  for  the  research  project described in this thesis identified the need for analysis of a substantial amount of tear samples. The  issue  of  material  and  method  costs  was  therefore  important  to  discuss  as  relying  on commercial ELISA kits could become very expensive. Consequently, an aim for this research was to  construct  a  laboratory based ELISA  to  keep  the  costs  low. The procedure of  constructing  a sandwich  based  ELISA  protocol  for  the  determination  of  albumin,  upon which  a  considerable amount  of  time  was  expended,  is  detailed  in  appendix  A.  The  present  chapter  provides  the materials  and  buffers  used  in  the  development  of  the  assay.  Ultimately,  this  laboratory  based human albumin ELISA was unable to provide acceptable accuracy and precision for the project and a commercial assay was chosen for the analysis of tear albumin. Nevertheless the time spent on ELISA development provided valuable insight into the assay components and the technique itself. 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2.6.1 Principle of the ELISA assay  ELISA is a colorimetric analytical technique based on the specific interaction between antibodies and  their  antigens.  An  antigen  is  any  entity  able  to  elicit  an  antibody‐mediated  immune response.  The  ELISA  procedure  involves  the  stepwise  addition  and  reaction  of  reagents  to  a solid phase‐bound substance. Four ELISA systems are available: direct,  indirect,  sandwich and competition.  Due  to  the  small  working  volume  in  tear  sample  analysis  it  was  found  that sandwich ELISA was the most suitable technique. In sandwich ELISA, capture antibodies specific to the antigen of interest are coated onto wells in a microtiter plate. Samples are then added to the wells and the capture antibodies  identify and bind any antigen present  in sample solution. The antigen is then retained in the system for quantification.   A  key  feature  is  the  addition  of  another  antibody,  which  is  enzyme‐conjugated,  and  also recognises  and  binds  to  the  antigen.  This  antibody  is  known  as  the  detection  antibody.  The enzyme  bound  to  the  detection  antibody  catalyses  a  subsequently  added  reagent  and  this produces a quantifiable change in colour. The colour intensity corresponds to the enzyme‐linked antibody, which in turn corresponds to antigen concentration in the sample, and this is how the method has received its name: enzyme‐linked immunosorbent assay.   Benefits of the sandwich ELISA are: high specificity and the conservation of antigen sample volume, as antibodies are the entity needed in excess. Although components of the ELISA assay had been previously described, publication  of  the  complete  ELISA  procedure  can  be  attributed  to  two  papers:  Engwall  and Perlmann (1971) and Van Weemen and Schuurs (1971). Several sandwich assay varieties exist but this project focused on the most common procedure which utilises a horseradish peroxidase (HRP) ‐ 3,3’,5,5’‐tetramethylbenzidine (TMB) system. The assay method is exemplified in Fig 2.4 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Fig 2.4.  Example protocol of a sandwich ELISA   Further explanation of the steps illustrated in Fig 2.4 is given below:  1. Specific antibodies, raised against the antigen of interest, are coated onto the bottom of wells in  microtiter  plates  at  set  concentrations.  Standard  plates  are  conventionally  made  of polystyrene and have 96 wells, although other materials and sizes are available. Well volume is normally  between 300‐400  µl.  After  incubation with  the  coating  antibody,  a  blocking  agent  is added to the wells to adsorb to empty sites. The role of the blocking agent is to limit interactions with the plate material and other assay components.   2. Pre‐diluted sample  fluid  is added  to wells  in duplicate. The coated “capture” antibodies will form a strong specific interaction with any antigen present in the sample added to the well. This is a normally a 1: 1  interaction making the system very precise.   After  the  incubation with the sample  solution,  the  plates  are washed with  a  surfactant  solution.  This  removes  all  unbound material.   3. A solution containing HRP enzyme‐labeled antibodies, which are also specific to the antigen, is then added. This secondary antibody binds the antigen and the structure formed is known as the sandwich  complex.  The  plate  is  incubated  to  allow  the  interaction  between  the  secondary 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antibodies  and  the  antigen  to  proceed.  Subsequently  all  unbound  matter  is  washed  away; ensuring that only antibody‐antigen complexes remain in the wells.    4. The chromogenic substance, TMB  is added  to  the wells. The conjugated enzyme attached  to the secondary antibody catalyses the TMB and the reaction gives rise to the quantifiable change in colour. The incubation during this step takes place in the dark to prevent colour amplification by sunlight.   5.    The  catalysis  reaction  is  stopped  by  the  addition  of  a  weak  acid  solution  e.g.  0.5  M hydrochloric  acid  (HCl).  The  intensity  of  colour  is measured by  spectrophotometry  at  450nm. Concentration of antigen in the sample is directly correlated to concentration of bound enzyme‐antibody and  this  in  turn  is directly  correlated  to  the  colorimetric  change.   A  set of  standards with known antigen concentrations  is  included on  the plate and  these  constitute  the  standard curve from which the sample concentration is determined.   2.6.2 Specific component information  The  sections  below  discuss  the  components  of  the  ELISA  system  in more  detail  with  specific attention to the conditions necessary for a working sandwich ELISA protocol.  2.6.2.1 Immunoglobulins  Immunoglobulins, or antibodies, are the key part of the acquired immune response, which is the selective  intervention  of  the  body  against  a  specific  foreign  invader.    Antibodies  are  proteins secreted by plasma B cells with tailored functions towards the identification and eradication of extracellular pathogens. The structures and generation of antibodies, as well as the applications of  the  antigen‐antibody  interaction  for  immunoassay  use  are  well  explained  by  Price  and Newman (1997). 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The basic antibody molecule is Y‐shaped with four polypeptide chains; two identical light chains and two identical heavy chains (Fig 2.5.).   
 Fig 2.5.  Representation of an antibody molecule.  The  antigen  binding  terminal  of  both  light  and  heavy  chains  contain  variable  regions  with independently folded amino acids units that create highly specific paratopes. The differences in these amino acid units determine the antibody complementarity towards antigens. The antibody proteins contain  inter‐ and  intra‐chain disulphide bonds and renders some flexibility  from the disulphide  bridge  hinge  region.  The  shorter  Fab‐regions  express  the  variable  domains  that determine  the  antibody  specificity  whilst  the  Fc  region  determines  the  class  of  the immunoglobulin. There are 5 classes of immunoglobulins: IgG, IgA, IgE, IgM and IgD (Table 2).  Table 2. Immunoglobulin classes and characteristics     Molecular mass (kDa)  Structure   Normal Concentration in 
serum (mg/ml) 
Function 
IgG  150  Y shape  10  Primary  antibody  in  the blood.  Secondary  antibody after  IgM  detection  but with much stronger response. 
IgA  160  Y shape or Dimeric  2  Mucosal  and  secretory immunity. 
IgM  950  Pentameric  1  Initial  antibody  detecting foreign  entities.  Efficient  at complement fixation. 
IgD  190  Y shape  0.04  Poorly  understood.  Possibly a  regulator  of  the  immune system. 
IgE  190  Y shape  0.0003  (increases significantly during allergic response) 
Allergic  responses  by activating  mast  cells  and basophiles.  Also  targets parasitic invasions. 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The antibodies are raised in a host animal by an injection of the desired protein antigen into the bloodstream. The B‐cell  lymphocytes  in  the animal, often a sheep or a rabbit, produce specific antibodies to the injected foreign protein. These antibodies are then harvested. IgG is the most commonly used ELISA antibody, because of  its  strong  response  to  the presence of  an antigen. This results in a higher serum concentration, or a higher yield, compared to the other antibodies.  Antibodies and can be either monoclonal or polyclonal. Monoclonal antibodies are raised from a single  B‐cell  lymphocyte  and  this  generates  identical  proteins  capable  of  detecting  structural alterations as small as singular amino acid changes. The specificity of monoclonal antibodies has made  the  discovery  of  several  isoforms  of  proteins  possible.    Disadvantages  of  monoclonal antibodies are that they are usually provided by the fusion of B‐cells with myeloma lines at some cost. Polyclonal antibodies on the other hand originate from many B‐cells and it is comparatively inexpensive  to  produce  high  affinity  species  in  large  quantities  (Albert,  1984).  However  the antibodies are heterogeneous and able to bind more than one epitope on the antigen. There  is also a possibility of cross‐reaction between similar antibodies, especially if originating from the same species. It  is therefore recommended to use different host animals for polyclonal capture and detection antibodies.  Moonoclonal  antibodies  are  usually  derived  from murine  spleen  cell  lines  fused with murine myeloma cells (Kuus‐Reichel et al, 1994; Fernandez and Moller, 1991; Shan et al, 1994). Other animals, such as hamsters, rabbits or rats, are sometimes used but often lack the availability of species‐specific  fusion  cell  lines.  Mice  also  have  many  inbred  strains  so  can  usually  provoke aggressive immune response upon immunisation in at least one strain, which results in efficient antibody  harvesting.  Rabbits,  chickens,  sheep  and  goats  are  useful  for  harvesting  polyclonal antisera, where goats and sheep are particularly valuable for larger scale manufacture in terms of volume of serum available (Price and Newman 1997). 
 2.6.2.2 Solid‐phase microtiter plate materials  Common  plate  materials  are  polyvinyl  chloride  for  a  more  flexible  plate  and  polystyrene  for rigid  plates.  Although  available  in  several  sizes,  most  often  a  96  well  (8  x  12  well  format) microtiter plate  is used. Wells are available  in  flat‐bottomed or round‐bottomed styles but  the latter  is  less  suitable  for  spectrophotometric  readings.    Well  volumes  also  range  but  are normally around 300‐400 µl to accommodate for the addition of TMB and stop solution and to ensure that there is enough space for adequate washing. Observed difficulties are temperature gradients across the plates due to thermal insulation properties and concentration drifts across the  plates  due  to  pipetting  time  (Crowther,  2009).  Microtiter  plates  are  also  the  solid  phase 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material with the lowest antibody binding capacity. Reaction kinetics can however be sped up by incubation  at  37°C  and  by  vibration,  which  is  most  easily  achieved  by  placing  the  plates  on shakers.  
 2.6.2.3 Coating agents 
 Typically  ELISA  solutions  are  made  up  in  phosphate  buffered  saline  (PBS),  which  resembles bodily fluid conditions and is complementary to most proteins. Commercially they often contain sodium azide, which prolongs the potential storage life of the solution.  In the coating procedure, the capture antibody passively adsorbs to the plastic wells by hydrophobic interactions. The aim of  the  coating  buffer  is  to  aid  this  interaction, which  can  be  done  by  increasing  the  available hydrophobic  residues  displayed  by  the  protein  (Crowther,  2009).  Plate‐Protein  interaction  is dependent on  the net‐charge of  the protein and partial denaturation. Changes  in pH alters  the balance  and  exposes  more  hydrophobic  regions.    A  pH  value  a  couple  of  units  above  the isoelectric  point  of  the  protein  is  a  useful  starting  point.  It  is  important  that  no  other proteinacious  material  that  can  compete  with  the  capture  antibody  is  present  in  the  buffer. Typical example of a coating buffer is given in Table 3.  Table 3. Carbonate coating buffer  
Reagent      Amount Sodium carbonate   5.3g  Sodium bicarbonate   4.2g  Sodium azide   1g  Distilled water  900 ml 
Actions: 
• Adjust pH to 9.6 
• Adjust volume to 1L with distilled H2O  2.6.2.4 Blocking agents   Sufficient  blocking  of  the  plate material  is  imperative  in  order  to  keep  the  sensitive  reaction between antibody and antigen specific without  interference. For example, non‐specific binding of the detection antibodies to the plate material renders the results useless. Equally detrimental is  a  reaction  between  the  detection  antibody  and  the  blocking  agent.    A  good  blocking  agent must therefore be capable of saturation of any empty site of the coated plate whilst remaining passive in any further reactions taking place.  The quality of the blocking buffer also determines 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the level of background noise of the plate. This is reflected in the blank absorption value. A high blank OD reduces the sensitivity of the assay and the ability to detect and differentiate between low concentration samples.   Common blocking agents are: bovine serum albumin,  foetal calf  serum, casein and non‐fat dry milk. Added to this list are synthetic blockers and carbohydrates. Polyvinyl alcohol and Ficoll® (a  high molecular  weight  sucrose  polymer)  have  been  proven  effective  when  there  is  risk  of cross‐reaction with the protein based alternatives (Huber et al, 2009). The inclusion of a gentle surfactant such as Tween 20 may also be beneficial to reduce possible interactions between the blocking protein and the capture antibody.  A typical blocking solution is described in Table 4.  Table 4. Typical example of a blocking solution         2.6.2.5 Sample and conjugate components  The  conjugate  bears  its  name  from  the  conjugation  of  the  detection  antibody  to  an  enzyme. Horseradish  peroxidase  is  the  most  widely  used  enzyme  in  ELISA  procedures.  Other  options include  alkaline  phosphatase,  ß‐galactosidase  and  urease  (Crowther,  2009).  Detection antibodies  must  be  carefully  chosen  to  avoid  cross‐reaction  with  capture  antibodies  and/or blocking buffer. The purpose of the conjugate diluent is to inhibit passive absorption to the solid phase  surface  but  enable  an  immunological  reaction  with  the  capture‐body  antigen  complex. This can be done in two ways:  
• Include another protein at high concentration to compete for solid phase binding. 
• Include a detergent at low concentration, i.e. a blocking agent.  Sample and conjugate diluents also often contain a  tris‐buffered system as  tris  is considered a very effective inhibitor of further protein modifications. A typical sample and conjugate diluent is described in Table 5.    
Reagent  Amount Phosphate buffered saline solution  500 ml Sodium azide solution (10%)  1ml Bovine serum albumin  5 g 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Table 5. A typical ELISA sample and conjugate diluent   
Reagent        Amount Trizma base (tris‐HCl)  2.42g Sodium chloride  8.77g Sodium azide  1g Distilled water  1 L 
Actions 
• Adjust pH to 7.6 using 1M HCL  2.6.2.6 Washing solutions  The aim of washing the plate is to remove unbound material from the wells without disturbing the attached antibodies. Due to the covalent nature of the bond between the solid phase and the antibody, some de‐sorption can occur during the assay time. Vigorous washing could potentially lose  some  desorbed  material,  although  this  has  not  been  reported  as  a  common  problem (Crowther, 2009). Washing solutions are therefore usually buffered to maintain isotonicity and keep  optimal  conditions  for  the  formation  of  antibody‐antigen  complexes.  Flooding  the  assay wells with solution can sometimes be sufficient  for removal of unbound material although  the inclusion  of  surfactants  is  also  common;  normally  Tween  20  or  Triton  X.  A  disadvantage  of surfactants  is  the  generation  of  foam,  which  traps  air  and  results  in  uneven  distribution  of solution. Potential denaturation of  the antigen  is another problem reported. A  typical washing solution is described in Table 6.  Table 6.  A typical ELISA washing solution  
Reagent  Amount Phosphate buffered saline solution  4L Sodium azide solution (10%)  8ml Tween‐20  2ml  2.6.2.7 Substrate  ELISA  substrates  are  chromogenic  substances  that  are  catalysed by  the  enzyme  conjugated  to the detection antibody. The TMB‐HRP system was  the only system used  in  this  research. TMB functions  by  being  an  effective  electron  donor  for  the  reduction  of  hydrogen  peroxide  on  the conjugated horseradish peroxidase (Fig 2.6). The oxidation of TMB into the diimine form results 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in  a  blue‐green  colour,  measurable  at  a  wavelength  of  650  nm.  Colour  intensity  is  directly related  to  the  quantity  of  enzyme‐conjugated  antibodies  and  subsequently  directly  related  to antigen concentration.   































• TMB solution  Buffers for the ELISA protocol were prepared as detailed below. All buffer material was sourced from Sigma Aldrich (UK) unless otherwise stated. Stability of the solutions was varied due to the lack  of  sodium  azide.  Because  of  this,  buffers  were  assessed  visually  for  turbidity  or contamination before use and were used fresh when possible. 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2.6.5.1 Buffer preparation  Solution  recipes  for  the  preparation  of  buffers  used  in  the  ELISA  development  are  described below in tables 7‐13. The preparation of a TMB solution was more complicated than the other buffers and is described in more detail.  Table 7. Phosphate buffered saline              Table 8. Sodium carbonate/bicarbonate coating buffer  
Reagent        Amount Sodium carbonate  0.210g Sodium bicarbonate  0.265g Distilled water  50ml 
Actions 
• Adjust to pH 9.6 with the drop wise addition of 1M HCl   Table 9. Block buffer 1  
Reagent  Amount  Source Non‐fat dry skimmed milk  3g  Tesco PBS  100 ml      






Reagent  Amount  Source Stabilguard® Choice   5 ml   Surmodics, Inc Distilled water  5 ml     Table 11.Trisbuffered saline (TBS) sample diluent   
Reagent  Amount Trizma base (Tris‐HCl)  2.42g Sodium chloride  8.77g Distilled water  1L 
Actions 
• Adjust the pH to 7.6 with the drop wise addition of 1M HCl   Table 12. Wash buffer  
Reagent  Amount Tween 20  1ml PBS  1000ml   Table 13.  Conjugate solution and secondary antibody diluent  
Reagent  Amount Tween 20  0.5ml TBS  1000ml  TMB solution preparation initially required the preparation of a 0.1M citric acid solution (1.92 g citric  acid  in  100ml  deionised  water)  and  a  0.2M  dibasic  sodium  phosphate  solution  (2.84g dibasic  sodium  phosphate  in  100ml  deionised  water).    These  were  combined  to  formulate  a 0.05M  phosphate  citrate  buffer  by  the  addition  of  25.7 ml  0.2M  dibasic  sodium  phosphate  to 24.3ml 0.1M citric acid and 50ml of deionised water. The pH was adjusted to pH 5 with 1M HCl if necessary.  Two  TMB  substrate  tables  were  dissolved  in  2ml  dimethylsulphoxide  and  this solution was added  to 18ml of 0.05M phosphate citrate buffer.  Immediately before use on  the 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ELISA  assay,  2ml  of  fresh 30% hydrogen peroxide  solution was  added per 10 ml  of  substrate buffer.    2.6.6 Spectrophotometry instrumentation for ELISA analysis  The  Spectramax M2  (Molecular Devices,  California) was  used  for  the measurement  of  sample optical  density  for  ELISA  analysis.  It  is  a  monochromator‐based  microplate  reader  (Fig  2.7), which  is able  to measure absorbance and  fluorescence  in various standard microplate sizes as well  as  in  a  cuvette.  Absorbance  wavelengths  can  be  set  between  200nm  and  1000  nm, excitation wavelengths between 250nm and 850nm and emission wavelengths between 360nm and  850nm.  Absorbance  was  read  on  ELISA  plates  at  450  nm  according  to  commercial specifications.   
  Fig 2.7. The Spectramax M2 instrument used for ELISA analysis.   Sample  absorbance,  or  optical  density,  is  the  quantification  of  the  amount  of  light  passing through  solution  compared  to  the  amount  of  light  available  in  the  system.  This  includes  the absorbance  of  the  sample  solution  and  any  light  scattering  brought  on  by  turbidity.  In  the absence of  turbidity, optical density  is equal  to  the sample absorbance calculated according  to the Beer‐Lambert equation below:  
A = log (Io/I)  Where, Io is the incident light and I is the transmitted light of the sample. All samples analysed in this research were visually assessed to be absent of turbidity. 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A  6255  10 µl Human alb calibrator  990 µl 6  200  22 µl standard A  666 µl 5  100  300 µl standard 6  300 µl 4  50  300 µl standard 5  300 µl 3  25  300 µl standard 4  300 µl 2  12.5  300 µl standard 3  300 µl 1  6.25  300 µl standard 2  300 µl Blank  0    500 µl 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2.7.3 Immunology Consultants Laboratory ELISA running protocol  
• Tear samples were diluted 1:200 in sample diluent when enough tear fluid was available, otherwise,  nearest  possible dilution was used. The deviation was  recorded  so  that  the proper dilution factor was applied during analysis of the data.  
•  The standards and the samples were pipetted in duplicate into pre‐designated wells on the microplate at a volume of 100µl / well. The plate was then covered with a plate lid and incubated for 60 minutes at room temperature  
• The contents of wells were  then emptied down  the sink and  the plate was banged dry against  paper  towels  until  no  more  wet  spots  appeared.  The  wash  solution  was subsequently  pipetted  into  all  wells  at  300µl  per  well  and  the  solution  was  emptied down the sink and banged dry. This was repeated three times for a total of four washes.  
• 100µl of enzyme conjugated antibody solution was then pipetted into each well and the plate  was  covered  and  incubated  for  30  minutes  at  room  temperature.  After  the incubation, another wash cycle as the one previously described took place.  
• 100 µl of TMB was then pipetted into each well and the plate was covered and incubated in the dark at room temperature for ten minutes.  
• Lastly, 100µl of HCl  stop solution was pipetted  into each well  and  the absorbance was read on the Spectramax M2 at 450 nm.   2.7.4 Assessment of Immunology Consultants Laboratory ELISA  Although the lowest standard has a value of 6.25 ng/ml, OD comparison with the blank revealed the potential  to  identify even  lower albumin concentrations by extrapolation of  the curve. The actual  sensitivity  threshold was determined experimentally  to be 1 ng/ml by additional  serial dilution  of  standard  6,  which  leaves  plenty  of  room  for  determination  of  low  concentration albumin  samples.  Seven  standard  curves  run  on  different  days were  also  compared  for  inter‐assay homogeneity (Fig 2.8), showing some disparity in terms of OD but consistency in shape. 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Fig  2.8.  Comparison  of  standard  curves  from  the  Immunology  Consultants  Laboratory  ELISA kits.  ICL Duplicate precision was well below 10% CV for  the  large majority of  test samples assayed and  the  few  high %  CVs  present  were  presumed  to  be  results  of  human  error.  Samples  that produced  high  %CVs  were  re‐assayed  at  a  later  date  and  precision  was  then  found  to  be satisfactory.  Inter‐assay  precision  and  accuracy  was  found  to  be  excellent,  even  with  low concentration samples assayed two weeks apart (5.3 µg/ml, 5.13 µg/ml). The small difference in concentration  can  be  attributed  to  loss  through protein  adhesion  to  the  storage  eppendorf  or assay  condition  differences.  Double  dilutions  of  tear  samples  also  provided  accurate  values. Although  tear  albumin  concentrations  differ  significantly  between  studies  the  sensitivity  and range of  the  commercial  assay  ensure  that  samples  as  low  in  concentration  as 1µg/ml  can be determined with confidence. This is sufficient for the detection of albumin in reflex tears, which suffers increased dilution with lacrimal gland fluid (detailed in chapter 3).  Assayed tear samples also diluted in a linear manner confirming repeatability and accuracy in albumin determination. This  supports  the  notion  of  utilising  several  different  dilution  schedules  to  account  for differences in volume available without affecting the results.  The  level of  colour  formation,  and  the  resultant OD,  is decided by  the extent of  the enzymatic reaction  and  the  ambient  temperature  will  affect  the  final  OD  value.  A  higher  ambient temperature will speed up the reaction time and a higher OD will develop before the reaction is stopped. It is therefore reasonable to assume that some of the discrepancy between the curves in Fig 2.8 could be related back to temperature differences experienced in the laboratory. Batch to  batch  variation  of  assay  components  could  also  infer  some  differences  between  standard 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curves. All albumin concentration results have been read off the standard curve present on the same plate as the samples. Any difference in colour development between plates will not affect the  results  as  they  are  related  back  to  their  specific  curve,  which  has  been  individually scrutinised every run. The ELISA technique is a viable option for the analysis of human albumin concentrations  in  tear  samples  and  the  ICL  sandwich  ELISA  was  found  to  be  a  suitable instrument for further albumin analysis.  
2.8 Point­of­care technology (POC) for the measurement of tear albumin 











• 20  µl  of  sample  fluid  was  pipetted  onto  a  small  square  of  parafilm.  Although  the minimum  specified  volume  is  18  µl  it  was  found  that  any  air  bubbles  present  in  the cuvette would  ruin  the  analysis.  The  higher  amount  of  20  µl  was  therefore  used  as  a precaution against this.   
• The sample fluid was absorbed by the HemoCue albumin cuvette containing polyclonal rabbit  anti‐human  albumin  antibody.  The  sides  of  the  cuvette  was  wiped  with  paper tissues to remove excess fluid and the cuvette was then placed into the albumin analyser.  
• The analyser measured the light absorbance of the sample at 610 nm and the calculated amount of albumin was displayed in mg/L.   2.8.2 Principle of the AfinionTM AS100 Analyser assay (Kvam et al, 2007)  The AfinionTM AS100 Analyser  is  an automated  instrument  that uses  chemical  and mechanical assay  methods  to  perform  multiple  analyses  in  individual  test  cartridges.  All‐in‐one  reagent cartridges  are  supplied  specific  for  the  entity  to  be  analysed  and  are  labelled with  a  barcode, which is scanned by the analyser to determine the assay procedure. The present research used the  AfinionTM  ACR  cartridges,  designed  for  the  determination  of  albumin,  creatinine  and  the albumin/creatinine ratio  in human urine. The volume requirement of the ACR cartridge is 3 µl and  the measuring  range  is  5‐200  µg/ml.  Two  control  solutions  are  also  supplied  to  test  the accuracy  of  the  system. The  analysis  is  performed using  a  solid  phase  immunochemical  assay contained  in  the  cartridges.    A  detachable microcapillary  is  used  to  absorb  the  sample  and  is then replaced into the cartridge, where the sample is soaked through a membrane coated with 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The  aim  of  the  research  presented  in  this  chapter  was  to  critically  assess  the  disparities  in published tear albumin concentrations and to use that information to design subsequent studies. Objectives of the research were therefore to establish what factors affect the determination of a true  albumin  baseline  scenario  and  what  conditions  have  an  added  impact  on  the  resultant sample value.  Because of the scattered nature of reported tear albumin concentrations and lack of previous collation and analysis of the data, this was a very significant task. 
 
3.2 Introduction 
 Blood‐borne  albumin  has  been  extensively  researched  but  albumin  in  tears  has  received  less focused  attention.  Reported  tear  albumin  concentrations  have  not  been  evaluated  collectively and  the  role  and  function  of  albumin  in  the  tear  film  remains  unclear.  Early  published  tear albumin  concentrations  were  obtained  using  less  sensitive,  or  semi‐quantitative  techniques, (Berman et al, 1973; Janssen and Van Bijsterveld, 1986) and subsequently, are less accurate than results obtained from modern techniques, such as ELISA, high‐pressure liquid chromatography and mass  spectrometry.  The heightened  sensitivity  provided by modern  analytical  techniques have made it more attainable to accurately determine albumin concentrations and consequently to  investigate  the  purpose  of  albumin  in  tears.  However,  the  investigation  of  albumin  also requires the understanding of natural variations and external factors that affect concentrations. Several  conditions have been  identified  to be  related  to higher  albumin  concentrations. These include: ocular disorders (Sen and Sarin, 1986b), contact lens wear (Lundh et al, 1984) and the closed eye scenario  (Sack et al, 1992).  It  is  intuitively predictable  that conditions affecting  the integrity of the blood tear barrier would result in increased plasma influx but the specific links between  external  factors  and  albumin  concentrations  are  still  unclear.  Sampling materials,  in particular  the  Schirmer  strip,  have  also  been  correlated  to  an  increase  in  serum  protein concentrations (Stuchell et al, 1984) although the level of impact has yet to be fully determined. The  most  recent  review  relating  to  tear‐borne  albumin  focuses  mainly  on  contact  lens deposition  phenomena  (Luensmann  and  Jones,  2008).  Consequently,  albumin  levels  in  tears have  remained poorly  defined,  as  the  available  data  are  not  completely  understood. Available 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information  on  reported  albumin  levels  in  tears  has  been  assembled  here  in  an  attempt  to summarise the modest amount of information that exist regarding this major plasma protein in tears.  Factors  affecting  albumin  concentrations  in  tears  have  been  identified  and  compiled  in order  to  assess  the  conflicting  nature  of  the  published  albumin  concentration  data.  These variables will be dealt with individually in the chapter and are:  




• Assay technique (e.g. immunodiffusion techniques, ELISA and SDS‐PAGE)  The  implications  of  individual  determinations  of  albumin  tear  concentrations  are  difficult  to determine unless  the  factors  that  affect  them are  fully  comprehended and  taken  into  account. The Interrelationship between the different variables e.g. sampling technique, ocular health and contact lens wear is also of importance as influences on albumin concentration variation in the tear film may be multifactorial. 
 
3.3 Effect of tear flow rate on measured tear albumin concentration  3.3.1 Introduction  Tear  volume  and  tear  protein  composition  are  dependant  on  the  interaction  between  the autonomic  nervous  system and  the  endocrine  system alongside  localised  effects  by  cytokines. The  eye  can  exhibit  different  states  during  tear  collection,  which  produce  distinguishable differences in the qualities of the sampled tear fluid. States are characterised by the effect they have on tear flow rate and tear protein composition and can be divided into:  
• Basal tears 
• Reflex or stimulated tears 
• Emotional or psychogenic tears  Basal  tears  are  defined  as  the  normal  tear  production  required  to  replenish  the  continuous turnover  of  tear  fluid.  Tear  flow  rates  close  to  the  innate  tear  production  of  1‐2  µl/min  are therefore  representative  of  basal  tears.  Reflex  tears  demonstrate  increased  volume  from  the lacrimal  gland,  often  due  to  physical  stimuli  such  as  ocular  irritation.  The  increased  volume 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provides flooding of the system and removal of potential pathogens. Reflex tear flow rates cited in  literature vary but  tend  to  lie within 20‐50 µl/min  (Berta, 1986; Fullard and Tucker, 1991; Sitaramamma  et  al,  1998a).  Emotional  stimulus  induces  excessive  lacrimation,  similar  to physical stimulus, but exhibits significant differences in protein composition (Frey et al, 1981).   3.3.2 Effect of tear flow rate on measured total protein concentration  The  aim  of  this  section  is  to  describe  how  total  tear  protein  and  other  tear  components  are affected  by  alterations  in  tear  state  and  tear  flow  rate.  These  data  will  subsequently  be compared to the variations  in tear albumin concentrations with flow rate and tear state. Table 15 shows a cross‐section of reported total tear protein concentrations collected in the three tear states. Only studies  that used atopic subjects and microcapillary tubes to collect samples were included in Table 15 to keep sampling technique consistent across the comparisons. 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Table  15.  Total  protein  concentration  in  atopic  normal  subjects  collected  by  microcapillary, distinguishing between basal, stimulated and emotional tears. (n/s =  not stated). 













     5.0 ‐ 3.9     5.8 ± 1.0   6.0 ± 2.5    6.01 ± 2.11   4.6 ‐ 6.9   5.47 
    10    7  6             16   5  61 
    Fullard and Tucker, 1991    Fukuda et al, 1996  Sack et al, 1992   Markoulli et al, 2011  Coyle et al, 1989  Frey et al, 1981 
Emotional  6.50            42  Frey et al, 1981 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The stimulation of reflex tears can be brought about by a variety of procedures that increase tear flow, and can be chemical, physical or physiological, as illustrated in Table 15. It is important to recognise  that  tear  proteins  are  not  uniformly  affected  by  external  stimulation.  Lactoferrin, lipocalin  and  lysozyme  maintain  a  constant  proportion  of  total  tear  proteins  during  reflex tearing  (Fullard  and  Snyder,  1990).  SIgA  on  the  other  hand  is  significantly  reduced  from 15.5±3.2  %  to  9.5±3.5  %  of  total  tear  protein  during  reflex  lacrimation  (Sitaramamma  et  al 1998a). The different dilution pattern of sIgA to the other three major lacrimal gland produced tear  components  is  due  to  the  different  secretion  pathways  mentioned  in  chapter  1  (section 1.3.3.1).   Emotional tears also have decreased total tear protein content (6.50 mg/ml) compared to basal tears  (8.1 mg/ml)  but  not  as  low  as  externally  stimulated  tears  (5.6 mg/ml).  This  could  be  a reflection  of  the  limited  studies  on  emotional  lacrimation  or  alternatively,  the  psychogenic response might not be as strong as direct physical insult. A lower tear flow compared to reflex tearing by physical stimulus would lead to less flooding of the system and the marginally higher tear protein concentrations reported in emotional tears.   3.3.3 Effect of tear flow rate on measured albumin concentration  In the same way as total protein, serum albumin is detected in higher concentrations in low flow rate tear samples and lower concentrations in stimulated tears. One study reported a decrease from 750µg/ml at ~1µl/min to 250µg/ml at a flow rate of 20µl/min, following increased nasal stimulation with 80% ethanol (Berta, 1986). Similar experiments using nasal stimulus, although with  dilute  ammonia  vapour,  also  found  a  decrease  in  albumin  concentration with  increasing flow rate (Fullard and Tucker, 1991). A significant decrease from 42.0µg/ml in non‐stimulated basal  tears  to 3.0µg/ml, collected at a  flow rate of 50µl/min, was observed. As opposed  to  the total tear protein data exhibited in Table 15, tear albumin concentrations measured in basal and reflex tearing are not consistent between studies. This is apparent by comparing the data from Berta (1986) and Fullard and Tucker (1991), who determined albumin concentrations in basal tears  to  be  250  µg/ml  and  42  µg/ml,  respectively.  Assay  methodology  and  tear  collection technique are further variables, which affect tear albumin concentration and these are discussed in subsequent sections.   Interestingly the study done by Frey et al (1981) on emotional tears (Table 15) also measured the albumin fraction of total tear protein. The mean concentration of total protein in emotional tears was 6.50 mg/ml compared to the irritant induced reflex tear concentration of 5.47 mg/ml.  This  represents  a  difference  in  total  protein  of  16%  between  the  two  states.  The  albumin 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fraction  was  however  24%  higher  in  emotional  tears  than  in  irritant  induced  reflex  tears. Further research into these two states with respect to albumin would be beneficial as the studies are very limited.  3.3.4 Summary of effect of tear flow rate on measured albumin concentration 
 Even though further study is necessary,  it  is clear that albumin concentrations in the tear film, and  its  relative  fraction of  total  tear protein, are able  to vary over  large ranges  in response  to tear flow stimulus. The full effect of tear flow stimulation is difficult to de‐convolute from other variables,  such  as  tear  collection  and  assay  methodology.  This  is  apparent  when  comparing measured tear albumin concentration collected under both basal and reflex tearing conditions. Some doubts exist about whether  there  is such a  thing as a  true basal  tear or whether all  tear fluid has some fluid resulting from the reflex lacrimation pathways (Jordan and Baum 1980). To avoid confusion, basal tear in this thesis denotes tears, which were visibly un‐stimulated during the time of collection and have a flow rate comparable to that reported by Mischima (1966) (1.2 µg/min).   Other  tears will be described as  reflex  tears,  although details,  regarding  stimulation are  given  to  distinguish  between  modes  of  collection.  Tears  that  exhibit  some  degree  of increased stimulus but not reaching the flow rate of 20‐50 µl/minute are described as medium flow rate tear samples.  
 
3.4 Effect of prolonged eye closure on measured tear albumin concentration 
 3.4.1 Introduction  The closed eye environment is a unique state with vastly different tear composition compared to the  open  eye  and  more  research  is  required  to  fully  understand  its  implications.  It  can  be described as exhibiting the opposite attributes of stimulated tear flow. The closed eye tear film is characterised by decreased or stagnant tear flow, due to lack of blinking and lack of refreshment of  tear  fluid  during  sleep  (Sack  et  al,  1992).  Total  protein  concentrations  determined  in  the closed  eye  are  18.0±7.4mg/ml  and 15±3mg/ml  (Sack et  al,  1992;  Sitaramamma  et  al,  1998a). The significant increase in total protein concentration during the closed eye could be attributed to  the  stagnant  tear  film  environment with  limited  tear  component  turnover  and  drainage.  It could also be representative of a beneficial active ocular defence mechanism involving  the up‐regulation of sIgA, complement proteins and albumin. 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3.4.2 Effect of prolonged eye closure on measured tear albumin concentration 
 Despite  the  research  interest  in  closed  eye  tear  fluid,  quantitative  information  of  albumin concentration  in  this environment  is scarce. Sitaramamma et al  (1998a) used HPLC to analyse SigA  and  albumin  in  the  closed  eye  tear  fluid  but  results were  only  presented  as  a  combined fraction  percentage  of  total  protein.  Albumin  concentrations  measured  at  hourly  intervals throughout  the  sleep  cycle have been  shown  to  increase progressively  and  to  reach  statistical significance after 5 hours of sleeping (Tan et al, 1993). A figure in the paper by Tan et al (1993) showed  albumin  concentrations  between  800  and  1000  µg/ml  at  this  point  of  statistical significance but no definite value was given. Only two studies have been identified that provided quantified albumin concentrations in the closed eye tear fluid. These are presented in Table 16.  Table 16. Albumin concentrations in the closed eye sampled by microcapillary.  
 Closed eye  (µg/ml) (Range where given) 
 Population  Time of day stated   Analysis method   Reference 
 200 (150 ­ 580)   8   Y   SDS‐PAGE   Choy et al, 2004 1100 ± 760  4  Y  Immunofixation, Immunodiffusion  Sack et al, 1992  The magnitude of albumin increase in the closed eye is significantly different between the two studies.  Research  done  by  Sitaramamma  et  al  (1998a)  on  total  tear  protein  in  the  closed  eye reported  a  decrease  from  15 mg/ml  at  first  time  of  eye  opening  to  12,  9,  6  and  eventually  4 mg/ml with consecutive collections over seven minutes. Thus, collecting the sample a couple of minutes  after  eye  opening  could  result  in  the  decreased  levels  reported  by  Choy et  al  (2004) compared  to  Sack  et  al  (1992).    Both  studies  have  however  detailed  that  sampling  was conducted  as  soon  as  possible  after waking, making  acclimatisation  a  less  likely  cause  for  the disparities seen in concentration. Disparities in the reported closed eye concentrations in Table 16  are  therefore  most  likely  due  to  differences  in  analysis  method  and/or  population  as  the same tear collection method was employed.  3.4.3 Summary of effect of prolonged eye closure on albumin concentration  The closed eye is characterised by  its  increase  in albumin and other components such as sIgA, plasmin, vitronectin and pro‐inflammatory mediators. The magnitude of albumin increase in the 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closed  eye  tear  film  varies  between  reports  but  it  appears  to  increase  progressively  during prolonged eye closure. Tear  fluid sampled  immediately post‐waking represents  the closed eye tear sample and exhibits increased albumin levels, compared to the open eye state. 
 





In  general,  the  higher  albumin  levels  were  determined  in  conjunction  with  Schirmer  strip collection and the  lowest detected albumin concentrations were collected by microcapillary.  It should be noted that results derived from filter paper disc sampling all originate from the same research group (Janssen and Van Bijsterveld), which could bring some bias to the results. Mean albumin concentration reported by stimulated microcapillary collection is 86.2 µg/ml compared to 954.5 µg/ml with filter paper techniques. Here it  is evident that the harsher collection tools such  as  filter  paper  discs  and  Schirmer  strips  cause  irritation  and  present  the  highest concentration detected.    Schirmer  strip  tear protein profiles have been  found  to  contain more cellular  products  (Green‐Church  et  al,  2008)  and  more  low  molecular  mass  peaks  than  the profiles  of  subjects  sampled  by microcapillary  (Grus  et  al  2005).  Similarly,  samples  taken  by microcapillary result in a lower concentration of endogenous antibodies compared to Schirmer strip samples (Remington et al, 2009). These results further support that the insertion of filter paper  into  the  eyelid  margin  is  able  to  disrupt  the  ocular  epithelium,  leading  to  increased availability  of  albumin  and  cellular  components.  Schirmer  strip  tear  sampling  has  long  been reported  as  an  invasive  uncomfortable  experience.  Even  back  in  1982  it  was  suggested  that surgical sponges or filter paper should be avoided for the collection of tears, particularly when investigating albumin where higher values will occur due to irritation (Gachon et al., 1982).   Lower  albumin  concentrations  reported  in  the  literature  (Table  17)  were  almost  invariably collected by microcapillary under stimulus. The highest stimulated microcapillary concentration recorded was by Berta (1986) at 750 µg/ml. This significantly different albumin concentration compared to other microcapillary results may originate from a number of causes, the most likely being  the mode  of  stimulus  used.  The  presentation  of  80%  ethanol  into  the  nasal  passage  is potentially  enough  irritation  to  disturb  the  blood‐tear  barrier  and  result  in  increased  serum leakage. Prolonged  reflex  tearing has  also been  shown  to produce an  increase  in  albumin and other plasma protein levels (Fukuda et al, 1996). The assay technique used by Berta is replicated in a number of other studies detecting much lower albumin levels and is therefore unlikely to be a dominant factor. Excluding the possibly erroneous results of the study by Berta (1986), which used harsh stimulation techniques, the mean stimulated microcapillary concentration is reduced even further to 19.9 µg/ml. Compared to 19.9 µg/ml, concentrations sampled by Schirmer strip and filter paper discs represent an almost 50 times increase in reported albumin levels reported in normal subjects. The vast differences seen in albumin concentration between Schirmer strip and  microcapillary  techniques  are  however  unlikely  to  be  due  to  the  dilution  of  protein  by stimulus  in  microcapillary  pipette  samples.   This is exemplified in Table  18,  which  shows albumin  concentrations  in  normal  asymptomatic  tears  sampled  by  microcapillary  without external stimulation. The concentrations are tabulated in order of increasing magnitude. 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Table 18. Albumin concentration in non‐stimulated tears from normal healthy control subjects collected by the non‐invasive microcapillary pipette technique. 






 10.3 ± 4.6 (1.4­21.6)   53   N   Microelectroimmunoassay   Prause, 1983 10.3 ± 9.2  n/s  Y  Microelectroimmunoassay  Thygesen, et al 1987 11.85 ± 5.97  50  N  Immunodiffusion  Sen and Sarin, 1986a 14.60 ± 8.60  11  N  ELISA  Balasubramanian et al, 2012 20.50  24  N  Immunodiffusion  Zavaro et al, 1980 21 ± 28  30  Y  SDS‐PAGE  Ng et al, 2000a ~ 40  n/s  N  n/s  Bron and Mengher, 1989 42.0 ± 11.7  30  N  SE‐HPLC, ELISA  Fullard and Snyder, 1990 42.0 ± 4.7  10  N  SE‐HPLC, ELISA  Fullard and Tucker, 1991 45.1 ± 32.5  11  Y  ELISA  Baleriola‐Lucas et al, 1997 54  88  N  SDS‐PAGE, Behring laser nephelometer  Gachon et al, 1982 60± 20  4  Y  Immunofixation, Immunodiffusion  Sack et al, 1992 10‐200  4  N  Immunodiffusion  Berman et al, 1973 
n/s = not  stated 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albumin  concentration,  and  of  stimulation,  which  increases  tear  flow  are  difficult  to  de‐convolute and add to the complexity of assessing albumin concentrations. 
 
3.6. Effect of sampling material on measured tear albumin concentrations  3.6.1 Introduction  Some  sampling  techniques  (Schirmer  strips,  filter  paper  disks,  wicks  and  sponges)  require extraction,  as  they  collect  tears  by  the  absorption  of  fluid  onto  a  solid  substrate. When  using these methods, the extraction efficiency of the tear fluid must be taken into account in addition to any direct material influences on the tear film. Several different extraction possibilities exist, which produces  further variables  for  tear sampling studies and makes comparisons of protein concentration more complex. Table 19 shows the available extraction protocols reported in the literature.   A closer investigation of these protocols revealed a common feature between studies, of lack of attention to extraction methodology design. An example is the group of Shoji et al, (2003), who investigated  eosinophil  cation  protein  concentrations,  sampled  by  Schirmer  strips,  in  subjects with Sjögren’s syndrome or allergic conjunctivitis. Only the first 5 mm of the Schirmer strip was used for analysis and was  incubated  in phosphate buffered saline surfactant solution  for  three hours  at  room  temperature.  Shoji  et  al,  stated  that  the  recovery  efficiency  of  this  elution procedure was above 80% with respect to eosinophil cation protein but there are no details on how this was measured apart from unreferenced preliminary studies. 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Table 19. Extraction protocols for the determination of tear proteins sampled by absorptive tear collection techniques. 
 Several other studies showed distinct neglect to comment on the reasoning behind the protocol chosen and the extraction efficiency with respect to the investigated protein. Discussions of any error or variation that the protocol could add to the results were also deficient. Research studies that  did  report  investigations  of  material  influence  are  discussed  below  with  their  relative approaches.  3.6.2 In vitro spike and recovery  In vitro spike and recovery of proteins from the substrate provides the extraction efficiency for the  specific  protein  of  interest.  Van  der  Meid  (2011)  assessed  cytokines  and  matrix 
Extraction Protocol  References Phosphate  buffered  saline  with  and without surfactancts  Janssen and Van Bijsterveld  (1981, 1983, 1985, 1986) Grus et al, (2005) Shoji et al, (2003) Zhou et al, (2008) Kramann et al, (2011) Denisin et al, (2012) Sodium chloride buffer with surfactant  Van der Meid,( 2011) Ammonium  bicarbonate  buffer  with acetone precipitation  Green‐Church et al, (2008) Lema et al, (2010)  Li et al, (2010) Sodium barbitol buffer  Prause (1979) TMED‐acetic acid buffer  Stuchell et al (1984)  Farris (1985, 1986) Ethylebediaminetetracetic acid (EDTA)  Proud et al, 1990 Centrifugation   Thyegesen et al, (1987) Tuft and Dart, (1989) Jones et al, (1997) Afonso et al, (1999) Solomon et al, (2001) Koo et al, (2005) Remington et al, (2009)  Kim et al, (2012) 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metalloproteinases (MMPs) in Schirmer strips from clinical studies. Samples were eluted in a 0.5 M sodium chloride 0.5% Tween 20 buffer and efficiency of protein recovery was determined on in‐vitro  spiked  Schirmer  strips.  A  known  concentration  of  sample was  added  to  the  Schirmer strip and then compared to the eluted concentration. Results showed that cytokines on average have an extraction efficiency of 62.3% and MMPs an average of 79.6% under this protocol.   3.6.3 Comparison with microcapillary sampling  Another  widespread  method  of  assessing  extraction  protocols  is  to  compare  electrophoretic profiles between the extracted sample and a microcapillary sample (Tuft and Dart, 1989; Jones 
et  al,  1997;  Grus,  et  al  2005;  Green‐Church  et  al,  2008;  Remington  et  al,  2009).  Whilst  this approach does not provide quantitative information of protein recovery it can assess if inherent ratios between tear proteins remain similar between the two techniques. Studies done by Tuft and Dart (1989) and Jones et al, (1997) showed comparable concentrations between centrifuged sponge samples and microcapillary samples. The entitites studied were IgE (Tuft and Dart) and lactoferrin and ephithelial growth factor (Jones et al). The groups of Green‐Church, Remington and  Grus  all  found  differences  between  tear  protein  profiles  with  Schirmer  strip  and microcapillary  sampling  techniques.  The major  lacrimal  gland  proteins  remained  similar,  but Schirmer  strip  samples  contained  more  cellular  products,  endogenous  antibodies  and  low molecular weight entities compared to microcapillaries.   3.6.4 Volume recovery  Centrifugation, with or without added buffer,  is  the dominating technique for the extraction of sponge materials  but  has  also  been  used  for  Schirmer  strip  analysis.    Collection  efficiency  of sponges by centrifugation is often calculated by volume recovery. Studies by Esmaeelpour et al, (2008) and Lopez‐Cisternas et al, (2005), attempting to develop new absorptive tear collection materials,  compared  a  variety  of  substrates.  Their  results  are  shown  in Table 20  and  concern volume recovery rather than specific protein recovery. References are denoted by author initial.  Table 20. Comparison of collection efficiency by centrifugation in various sponge materials.  
  Cellulose acetate rod  Poly urethane  Poly vinyl acetyl  Polyester  Cellulose sponge Collection efficiency (%) (Ref)  76 ± 1.5 (E)  88.6 (L‐C)  58.2 (L‐C)  82.2 ± 2 (E) 
 42 ± 31(E) 53.4 (L‐C) 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Here  it can be seen that significant differences exist between substrates and that no collection protocol was 100 % efficient even without taking specific protein adsorption into account.  3.6.5 Effect of sampling material on measured tear albumin concentration  Albumin  concentrations  determined  by  absorptive  techniques  are  detailed  in  Table  17  and protocols  used  are  shown  in  Table  19.  Similar  to  other  published  tear  protein  investigations using  absorbable  techniques,  extraction  efficiency  was  often  neglected  in  the  description  of methodology for tear albumin analysis. Extraction protocols used for the determination of tear albumin are described in the subsequent section, which, is followed by the only two studies that provide actual efficiency data for the extraction of tear albumin.  3.6.5.1  Extraction  protocols  for  the  determination  of  tear  albumin  sampled  by  absorptive techniques.  Li  et  al,  (2010)  used  a  combination  of  100Mm  ammonium  bicarbonate  elution  buffer  and centrifugation at 14, 000 g for 10 min to elute Schirmer strips from controls and subjects with allergic  conjunctivitis.  Sample  volumes  of  the  Schirmer  strips  were  produced  by  in  vitro additions of known concentration solution of 1mg/ml of BSA and differences in weights between dry and wetted strips. Differences between the two study groups were apparent in total protein concentration as well  as  albumin  concentration.  Stuchell et al  (1984) and Farris  (1985, 1986) also  performed  in  vitro  spiking  of  Schirmer  strips  to  assess  tear  volume,  although  with  a different study setup and elution protocol. Schirmer strips were incubated in TMED‐acetic acid buffer    (0.01M N,N,N’N  tetra‐methyl‐1‐2‐deamoethane  in  0.029 M  acetic  acid)  at  a  pH  of  5.0. Volume  of  elution  buffer  was  measured  to  represent  a  1:10  dilution  of  the  calculated  tear volume.  The aim of the study by Stuchell et al was to compare Schirmer strip to microcapillary sampling and differences in concentrations of IgG, transferrin and albumin were found between the  two  techniques.  Studies  by  Farris  on  the  other  hand  investigated  contact  lens  wear  and keratoconjunctivitis  sicca  and  found  no  difference  in  serum  albumin  compared  to  controls. Whilst  the  in  vitro  spiking  of  Schirmer  strip  and  the  resultant  wetting  length  standards  help quantify  the  volume  collected,  neither  Li  et  al,  Stuchell  et  al  nor  Farris  focused  on  extraction efficiency.   Proud et al, (1990) used a different protocol for the elution of Schirmer strips to investigate the ocular allergic response. 300 µl of ethylenediaminetetracetic acid (EDTA), at a concentration of 40 mMol/L in saline, were added to the Schirmer strips prior to storage.  Volume collected was 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measured  by  comparison  the weight  of  strips  before  and  after  sampling  had  been  conducted. The  extraction  efficiency  of  the  protocol  was  not  detailed  but  the  group  were  able  to  show differences  between  subjects  receiving  an  allergic  challenge  (by  allergens  such  as  ragweed pollen and cat hair) and controls. Albumin concentrations sampled in the studies by Janssen and van  Bijsterveld  (1981,  1983,  1985,  1986)  using  filter  paper  discs, were  extracted  by  a  1  in  4 dilution of tear fluid in phosphate buffered saline but extraction efficiency was not determined. Thygesen  et  al  (1987)  measured  albumin  in  samples  collected  from  cellulose  sponges centrifuged at 2500 g  for  five minutes. They were able  to  identify  increased serum albumin  in study groups exposed to organic gases and vapours at fixed intervals, compared to controls. The extraction efficiency of the cellulose sponges was however not discussed.  3.6.5.2 Studies recording actual extraction efficiency of tear albumin from the Schirmer strip  An  early  study  by  Prause  (1979)  investigated  extraction  efficiency  of  albumin  from  spiked Schirmer strips. 10 µl of diluted albumin solution was applied to the notch of the Schirmer strip and allowed to diffuse for 1 minute. The filter paper strip was then cut up into pieces of 1 mm and placed into 500 µl of 0.002 sodium barbitol buffer at pH 8.6, after which it was centrifuged for  15 min  at  500g.  This  was  repeated  for  a  total  of  8  experiments  and  concentrations were assayed using immunoelectrophoresis. Elution of albumin using this protocol was shown to be incomplete and Prause recorded an average of 32 ng of residual albumin on the Schirmer strip.    Denisin  et  al  (2012),  recently made  a more  thorough  investigation  of  diffusion  based  elution from Schirmer strips. Recovery of lysozyme, human serum albumin, sIgA, lactoferrin and MUC4, amongst others, was determined  from spiked Schirmer  strips.  Five µl of protein  solution with known  concentration were  added  to  5mm2  squares  of  Schirmer  strip  paper, which were  then incubated  with  10µl  phosphate  buffered  saline  for  3  hours.  Concentrations  of  the  recovered solution were tracked over time and it was found that maximum extraction was reached after 3 hours.  Extraction  efficiency was  shown  to  be  highly  protein  dependent  and molecular weight and surface hydrophobicity were significant factors for retaining proteins on the Schirmer strip. Albumin was one of the proteins tested, which exhibited the best recovery efficiency where an average  of  9.5% were  lost  to  the  Schirmer  strip.  The  repeatability  of  the  protocol was  tested over  a  period  of  12 months with  270  Schirmer  strips  spiked with  BSA  and was  shown  to  be consistent. 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3.6.6 Summary of effect of sampling material on measured tear albumin concentration  A large variety of extraction protocols exist for tear fluid sampled by absorptive techniques but no  one  protocol  has  been  proven  superior  to  the  others.  These  investigations  show  that assessment of  the extraction of absorptive material  is something that  is often  ignored in study design.  By  keeping  sampling  technique  and  extraction  constant  across  the  study  population, discriminations between protein concentrations in different study groups can however be made. It is unadvisable to provide quantitative data without recognising study limitations and possible effects  of  selective  adsorption  to  the  substrate.  There  is  no  one  extraction  protocol  for  the analysis  of  albumin  concentrations  sampled  with  absorptive  techniques.  Taking  sampling material  into  account  is  important,  as  results  using  absorptive  techniques  could be  erroneous due to insufficient removal of albumin adsorbed to the substrate surface (Prause, 1979; Denisin, 2012). 
 








Table 21 demonstrates that an increase in albumin levels is exhibited with ocular disorders such as  dry  eye  (keratoconjunctivitis  sicca),  ocular  allergy  and  contact  lens‐related  problems, although it is unclear in these conditions whether leakage is causative or consequential.   Apart from  the  paper  of  Sen  and  Sarin  (1986a),  which  describes  albumin  concentrations  in  a  large range of disorders, reports of albumin in ocular disorders and diseases are fairly limited in their scope.  The  majority  of  research  focusing  on  albumin  and  ocular  disorders  identified  in  the literature concerned dry eye related syndromes and various  forms of conjunctival and allergic reactions.  Elevated  albumin  levels  have  not  been  effectively  linked  to  any  specific  disease  or ocular  pathology.  Thus  albumin  is  not  as  yet  a  biomarker  specifically  used  to  monitor  any individual ocular pathology. Bjerrum (1997) suggested  that an albumin:lactoferrin ratio above 2:1 was indicative of primary Sjögren’s disease, as this ratio was not seen for other connective tissue disorders. This has however not translated into clinical use and, as can be seen in Table 21, increase in albumin concentration is apparent in a range of disease states.   It  is  again  apparent  in  Table  21  that  the  use  of  the  less‐than  gentle  Schirmer  strip  and  filter paper  techniques  to  collect  tears  results  in  higher  albumin  levels  quoted.    For  example  two individual papers, which investigated albumin concentration in the tears of patients with allergic conjunctivitis  recorded mean  values  of  1430±820 mg/ml  (Li et  al,  2010)  and  the  significantly less 170±21.61 mg/ml (Sen and Sarin, 1986a).  Schirmer strip collection was used in the former study and microcapillary pipette was used to collect the tears in the latter.   The discrepancy in albumin  levels  detected  between  the  two  studies  is  likely  again  to  be  that  of  the  mode  of collection.  Irritation  of  the  conjunctiva,  seen  in  allergic  and  other  conjunctivitis  disorders,  is associated with symptoms like itching, burning, red eye and inflammation. This type of reaction can vary  in  severity, possibly  explaining  the  range of  concentrations  reported  in  and between studies of these disorders. Vernal conjunctivitis concentrations reported by Zavaro (1980) (590 µg/ml) and Sen and Sarin (1986b) (12.31±7.50 µg/ml) are however significantly different. Both studies sampled tears using microcapillary and analysed samples with immunodiffusion. Vernal conjunctivitis is characterized by massive infiltration of inflammatory cells (Leonardi et al 2008) leading to the expectation of increased plasma in the tear film and consequently higher albumin concentrations.  Different  population  subsets  and  stage  of  disease  during  sampling  might  be attributed to some of the disparity but further investigation would be valuable. Concentrations reported  by  Sen  and  Sarin  (1986b)  fall  within  the  range  of  normal  values  reported  in  atopic subjects  in  tables  17  and  18  on  several  occasions.  This  highlights  the  notion  that  “normal” albumin concentrations  in  the asymptomatic control and relative magnitude of  increase  in  the disease state might be dependent on the individual subject to a high degree. 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Albumin  concentrations  in  Table  21  are  shown  to  be  significantly  increased  in keratoconjunctivitis sicca, or as its more commonly known, dry eye.  Keratoconjunctivitis sicca is a  complex  syndrome  with  an  aetiology  that  is  not  wholly  understood.  A  good  review  of  the subject  is provided by  Johnson and Murphy  (2008).   Causes of dry eye  can be  related back  to deficiency in providing the aqueous tear portion or excessive evaporation. Tear ceruloplasmin, another diffused plasma protein, is increased in established dry eye but not in questionable dry eye  or  ocular  pemphigoid  (Mackie  and  Seal,  1984),  which  further  supports  multiple  disease pathways able to affect extent of plasma leakage.   3.7.3 Summary of effect of ocular health on measured tear albumin concentration  Research and an understanding of disease aetiology is needed to establish whether the presence of albumin in ocular disorders is purely a marker of the extent of inflammation or if other factors are  involved.  Inconsistent  tear  collection  and  assay  methodologies  make  cross‐study comparisons difficult.  Presently, the solitary diagnostic role of albumin in tears is as a marker of vascular permeability and plasma leakage.    In general however,  it  is clear that the incidence of ocular disorder results in the influx of this plasma leakage marker, although there is no link to specific diseases.   
3.8 Effect of contact lens wear on measured tear albumin concentration  3.8.1 Introduction   The  contact  lens  is  approximately  ten  times  thicker  than  the  aqueous  layer  of  the  tear  film within which  it sits  (approximately 70 µm vs. 7µm).  Interactions of  the  lens with  the  tear  film are both dependent on the material and the individual tear film of the wearer. Despite rigorous material development strategies and care regimes to reduce contact lens disorders, a portion of the population are still unable  to wear contact  lenses  for a prolonged period of  time, or at all. Symptoms most  often  experienced  are  end  of  day  discomfort  and  ocular  dryness.  It  has  been estimated that over 50% of contact lens‐wearers suffer from contact lens related dry eye, which affects the stability and integrity of the tear film (Begley et al, 2000; Nichols et al, 2002; Nichols and Sinnott, 2006). 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3.8.2 Effect of contact lens wear on measured tear albumin concentration  The current literature provides a very conflicting view on whether contact lens wear is causative of increased albumin levels or not. Studies can be split up into those assessing symptomatic and non‐symptomatic wear:  3.8.2.1 Non‐symptomatic wear  A study of albumin concentrations  in neophytes by Carney, et al  (1997) showed no significant difference at baseline compared to after one night, six nights or six months of extended contact lens wear. Similarly, subjects with long contact lens wearing experience exhibited no difference in concentration compared to non‐wearers (59.2± 54.0 µg/ml vs. 45.1± 32.5 µg/ml)(Baleriola‐Lucas et al 1997). Differences in the study by Baleriola‐Lucas were however found if the contact lens‐wearers were split up into groups with and without bacterial deposits on lenses. Albumin concentrations in subjects with bacterial deposits on lenses were 79.0 ± 60.1 µg/ml compared to 26.3 ± 12.1 µg/ml in the non‐bacterial deposit group.   3.8.2.2. Symptomatic wear  Lundh  et  al  (1984)  found  an  increase  in  tear  albumin  in  contact  lens‐wearers  experiencing difficulties with wear  ‐  termed abnormal wearers. These abnormal wearers presented with an altered  tear  eletrophoresis  profile,  trouble  when  wearing  lenses,  hyperemia  and/or  bulbar injection.  In  total  30  subjects  wearing  different  contact  lens  materials  (42  soft  hydroxyethyl methacrylate  lens‐wearers,  6  hard  polymethyl  methacrylate  lens‐wearers  and  2  methacryl methyl siloxane lens‐wearers) were analysed. Mean tear albumin concentrations were 85 µg/ml (25‐630), where levels inferior to 50 µg/ml were termed normal by the authors. Concentrations above 50 µg/ml were found in 70% of the determined abnormal wearers.  Farris (1985) on the other  hand  found  no  significant  difference  between  control  groups  and  phakic  or  aphakic contact lens‐wearers using either daily or extended wear modalities.  Interestingly, a significant difference  was  however  found  between  albumin  levels  in  the  different  control  groups  not wearing lenses. Sampling was conducted using periopaper (absorbent strips used for collecting gingival fluid) and the Schirmer strip, which might explain the larger concentrations of 380±640 µg/ml and 1830±2440 µg/ml  reported  in  reflex and basal  tears of  these  controls. Nichols and Green‐Church  (2009)  were  able  to  show  significant  increase  of  albumin  in  subjects  with identified  contact  lens  related  dry  eye  (by  questionnaire)  compared  to  normal  contact  lens‐wearers. 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The  over  night  tear  film  is  associated  with  albumin  increase  and  it  appears  that  overnight contact lens wear amplifies this increase (Choy et al 2004). Post‐sleep concentrations rose from 200  (150‐580)  µg/ml  to  540  (330‐1240)  µg/ml  with  lens  wear.    Extended  wear,  which incorporate  sleeping  in  the  lenses,  on  the  other  hand does  not  appear  to  affect  open  eye  tear albumin  concentrations  in  asymptomatic  subjects  on  the whole  (Carney et  al  1997; Baleriola‐Lucas et al 1997).   3.8.3. Summary of effect of contact lens wear on measured tear albumin concentration  Non‐symptomatic  wearers  of  contact  lenses  have  not  exhibited  any  differences  in  albumin concentrations  apart  from  groups  with  bacterial  deposits  on  the  lens.    Studies  investigating symptomatic  contact  lens  wear  on  the  other  hand  have  reported  some  changes  in  albumin concentrations,  although  sampling,  wear  modalities  and  control  variables  are  confounding factors.  Dry  eye  is  already  linked  to  increase  in  albumin  concentration  and  the  wearing  of contact  lenses  may  potentiate  or  initiate  dry  eye  symptoms  in  susceptible  subjects.  In  this scenario,  albumin  increase may  be  linked  to  the  presence  of  dry  eye  rather  than  contact  lens wear itself.  
3.9  Effect  of  analytical  technique  and  study  population  on  measured  tear  albumin 
concentration  3.9.1 Introduction  Choice of assay technique is limited by sample volume. Normal tear production rate is estimated to be between 1 and 2 µl/min and total tear volume has been estimated to be 7µl, whereof 3 µl is present  in  the  meniscus  of  the  eye  (Mischima,  1966).  Many  analytical  techniques  require volumes collected to be of a certain size to be able to identify lower levels of proteins or changes in concentration. Current proteomic and chromatographic techniques such as ELISA and HPLC are able to analyse smaller samples (1‐2 µl), as their sensitivity levels are in the range of ng/ml. Tear protein determinations made over 20 years ago were made with less sensitive techniques and  are  consequently  less  accurate.  Comparisons  between  different  studies  therefore  need  to address which analytical techniques were used to obtain the results. 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3.9.2  Effect  of  analytical  technique  and  study  population  on  measured  tear  albumin concentration  A variety of assays have been used over  the years  to ascertain albumin concentration  in  tears but no pattern of assay  influence has emerged  to  suggest  that  the assay of  investigation has a significant detrimental bearing on  the outcome. Effect of assay methodology  in  this  thesis was assessed  using  information  from  Table  18,  which  is  illustrative  of  albumin  concentrations without  the  confounding  factors  of  invasive  sampling  and  previous  stimulus.  Concentrations range from 10.3 µg/ml to 200 µg/ml, suggesting the presence of individual subject variation or variation  in  assay  sensitivity.  Immunodiffusion  is  only  a  semi‐quantitative  technique  and,  as represented by the range reported in four asymptomatic subjects (10‐200 µg/ml) by Berman et 






3.10 Factors affecting tear albumin concentrations: conclusion  This chapter was important for the identification of factors that affect albumin concentration in tears  and  their  interrelationship.    In  order  to  investigate  the  role  of  albumin  in  tears  (i.e. whether  albumin  is merely  present  as  a marker  for  the  leakiness  of  the  blood‐tear  barrier  or present  as  a  response  to  ocular  deviation  from  the  normative  state)  confident  albumin measurements must be possible. Any factors,  irrespective of whether  internal or external,  that produce albumin rich or deficient environments and mask the true tear film concentrations need to  be  evaluated  and  controlled.  Three  key  variables  were  identified  during  the  investigation presented in this chapter. They are summarised below:  
• Sampling  technique  is  critical  in  the  determination  of  albumin  concentration:  harsher techniques  (e.g.  Schirmer  strip)  stimulate  concentrations  that  are  significantly  greater than when the less invasive microcapillary method is used.  
• Insult  to  the  eye  and/or  ongoing  disease  states  are  associated  with  an  increase  in albumin levels but a direct link between albumin levels and disease aetiology is lacking.  
• Assay methodology  can  influence measured  albumin  concentrations  but  it  is  the  least influential  factor.  Modern  sophisticated  techniques  are  highly  sensitive  and  therefore this influence is less important than other factors.   Sampling  technique  appears  to  be  the most  influential  variable where  the  trend  of  increased albumin concentration with  filter paper  techniques  is  apparent even during ocular discomfort and disease (Table 21.). This trend could in part be explained by the fact that certain disorders, such as keratoconjunctivitis sicca and Sjögren’s Syndrome, are associated with a decrease in tear volume and flow rate and require a more invasive technique to collect adequate volume of tears. Nevertheless,  filter  paper  techniques  represented  a  mean  of  48  times  increase  compared  to microcapillary  levels  in  asymptomatic  subjects.  The  combined  effects  of  stimulation/irritation (which directly  affects  albumin  concentration),  and of  stimulation  (which  increases  tear  flow) are difficult to de‐convolute and also add to the complexity of assessing albumin concentrations. On‐going disease states and ocular insult are associated with an increase in albumin levels, but a specific  link  between  albumin  levels  and  disease  aetiology  and  insult  is  lacking.    The aforementioned  sampling  and  analytical  variability  make  this  link  all  the  more  difficult  to quantify. Reports of  increase in tear albumin concentration during contact  lens wear appeared to  be  limited  to  symptomatic  subjects. Whether  the  increase  is  a  result  of  subjects with  poor compatibility to the lens itself, or a result of subjects with an underlying ocular condition being 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4.1 Aim   No  systematic  research  into  diurnal  variation  of  albumin  in  the  waking  tear  film  has  been produced.  Diurnal variations are already established in albumin at other mucosal surfaces and also  in  other  blood  and  tear  components.  The  determination  of  albumin  concentrations throughout  the  day  is  necessary  for  further  research  into  albumin  and  could  also  supply important additional information regarding the extent and onset of the albumin increase in the closed eye. Consequently the aim of the research carried out  in this chapter was to  investigate albumin concentrations during waking hours and to observe the transition to the overnight tear film.  This  was  to  assess  if  albumin  levels  were  relatively  stable  (or  demonstrated  periods  of stability)  or  if  levels  had diurnal  variations,  similar  to  the  trends  observed  in  other  biological fluids.   
4.2 Introduction  Chapter 3 introduced the fact that relatively little  is known about human albumin levels  in the tear  film  under  normal  ocular  conditions.  Three  key  variables  were  identified:  sampling methodology,  ocular  health  and  analytical  technique.  Sampling  and methodology  factors  only represent external sources of variation, however, and internal variations differentiating albumin concentrations  in  subjects  are  just  as  important.  Unstimulated  microcapillary  collected  tears from healthy subjects were observed to have a range of albumin concentrations between 10.3‐200 µg/ml (section 3.5.2).   Disregarding the influence of assay variability, the large differences between  studies  suggest  the  presence  of  individual  variability  between  subjects. Acknowledgement of  subject‐to‐subject variation  is  important  in  the design of  future  research studies,  especially with  regards  to population selection. Differences between  individuals  could also  clarify  the  role  of  albumin  and  its  potential  benefits  in  tears,  or  alternatively  reveal individual  susceptibilities  towards  ocular  irregularities.  In  order  to  evaluate  the  possibility  of innate  albumin  concentration  differences  between  subjects  or  populations,  all  possible variations need to be excluded.   4.2.1 Diurnal variations of tear proteins  A review of data from the literature suggests that diurnal variation could have an affect on tear protein  concentrations.  Variations  across  the  day  of  several  tear  components  have  been 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observed.  For  example,  matrix  metalloproteinase  9,  an  enzyme  important  for  tissue maintenance and degradation of proteins in the extracellular matrix, is significantly elevated in the morning compared to the rest of the day (Markoulli et al, 2012).  Group IIa phospholipase A2, an‐  antimicrobial  protein  with  functions  similar  to  lysozyme  and  lactoferrin,  has  also  shown some diurnal variation. Concentrations in tears sampled with microcapillary increased between 8:00 hrs and 12:00 hrs and then decreased between 16:00 hrs and 20:00 hrs (Aho et al, 2003).  An  18  month  study  of  total  antioxidant  activity  in  tears,  measuring  low  molecular  weight antioxidants, also revealed a diurnal variation where concentrations peaked within 10 minutes of waking at 8:00 hrs and then decreased, reaching a minimal value at 12:00 hrs (Kowalski et al, 2009).  4.2.2 Diurnal variation of blood proteins  Diurnal variations of proteins in serum could potentially point towards similar variations when the  proteins  are  present  in  tear  fluid.  For  example,  inflammatory  cytokines  in  blood  have circadian or diurnal rhythms. IL‐1, IL‐10, TNF‐alpha and IL‐12 in blood are linked to the diurnal rhythm of  cortisol with  low  concentrations during  the  afternoon  and high during  the  evening (Petrovsky et al, 1998). Similarly, cytokines sampled in tears (IL‐1ß, IL‐1, IL‐10, IL‐12p70, TNF‐alpha)  have  been  observed  to  have  a  moderate  increase  in  concentration  in  the  morning, followed by a slight decrease  in  the afternoon and finally a significant  increase between 21:00 and 24:00 hrs  (Uchino et al,  2006). Total  serum protein has also exhibited a diurnal variation pattern (Seaman et al, 1965) with decrease in concentration during the night and early morning hours. Naturally, correlations cannot always be made between variations in plasma proteins and tear  proteins  but  investigation  of  alterations  in  plasma  may  give  some  information  about variations in tears.   4.2.3 Albumin in other biological fluids and mucosal surfaces  Diurnal variation has been shown to be a hugely influential factor on albumin levels detected in biological  fluids  and  mucosal  surfaces  other  than  tears.  In  blood,  serum  albumin  exhibits circadian  variation where  levels  remain  constant  during  the  day  (38‐45 mg/ml)  but  decrease significantly at night‐time to reach a low point between 02:00 hrs and 04:00 hrs (35‐38 mg/ml) (Jubiz et al 1972). Fluids at mucosal surfaces such as nasal secretions also appear to be subject to diurnal variations. Passàli and Bellussi (1988) found a progressive increase in albumin levels in  nasal  secretions  sampled by  cotton wool  swabs. A  25%  increase  in  concentration  from  the 10:00 hrs baseline was established every three hours up until and including the last time point at  04:00  hrs.  Two  other  studies,  assessing  nasal  lavage  fluid  (Greiff  et  al,  1996;  Zhang  et  al, 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4.3 Methods  4.3.1 Study population and sampling   4.3.1.1 Study population  13 healthy subjects without any observed ocular disease or disorder were recruited within the department for this study. The population consisted of 6 male and 7 female subjects with a mean age of 30 (range: 23‐46). No contact lenses were worn for the duration of the sampling period. In the case of subjects wearing contact lenses outside of the study, wear was stopped at least two days prior to the start of  the study. The sleep patterns  for all  the subjects were normal,  i.e. no subjects with  ‘unusual’  sleep patterns or  insomnia were  included. Subjects were also asked  to report any observations or discomfort during the sampling.    4.3.1.2 Tear collection  Sampling was  conducted  using microcapillary  tubes  as  detailed  in  the materials  and methods section.  Chapter  3  showed  that  a  relationship  between  tear  flow  stimulus  and  albumin concentrations  exists  and  these  variables  were  therefore  monitored.  Tear  flow  rate  was determined for all samples using the microcapillary tube etching and samples were recorded as being basal, medium or reflex tears.   Initially tear samples were collected by an experienced researcher but in order to sample during out of office hours, a subset of the study population were taught to self‐sample to collect these later  time  points.  Self‐sampling  was  done  by  standing  in  front  of,  or  holding,  a  mirror  and positioning the microcapillary pipette against the tear film in the lateral canthus, taking care not to touch the conjunctiva.  A stainless steel wire plunger was then used to dispel the sample into a labelled microcentrifuge tube. Samples were stored in microcentrifuge tubes at ‐80°C until time of  analysis but not  longer  than one week after  collection. For  the  sampling  time points  taking place  out  of  work  hours,  samples  were  stored  in  the  fridge  until  transit  to  a  ‐80°C  freezer. Studies by Sitaramamma et al  (1998b) detected no significant change in protein concentration after  1  week  of  storage  at  4°C.  Losses  of  albumin  due  to  the  handling  and  storage  in 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polypropylene microcentrifuge tubes have been estimated to be in the region of 10% (Denisin et 
al,  2012)  and  consequently  results  have  to  be  interpreted  with  this  error  margin  in  mind. Adherence to the microcapillary tubes during sampling is also a factor of variation but likely to be more  important  for  the  analysis  of  positively  charged  proteins  attracted  to  the  negatively charged glass surface, rather than albumin.  
 4.3.2 Sampling schedule 
 Subjects were divided into two populations according to the sampling schedule in Table 22.  This division was based on subject availability as well as  level of experience and confidence in self‐sampling by microcapillary.   Table 22. Sampling schedule  for both populations examining diurnal variation of albumin. 106 samples are common to both groups.  
    Subjects    Sampling Duration   Interval   Tear Samples Analysed 
 Number of Days 
 Group 1   13   10:30‐16:30 hrs   2 hours   199   2‐6 Group 2  5  Waking‐Bedtime  2 hours  307  9‐11   Group  1  (n=13,  7  female,  6 male)  had  tear  samples  collected  at  various  time  points  over  the working  day  for  a  minimum  of  2  consecutive  days  to  assess  diurnal  and  subject‐to‐subject variation.  199 samples were analysed in this group.  Group 2  (n=5, 4  female, 1 male)  comprised  the  subset of  subjects  trained  to  collect  their own samples.  Their first sample of the day was collected within 10 minutes of waking (before 8.00) and  then  a  sample was  collected  every  two  hours  until  22.30  in  the  evening  for  a  number  of consecutive  days  (3‐5  depending  on  subject  availability).  Early  assayed  results  suggested  a change  in  albumin  concentrations  as  the  day  progressed  into  evening.  Consequently,  Group  2 subjects  were  asked  to  extend  the  self  tear  sampling  to  include  extra  samples  up  to  and including a pre‐bed tear sample; the last two measurements being half an hour before bedtime and pre‐retiring  to bed  (at >17 hours post‐waking).   This was done  for  six additional days.  In total, 307 individual  tear samples were analysed for this part of  the study.   The sampling time for each subject in Group 2 was clock‐matched relating each subject’s rising to sleep pattern to 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time. This allowed for comparison between subjects with different sleep patterns and to relate the early risers and early to bed subjects with the late risers and late to bed subjects. The actual times of waking  and  retiring  to  bed  did  not  vary  between  subjects with more  than  an  hour  and  no subject woke up later than 08:00.  




 Distinct  variations  in  albumin  concentration  were  seen  in  the  study  population  between different subjects and in the population as a whole. The levels of albumin for individual subjects appeared to show minimum values and greatest stability during the time points 10:30  ‐ 14:30 hrs.  Concentrations    measured  over  successive  days  consistently  showed  little  variation  in subjects over  this  four hour period. Fig. 4.1  shows  the mean  tear  film albumin concentrations over successive days during these hours  for the 13 subjects.   Standard deviation  identified the slight  variability  for  each  individual  subject  between  sampling days,  indicating  the day  to day variation.  The  degree  of  between‐day  variability  differed  between  subjects  but  did  not overshadow the wide subject‐to‐subject variation evident by the distinct distribution curve. 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Figure. 4.1. Individual baseline albumin concentration for all subjects.  The results are expressed as mean concentration from sampling times between 10:30 ‐ 14:30 hrs for each individual over a period of  2‐6 successive days.  The relative stability during this daytime period can also be illustrated by looking at the mean, minimum  and  maximum  of  albumin  concentrations  for  all  subjects  at  three  individual  time points (10:30, 12:30 and 14:30 hrs).  These data presented in Fig. 4.2 show a small variation in mean  albumin  values  (8.4  –  11.6 µg/ml),  suggesting  again  that,  as  a  population,  this  is  a  time suitable for determining albumin concentrations.   
 Figure 4.2. Mean ‘stable’ albumin concentration for the study population, between the hours of 10:30 – 14:30 hrs over 2‐6 days. An average of 130  tear  samples were  taken during  this  time schedule. 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Furthermore, variations between subjects at these time points indicate the existence of a range of indigenous albumin concentrations in a population. This information is important for albumin studies and potentially the study of other proteins that albumin may be a marker for. It  is also valuable  for  the  investigation  of  whether  albumin  is  responsive  or  reactive  in  terms  of  its presence in the tear film as it might enable the distinguishing between different subject groups.   4.4.2. Evening rise in albumin concentration 
 Variation in albumin levels outside of the daytime period of relative stability was investigated in a  subset of 5  subjects  (Group 2).    Samples were  initially  taken at  two‐hourly  intervals  for 3‐5 successive days, which suggested a potential shift  in albumin concentrations towards the  later part of the day.   The study was then extended by 6 days and sampling times were amended to include a sample 30 minutes before bed and a pre‐retiring to bed sample. All sample data, within 10  minutes  post‐waking  (designated  0  hours)  to  immediately  before  retiring  to  bed  are displayed in Fig 4.3 in the form of a stacked graph.  
 Figure 4.3. Diurnal albumin concentration variation (n=5); all  sample  time points  including 10 minutes post‐waking (0 hours) and pre‐retiring to bed (17 hours).    The  data  collected  from  Group  2  revealed  a  previously  unreported  difference  in  albumin concentrations in subjects between daytime and evening, prior to bed, and show a clear pattern of variation within the waking day. These data illustrate that the levels recorded in Figures 4.1 and  4.2  (10:30‐14:30  hrs)  indeed  marked  the  period  where  albumin  concentrations  were  at 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their lowest and most stable for all subjects. From this it was decided to designate these hours a useful baseline period for the purpose of albumin sampling.   All  subjects  in Group 2  exhibited  the pattern of  variation  in  concentration between  the  stable time  period  and  the  evening  sampling  times.  The  data  indicates  the  presence  of  a  consistent asymmetric  diurnal  variation  during  the  hours  of waking  in  the  population.    The  asymmetric shift  is  illustrated  by  concentrations  decreasing  rapidly  in  the  first  two  hours  post‐waking followed by the period of stability.  Concentrations in the latter part of the day then exhibited a general  progressive  increase  up  to  16  hours  post‐waking  as  shown  in  Fig  4.3.  The  additional extended sampling time‐points, illustrated at 17 hours post‐waking, demonstrate an even more prominent  albumin  increase  similar  to  post‐waking  concentrations  (which  are  already established in the literature as being increased). Although all subjects showed an increase in the evening  albumin  levels,  some  disparity  among  the  subjects  existed.  Two  subjects  (3  and  13) showed  marked  increase  after  20:30  but  the  remaining  three  subjects  showed  an  earlier progressive  increase.    Subject  9,  interestingly,  differed  from  the  rest  and  did  show  increasing albumin concentrations from baseline but peaked at 12 hours post‐waking and exhibited a small decrease pre‐retiring to bed. Although the baseline levels of albumin varied among subjects, the data  shows  that  the  concentration  of  albumin was  higher  in  samples  collected  in  the  evening (and upon waking) compared to samples collected during the daytime schedule. This difference in  albumin  concentrations  between  the  daytime  and  the  evening  tear  film  was  shown  to  be statistically  significant  (P  <  0.05,  paired  student’s  t‐test).  The  differing  modes  in  which  the established diurnal variations present  itself merely highlights that albumin concentrations are, to a high degree, affected by individual subject variations in tear film response.   Although  the  rapid drop  in  levels  following waking  is  to  some extent predictable,  the gradual and consistent observed rise in albumin levels that has been shown here to take place during the evening  has  not  been  previously  characterised.    Samples  in  Group  2  taken  immediately  post‐waking  and  pre‐retiring  to  bed  were  significantly  higher  in  albumin  than  at  any  other  time.  These values  appear  to  characterise  a  transition  from and  to  levels  observed  in  the overnight tear film (Sack et al, 1992)(Tan et al, 1993). To further illustrate the apparent shift from lower to higher albumin concentrations during  the day, a  frequency distribution of all  sample data was calculated (Fig 4.4.). 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Figure  4.4.  Frequency  distribution  of  the  occurrence  of  specific  albumin  concentrations  in samples  collected  during  the  daytime  (2‐8  hours  post‐waking)  and  evening  (10  hours  post‐waking).    This  showed  that  76%  of  tear  film  measurements  during  daytime  hours  presented  levels  of albumin  below  15  µg/ml.    Higher  concentrations  of  albumin,  on  the  other  hand,  occurred predominantly  or  exclusively  in  the  evening  tear  film.  These  data  imply  that  the  evening  tear film  (post  10  hours  waking)  is  a  different  environment  to  the  daytime  tear  film  and  has  a significantly altered protein composition with respects to albumin.   
4.5 Discussion  
 A novel asymmetric pattern was  identified  in this study, which was evidenced by: a high post‐waking  albumin  concentration;  a  rapid decrease  leading  to  the  lower  ‘stable’ midday  albumin levels;  and  finally  a  progressive  increase  in  albumin  levels  towards  the  latter  part  of  the  day.  This  late‐day  increase may mark  the  early  compositional  changes  associated with  that  of  the closed eye overnight tear fluid, which has been shown to be a tear fluid rich in plasma proteins including  a  high  albumin  concentration  (Sack  et  al,  1992;  Tan  et  al  1993).  Excluding  the  two extremes related to the overnight tear film (within 10 minutes post‐waking and pre‐retiring to bed, there is still a trend of increased albumin towards the end of the day (Fig 4.3).  This pattern of  progressive  increase  differed  slightly  in  one  subject  (subject  9);  the  highest  levels  were detected  after  12  hours  post‐waking  with  a  slight  dip  immediately  pre‐retiring  to  bed.    The variation in behaviour supports the notion that the tear film is not uniform between individuals and indicates that there exist many divergent subsets of people with varying tear composition.  The  observed  end‐of‐day  concentrations were  between  two  and  four  times  higher  than  their daytime tear film baseline stable levels.  These variations observed go well beyond anything that 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could  be  explained  by  tear  flow  variation.    Subject‐to‐subject  tear  flow  may  differ  but,  as previously  stated,  each  individual  subject  demonstrated  the  same  response  to  the  stimulus  of microcapillary sampling throughout the sampling schedule.   The  significant elevation  in  concentration observed  in  the  current  study,  in  the  samples  taken within  10  minutes  post‐waking  accords  with  the  trends  observed  in  the  literature,  which demonstrate  similarly  high  post‐waking  values.  Two  previous  studies  have  assessed  albumin variation  in  part.  Ng  et  al.  (2000b)  investigated  between‐day  variation  over  a  period  of  three days  (samples  collected  between  the  hours  of  13:00  and  18:00  hrs)  and  found  no  statistical difference in either total tear protein content or major tear protein fractions, including albumin.  Secondly  a  study  by  Sack  et  al  (1992)  assessing  overnight  variation,  found  no  statistical difference in albumin concentration for the open eye state of the tear film (samples collected at 12:00 and 17:00 hrs) apart from elevated levels 10 minutes post‐waking.  Both studies present results,  which  correspond  to  the  present  findings  in  terms  of  the  stability  of  albumin concentration  in  the  tear  film  during  the  daytime  under  normal  ocular  conditions  and  the elevated  post‐waking  albumin  levels.  The  actual  concentration  of  albumin  in  the  post‐waking samples investigated in this study is however somewhat lower than those levels reported in the literature.  This can be explained by the fact that the levels reported in the literature correspond to  tears  collected  immediately  upon  eye  opening  (in  order  to  represent  the  closed  eye environment), whereas the samples analysed here represent a more acclimatised sample taken in the region of 10 minutes post‐waking.  The results presented in this chapter clearly demonstrate a pattern of diurnal variation during waking hours, which has not been previously identified.  This should perhaps not be regarded as unusual  as  it  is  similar  to  the  circadian  rhythms  of  many  mucosal  surface  fluids,  which  also experience  plasma  leakage,  that  have  been  explored  in  detail  and  show  clear  and  defined changes in albumin concentration during the day (section 4.2.3).  The assayed albumin levels in the present  study were  found  to be most  consistent at approximately  two and six hours post‐waking.  This represented the most stable tear film in terms of albumin concentrations and was subsequently  designated  as  baseline.    Whilst  concentration  levels  during  these  hours  varied slightly  within  individual  subjects  between  the  different  sampling  days,  they  tended  to  fall within  a  narrow  bracket  (i.e.  a  subject  displaying  lower  levels  of  albumin  would  do  so consistently).  The  range  of  albumin  levels  exhibited  at  the  designated  baseline  in  the  present population indicates that subjects appear to have indigenously lower or higher levels of leakage.  These variations at the defined baseline suggest the existence of a range, or range of subsets, of individual  albumin  concentrations  within  a  population.  The  underlying  baseline  albumin 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Concentrations  reported  in  the  literature were collected between  the hours of 9:30 and 17:00 hrs.  The  corresponding  concentrations  obtained  in  the  current  research  (3.5  –  19  µg/ml)  are within  the range of  literature concentrations minimum (1.1 µg/ml) and maximum (80 µg/ml). Apart  from deviation  related  to  assay methodology  (only Baleriola‐Lucas et  al,  1997 used  the same  analysis  method  as  the  present  research)  it  is  reasonable  to  attribute  concentration differences compared to the literature with variation in population, or more specifically subject‐to‐subject  variation.    Both  the  research  presented  in  this  chapter  and  the  reported  literature values exhibit standard deviation as large as the mean reported. This is identified as subject‐to‐subject  variation  in  the  current  research  and  presumably  a  result  of  a  similar  effect  in  the reported  literature  concentrations.  Subject‐to‐subject  variation  can  clearly  exert  a  significant influence  on  measured  albumin  concentrations.    In  this  table,  it  is  evident  that  only  by measuring albumin concentrations in the same individuals over various time points within and between days can the effect of diurnal variation be distinguished from that of subject variation and they can be effectively determined. The majority of other reported studies, not included in this  integrated  table (tables 17, 18 and 21), do not state sampling  times but are  likely  to have been  restricted  by  opening  hours  in  clinics  and  research departments.  Consequently,  albumin sampling will  have  been  performed within  this  time  frame, which  fortunately  falls within  the time  period when  albumin  concentration was  found  to  be most  stable  in  this  study.    Studies outside  of  this  stable  daytime  period  run  the  risk  of  adding  a  diurnal  variation  factor  to  the already long list of possible variations that can affect albumin concentration.    The evaluation of the literature in chapter 3 highlighted factors that affect the measurement of albumin  concentration  in  tears.  Similarly,  the  research  by  Sack  et  al,  (1992)  provided  some useful information on the design of this type of investigation.  In this study as many as possible of the factors identified in chapter 3 and by Sack et al were negated by the control of the careful selection  of  population.  Our  research  group  has  extensive  practice  in  tear  sampling  and  self‐sampling  results  were  validated  by  comparison  with  tear  samples  taken  by  experienced researchers.  Although different subjects responded in different ways to sampling stimulus, the behaviour  in  the assembled group was consistent  throughout the day. Other  important  factors that were considered for the assessment of diurnal variation in albumin concentration are tear flow  rate  and  tear  volume.  Menisci  heights  are  indicative  of  tear  volume  and  have  shown significant  increase  immediately  after  waking,  with  subsequent  stabilisation  to  normal  levels within an hour, supporting the notion of an altered ocular environment during sleep (Shen et al, 2008).  No  difference  however,  was  found  in  the menisci  height  throughout  the  day  or  in  the evening  just before bed, suggesting that altered tear volume is not responsible  for the evening shift  seen  in  albumin  concentrations  in  this  study.    This  is  further  supported  by  the measurement  of  tear  evaporation  by  Tomlinson  and  Cedarstaff  (1992).  Evaporation  was 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measured  at  two‐hourly  intervals  for  14  hours  using  resistance  hygrometry  and  was  lowest upon waking and then rises within two hours to consistent values  for  the rest of  the sampling period. Similarly diurnal variation of tear osmolarity, measured between 8:00 and 17:00 hrs by TearLab®, has been shown not to be statistically significant (Oncel et al, 2011).    In the present study,  tear  flow  rate  was  carefully  monitored  for  each  subject  using  the  grading  on  the microcapillary  and  correlating  collection  time with  collection  volume. While  tearing  response was  different  between  subjects,  tear  flow  rate  did  not  deviate  significantly  within  a  subject between collections throughout the day. This, together with the literature data above, suggests that the diurnal variation shift  in seen in the evening is a real phenomenon and not a result of altered lacrimation dynamics.   It  is  also  important  to  remember  the  variety  of  functions  performed  by  albumin  in  plasma (section 1.4.3). The versatility of albumin to bind a large variety of ligands with high affinity and its high concentration in plasma expands the possible consequences of the late evening albumin increase  in  tears.  It  might  denote  an  albumin  mediated  ligand  effect  rather  than  being  a reflection of albumin concentrations on their own. E.g. albumin could provide extra fatty acids to improve  the  stability  of  the  lipid  layer  or  bilirubin  to  increase  antioxidant  activity  in  the  tear film. In addition to this, other plasma components able to move in similar ways to albumin need to be evaluated as albumin may only be a marker of effects by other components. The potential consequences of the altered ocular environment in the evening presented in this study cannot be properly  ascertained  until  the  specific  roles  of  albumin,  its  ligands,  and  other  plasma  derived proteins which are also increased overnight have been determined.   
4.6 Conclusion  A  distinctive  asymmetric  pattern  throughout  the  waking  day  was  established,  which encompassed  individual  subject‐to‐subject  variation  in  absolute  concentration  levels.  Importantly,  this work highlights for the first time a consistent pattern of variation in albumin concentration  throughout  the  day.  The  effect  of  vascular  leakage  on  the  ocular  surfaces  is  at present  poorly  understood  and  it  is  unclear  whether  albumin  levels  rise  simply  as  a consequence of external  insult and vascular  leakage, or as a means of protection of  the ocular environment through the recruitment of plasma components. The fact that increases in albumin levels  occur  in  conjunction  with  a  number  of  ocular  disorders  has  been  widely  established (chapter  3).  Similarly,  the  closed  eye  environment  has  increased  albumin  and  is  described  as exhibiting sub‐clinical inflammation. In line with ocular disorders, this is a non‐specific link. The research  presented  in  this  chapter  shows  increases  in  albumin  in  the  seemingly  healthy  eye, prior to the eye closure that triggers the hypoxic state of the cornea and the change in tear fluid 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5.1 Aim  The aim of the experiments presented in this chapter was to further compare and assess the two most  commonly  used  and  commercially  available  sampling  techniques  (Schirmer  strip  and microcapillary) and their impact on the collection of tear albumin. Ultimately, the purpose was to  evaluate  their  suitability  for  use  in  conjunction  with  automated  point‐of‐care  analysis  in contact  lens  clinics.    Microcapillary  sampling  has  little  impact  on  the  observed  tear  albumin concentrations  and  is  comparatively  non‐invasive.  Schirmer  strip  sampling  is  harsher  but  has other benefits and is useful for subjects with low tear volume, where microcapillary sampling is more difficult. The Schirmer strip also requires less training than microcapillary before use, and tear  flow  is  easily  assessed.  Most  importantly,  the  Schirmer  strip  is  already  an  accepted  and widespread  technique  routinely  used  in  contact  lens  clinics  and  would  therefore  be  highly suitable  for point‐of‐care analysis. However,  these benefits are reduced if  the  induced albumin increase  overrides  any  possibility  of  discerning  and  discriminating  between  albumin concentrations in a population.  
5.2 Introduction 
 The  research presented  in  the previous  chapters highlight  the  fact  that  albumin  is  still  poorly understood in the tear film and that there is a need to gather additional data sets. Requirements for the undertaking of albumin research have also been identified. Important factors to consider are diurnal variations, consistency in sampling and assaying technique, and population selection. Contact lens clinics are ideal locations for recruiting larger populations for tear film research for several reasons. Follow up routines and regular eye checks for customers enable study subjects to  be  assessed  over  longer  time  periods without  extra  effort  involved  on  the  subject’s  behalf. Visual assessments of the tear film are also conducted during appointments, and can therefore be  correlated  with  any  subsequent  albumin  results.  Furthermore,  as  shown  in  chapter  4, albumin concentrations are  relatively  stable during  the daytime, which  corresponds well with normal  opening  hours  of  clinics  and  research  centres.  The  negative  aspects  of  sampling  in  a commercial  setting  are  the  issues  surrounding  sample  analysis  and  tear  collection.  Loss  of protein, through degradation and adsorption to the sample vial, has been shown to be a factor during long periods of storage (Sitaramamma et al 1998b) and sample transit between contact lens  clinics  and  laboratories  will  promote  such  degradation.  Additionally  there  are  few laboratories  available  for  tear  film protein  analysis, which will  increase  the  cost  and  the  time 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frame of obtaining the results. There will also still be a factor of variability imposed by the assay methods  employed  at  different  research  laboratories.  A  solution  to  sample  analysis  problems might  be  to  utilise mobile  analysis  devices  that  are  able  to  assay  the  tear  fluid  sample  in  the clinic and provide the practitioner with the results within the duration of the appointment. For these reasons, it was decided to investigate point‐of‐care analysis as a solution to avoiding some of  the  sampling  and  assay  related  albumin  variations.  Point‐of‐care  analysis  is  performed  by small automated bench‐top, or handheld, analysers and is usually fast (<10 minutes) and simple. It  is already prevalent  in  the quantification of proteins  in other biological  fluids  for diagnostic purposes e.g blood glucose  in diabetes and urinary albumin  in microalbuminuria (Warsinke et 
al, 2009). Further details on point‐of‐care analysis are provided in chapter 6.  Inconsistency in tear sampling protocol provides another source of variation between tear film studies.  In terms of use  in contact  lens clinics,  the choice of  tear sample technique also carries ethical  concerns. Microcapillary  tear  sampling  represent  the  least  invasive  sampling  tools  but requires  training  and  rigorous  assessment.  Schirmer  strips  on  the  other  hand  are  already routinely used in clinics and would not pose any ethical issues if used for albumin sampling. The assessment of reported albumin concentrations in the literature showed a correlation between increased levels of albumin and filter paper based sampling techniques (section 3.5.2). Reported albumin concentrations sampled by Schirmer strip are almost 50 times greater compared to the less  invasive  microcapillary.  Similarly,  directly  comparative  studies  revealed  an  increase  in plasma products, including albumin, with Schirmer strip sampling (Stuchell et al, 1984) although these were not always quantitative (Grus et al, 2005)(Green‐church et al, 2008). The literature, however,  lacked  detailed  commentary  on  Schirmer  strip  wetting  profiles  and  microcapillary stimulus,  which  require  more  in‐depth  analysis.  It  is  therefore  important  to  investigate  the suitability of Schirmer strip sampling further.  5.2.1 Objectives for the evaluation of Schirmer strip sampling  The  majority  of  assay  methods  used  in  the  literature  to  quantify  albumin  concentrations  by Schirmer strip were less sensitive compared to modern assays e.g. ELISA and HPLC (Table 17). Thus the  first research objective was to assess Schirmer strip sampling with ELISA analysis  to evaluate  if  the  technique  produces  similar  concentrations  and  good  discrimination  between subjects.  A  subset  of  sampling  protocols  in  the  literature  has  only  assayed  portions  of  the Schirmer strip  rather  than  the strip as a whole  (Shoji et al, 2003; Zhou et al, 2008; Grus et al, 2005).  Therefore,  the  distribution  of  albumin  in  worn  Schirmer  strips  was  also  assessed  to examine  the  diffusion  rates  of  albumin  and  the  validity  of  selecting  sections  for  analysis.  The second  objective  of  this  investigation  was  to  confirm  and  expand  upon  the  discrepancies  in 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albumin  levels  found  between  sampling  methodologies  in  the  literature.  This  was  done  by comparing albumin  levels  in  a population  sampled by both microcapillary  and Schirmer  strip, paying special attention to individual response to sample stimulus.   5.2.2 Choice of extraction protocol for the evaluation of Schirmer strip sampling  Schirmer strip extraction was discussed in chapter 3 (section 3.6) and showed a large variation in protocols. Furthermore, albumin specific extraction data was even more scarce and in some parts  conducted  more  than  20  years  ago.  Choice  of  extraction  technique  was  therefore important for the analysis of albumin in worn Schirmer strips. A study carried out in the Aston University Biomaterials Research Unit, prior to the present research, necessitated the evaluation of Schirmer strip extraction protocols. The aim of the study was to design an extraction protocol for Schirmer strips obtained from a contact lens clinic. Ten different protocols and five different extraction buffers were assessed, covering phosphate buffers at a range of pHs and acetonitrile trifluoroacetic acid buffer.   The experiments devised  to compare extraction protocol were of a spike and recover type, where 5µl of microcapillary tear samples were added to Schirmer strips and allowed  to diffuse. The wet portion of  the  strip was  then dissected and placed  in  a 500µl microcentrifuge tube before it was subjected to the various extraction protocols. Electrophoretic protein profiles of the extracted sample and the original microcapillary sample were compared using  the  Agilent  2100  Bioanalyzer,  as  described  by Mann  and  Tighe  (2007),  to  evaluate  the extraction protocols. Centrifugation without the addition of buffer solution was shown to be on par  with,  or  preferential,  to  the  other  protocols.  In  this  method,  a  hole  is  punctured  in  the bottom  of  the  500µl  microcentrifuge  tube  containing  the  Schirmer  strip  sample.  The  500µl microcentrifuge  tube  is  then  placed  in  a  1.5  ml  microcentrifuge  tube  and  centrifuged  for  5 minutes  at  10,000g,  after which,  the  residual  liquid  in  the  larger  tube  is  collected  for  analysis (section 2.4.3).    Benefits  of  the  described protocol  are  that  it  is:  fast  and  cheap with  a  simple procedure and  it exhibits a good protein profile  in comparison to  its respective microcapillary collected tear profile.   Schirmer  strip  samples  in  the  present  experimental  research were  therefore  collected  by  this centrifugation protocol without the addition of elution buffer. This choice was made with several factors  in  mind.  It  was  important  to  maintain  a  good  correlation  in  protein  content  with microcapillary  samples,  while  avoiding  extraction  mediums  that  could  affect  the  subsequent ELISA analysis or future point‐of‐care systems. Another factor was the ease and simplicity of the protocol  and  the  proven  usefulness  for  extracting  samples  obtained  in  a  clinical  setting.  An additional benefit was keeping sample techniques consistent within the departmental research. Information  in  the  literature did not  suggest  that  centrifugation was unadvisable compared  to 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other protocols  (section 3.5) but  it  is  fully  recognised  that  the  resultant  sample value  is not  a complete representation of the albumin concentration sampled by the Schirmer strip. It should also be noted that the present study was conducted before the research of Denisin et al, (2012), described in section 3.5, was published and was thus unable to benefit from the results of that particular investigation.  
 
5.3 Detailed concentration analysis along the sampling length of the Schirmer strip.   The aim of this experiment was to investigate the validity of choosing sections of Schirmer strips for  analysis  rather  than  extracting  the  whole  strip.  This  was  done  by  analysing  albumin concentrations in worn Schirmer strips to assess albumin diffusion through the Schirmer strip.   5.3.1 Schirmer strip collection and preparation  Samples used  for  the  assessment  of  diffusion of  albumin  along  the  filter  paper were obtained from 9 worn Schirmer strips. Schirmer strips were obtained both from an off site clinical study population (6) and from one subject in the university research department (3). Schirmer strips from the clinical study were collected from healthy non contact lens‐wearers and were supplied whole in eppendorf microcentrifuge tubes. Samples had been labelled with wetting lengths and eye  of  collection,  and  were  stored  at  –80  °C  until  time  of  analysis.  No  ocular  discomfort  or abnormality was reported in the subjects during the sampling. It was impossible to control time of sampling in the clinical population as rigorously as in the samples collected in the university department. All samples were however collected during working hours (9:00‐17:00 hrs).   Schirmer strips were cut up  into portions, using scissors, and assayed  in sections of 5 mm (0‐5mm, 5‐10mm, 10‐15 mm etc.), including the bent section forming the lip over the lower eyelid. The whole  Schirmer  strip was  dissected  for  samples  from  the  clinical  study,  which  had  been stored, but only  the visibly wetted sections were dissected  from the subject  from the research department. This dissection took place immediately after sampling, before the albumin had time to  diffuse  across  the  entire  strip.  The  dissection  protocol  provided  7‐9  samples  for  every Schirmer  strip.  Schirmer  strips  were  characterised  by  wetting  lengths  and  divided  into  two groups  17‐21 mm  and  35 mm,  to  distinguish  between medium  and  full wetting  of  the  strips. Schirmer  strip  sections  from  the  clinical  study  population  were  weighed  before  analysis  to assess  inter‐  and  intra‐Schirmer  strip  weight  differences  and  subsequent  relationship  to albumin concentrations. Dry unworn Schirmer strips were also manually dissected and weighed to assess the error associated with the procedure. 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 SS1  SS2  SS3 Bent lip  1.494  1.633  1.697 0‐5 mm  1.847  1.915  2.067 5‐10 mm  2.099  2.191  2.152 10‐15 mm  2.260  2.053  2.040 15‐20 mm  2.150  1.982  2.035 20‐25 mm  1.989  2.041  1.798 25‐30 mm  1.785  1.977  1.671 30‐35 mm  1.829  2.052  1.829 
Sum  15.453  15.844  15.289 
SD  0.2442  0.1619  0.1841  There was consistency across  the Schirmer  strips  in  terms of  total weight and section weight.  The  bent  lip  is  rounded  and  has  a  smaller  area  compare  to  the  other  sections.  Differences  in weights between the bent  lip and the other sections are therefore ascribed to  this variation  in size rather than an expression of error when cutting. Consecutive weighing of the same Schirmer strip  section was  also  shown  to  be  very  consistent.  Consequently, weight  differences  seen  on worn Schirmer strips are unlikely to be a result of the dissection procedure. 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20mm Bent lip  3.150  1.553  1.476  1.714  1.606  2.388 0‐5 mm  3.448  2.096  1.882  2.086  2.605  2.624 5‐10 mm  4.111  2.258  1.970  2.413  2.663  2.702 10‐15 mm  4.263  2.220  1.939  2.291  2.948  2.583 15‐20 mm  4.119  2.386  1.961  2.526  2.837  2.143 20‐25 mm  3.864  2.238  1.935  2.082  3.172  1.887 25‐30 mm  3.112  2.240  1.236  2.250  2.776  1.945 30‐35 mm  2.732  2.540  2.567  2.628  2.962  2.203 
Sum  28.799  17.531  14.966    17.990     21.569  18.475 




Section  SS1  SS2  SS3  SS4  SS5  SS6  SS7  SS8  SS9 
B­L  17.76  <6  83.74  >460  359.36  47.61  >460  >460  >R 
0­5 mm  15.50  60.28  194.63  >460  >460  25.76  413.42  110.1  66.1 
5­10 mm  19.16  73.00  190.62  >460  >460  37.03  202.70  105.5  67.2 
10­15 mm  22.77  <6  >460  >460  452.09  136.62  160.40  46.53  53.8 
15­20 mm  168.45  66.75  >460  146.26  216.43  >460  132.25  10.76  69.8 
20­25 mm  >460  25.62  >460  188.10  143.98  >460  146.74  /  48.3 
25­30 mm  415.31  <6  >460  192.23  <6  126.27  122.73  /  / 
30­35 mm  435.51  31.92  >460  208.54  <6  71.3  /  /  / 
 It  was  impossible  to  produce  the  aggregate  albumin  concentration  of  the  Schirmer  strips  as some samples had values outside the range of the ELISA assay. Samples were re‐assayed in these circumstances  but  this  was  only  possible  to  do  twice  due  to  limited  sampling  material. Consequently, a subset of samples are  labelled >460 or <6 µg/ml (above or below range). The majority of the bent lip sections were above the range of the assay. This is not surprising as the presence  of  the  Schirmer  strip  in  direct  contact  of  the  epithelial  lining  of  the  lower  eyelid  is likely to produce irritation and produce increased albumin concentration. Previous research on Schirmer  strip  albumin  sampling  revealed  a  larger  portion  of  epithelial  cellular  debris  in samples  taken  by  Schirmer  strip  compared  to  microcapillary  sampling  (Green‐church  et  al, 2008).  
 In  general  the  results  in  Table  26  show  significant  heterogeneity  in  albumin  concentrations within the Schirmer strip. SS1 exhibits significantly more albumin in sections 25‐30 mm and 30‐35 mm compared to the other sections. This Schirmer strip was also significantly heavier than the  other  Schirmer  strips  (Table  25),  which  signifies  large  volumes  of  tear  fluid.    During sampling, this large flow of volume, or reflex tearing, may have diluted the albumin bound to the top of the strip and transferred it to the bottom sections. Similarly to SS1, SS3 exhibits increased concentrations in the bottom sections whereas SS4 shows the opposite profile. SS2, SS5, SS6 and SS7 show more randomised albumin concentrations although the samples outside of the range makes  it  harder  to  determine  an  exact  profile. Here  it  is  apparent  that  only  assaying  the  first 5mm  or  10mm  of  the  Schirmer  strip  would  produce  results  inconsistent  with  the  profile obtained by assaying the whole strip. Only in SS8 and SS9, which were dissected before storage, can  this  approach  be  justified.  On  the  other  hand,  SS7 was  also  dissected  before  storage  and would not be suitable for analysing the first 10 mm only. 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5.4.    The  Analysis  of  albumin  concentrations  in  worn  Schirmer  strips  to  determine 




(µg/ml) 1015 SK  1:1000  >R   1:1500  304.2   1:2000  296.1 1017 MS  1:1000  >R   1:1500  261.5   1:2000  233.2 1019 MC  1:1000  21.2   1:1500  19.3   1:2000  18.9 1020 CS  1:1000  153.4   1:1500  159.7   1:2000  155.2 1028 HU  1:1000  23.2   1:1500  23.5   1:2000  23.4 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(µg/ml) 1019 MC  35  19.80 1024GBL  35  21.44 1028 HU  35  23.40 1024 GBR  35  27.25 1016 SK  35  27.30 1015 RA  35  38.60 1020 CS  33  156.11 1015 SK  31  300.17 1017 MS  13  247.37 
  117 
5.5  Comparison  between  Schirmer  strip  and  microcapillary  sampling  of  tear  albumin 
concentrations.   Albumin  concentrations  were  determined  in  a  population  sampled  by  Schirmer  strip  and microcapillary. The purpose of this was to further investigate the discrepancies between the two techniques  reported  in  the  literature.  Special  attention  was  paid  to  Schirmer  strip  wetting profile  and  tear  flow  stimulus  by  sampling.  Ultimately,  the  aim  was  to  see  whether  it  was possible to distinguish between albumin concentrations  in  individuals, or group of  individuals, with  Schirmer  strip  sampling  and  if  results  could  be  related  back  to  microcapillary concentrations.  5.5.1 Methods  5.5.1.1 Tear collection and study population  Albumin levels were examined within a population of 10 subjects (5 male, 5 female, mean age 30 years). None of the subjects wore contact lenses during the sampling or had any external signs of ocular disorder. Tear samples were collected by an experienced researcher and all sampling was conducted  in  the  same  one‐hour  period  (15:30‐16:30)  to  avoid  any  time‐related  variables. Firstly, tear samples were collected from the subject’s left eye using microcapillary and secondly from the subject’s right eye using the Schirmer strip. A detailed description of sample collection protocols  is  given  in  chapter 2. 4µl of  tears were collected by microcapillary  from  the  left  eye and samples were recorded as being reflex, basal or slightly stimulated (medium) based on tear flow  rates.  Post  microcapillary  sampling,  a  Schirmer  strip  was  placed  into  the  right  eye  and removed  after  5 minutes.  The wetting  length  at  this  time was  recorded.  If  the  strip was  fully wetted prior to the allotted five minutes, the strip was removed at the time of full wetting and this time was recorded. In total 20 samples were collected from the population.   5.5.1.2 Tear sample processing and analysis  Collected  microcapillary  tear  samples  were  expelled  into  individual  650  µl  microcentrifuge tubes by a sterile wire plunger. The Schirmer strip  fluid was collected by centrifugation of  the whole  strip  in  an  eppendorf  microcentrifuge  tube,  as  described  in  section  2.4.3.  It  should  be noted  that  1  Schirmer  strip  sample  (subject  3)  had  a  wetting  length  below  14 mm.  Previous studies  in  the  research  department  have  shown  that  this  low  wetting  length  necessitates  an addition  of  4  µl  of  deionised  water  to  the  Schirmer  strip  in  the  microcentrifuge  tube  before centrifugation to collect sufficient amount of fluid. Whilst this does have a small dilution effect, it 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doesn’t have a major effect on resultant concentration value, as can be seen in subsequent result sections where subject 3 still presented with the highest measurable amount of albumin.   Samples  were  analysed  using  the  Immunology  Consultants  Laboratory  ELISA.  Microcapillary samples were diluted at 1:200, which ensured that  the majority of samples were within range during assaying.   Assayed Schirmer  strips  in  the  clinical population produced a  large  range of concentrations  (section  5.4.3).  Samples  in  the  present  experiment  were  therefore  initially assayed at 1:1500, which appeared to place the majority of concentrations within the range of the assay.  5.5.2 Results  5.5.2.1 Population demographic and response to sampling technique  The sample collection data and population demographic  is displayed  in Table 29. This enables the comparison of Schirmer wetting length, wetting time and microcapillary tear sampling flow in the population.   Table 29. Population demographic and sample collection data of the parallel microcapillary and Schirmer strip sampling.   Subject  Gender   Age  Schirmer  length (mm)  Wetting time  (min, sec)  Microcapillary  tear sampling flow 1  F  25  21  5  Medium 2  M  22  26  5  Reflex 3  F  29  13  5  Basal 4  F  23  33  5  Basal 5  M  26  17  5  Reflex 6  M  44  35  3 min 20 seconds  Reflex 7  F  24  21  5  Basal 8  M  25  35  1  Reflex 9  M  39  30  5  Reflex 10  F  40  35  39 seconds  Medium 
 The mean Schirmer wetting length for the population was 26.6±8.2 mm, which corresponds well with  previously  reported  afternoon  values  of  25.9±10.6  mm  in  the  literature  for  51  subjects (Lira et al, 2011).  This indicates that the population was normative in terms of Schirmer wetting length  and  distribution.    Subjects  6,  8  and  10  gave  the  most  rapid  generation  of  Schirmer wetting. Half of  the study population produced reflex  tears when sampled with microcapillary tube.  Subjects  1,  6,  7,  8  and  10  have  been  previously  sampled  as  part  of  intra‐departmental 
  119 
research  and  have  been  well  characterised  in  terms  of  lacrimation  response.  The  remaining subjects produced reflex (three) and basal (two) tears in response to sampling. The distribution of  reflex  tearing  in  the population  is either merely a  representation of  the normal  state of  the subjects in terms of stimulus response or a reflection of sampling neophytes. Nevertheless there is no reason  to suggest  that  the study subjects were  in any way abnormal and unsuitable as a representation for a wider population.    The results  in Table 29 showed no apparent correlation between microcapillary  tear  flow and Schirmer strip wetting length in the population. This lack of relationship is further visualised in Fig 5.1.  Microcapillary samples were divided into medium, reflex or basal tears for each subject and compared to the Schirmer wetting length.   
 Fig  5.1.    Comparison  of  Schirmer  strip  wetting  length  and  response  to  microcapillary  tear collection in subjects. 
 Reflex  tearing during microcapillary sampling did not  lead  to  the  longest wetting  length when sampled by Schirmer  strip.    Subjects with medium  tear  flow  (neither basal nor obvious  reflex tearing) when sampled by microcapillary represented 20 mm and 35 mm of the wetting length distribution. 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agree? 8  0.75  8  3.0  Y 1  3.9  4  36.8  ‐ 9  4.9  10  89.0  ‐ 2  5.2  2  199.4  Y 5  7.1  7  >200  ‐ 10  7.5  1  296.5  ‐ 7  7.9  6  361.7  ‐ 6  13.9  9  >400  ‐ 4  16.3  5  >400  ‐ 3  21.5  3  >400  Y 
Mean  8.9    ~238.7    Microcapillary  sampled  albumin  concentrations  ranged  between  21.5  µg/ml  and  0.75  µg/ml with  a  mean  concentration  of  8.9  µg/ml.  These  values  are  slightly  lower  compared  to  the concentrations sampled by microcapillary in asymptomatic subjects in the literature (Table 18). Table  18  has  a  range  of  10.3‐200  µg/ml,  although  as  previously  discussed  in  chapter  3,  the higher values could potentially be traced back to assay techniques.  As half of the population in the  present  study  has  been  sampled  regularly  by  experienced  researchers  and  is  well characterised,  it  is reasonable to believe that the difference between results in the literature is related  to  a  difference  in  study  population  and  assay  technique.  In  terms  of  the  albumin distribution  in  the  whole  subject  population  (0.75‐>400  µg/ml)  results  are  within  a  similar range to the data obtained in the clinical population (19.80‐300 µg/ml) (shown in Table 28).  Four of the samples obtained by Schirmer strip sampling were out of range of the ELISA assay even  with  substantial  dilution  (Subjects  3,5,7,9)  and  a  minimum  value  was  only  able  to  be determined.  The  calculated  average  value  and  range  is  therefore  a  useful  description  of  the population  but  not  completely  accurate.    Mean  Schirmer  strip  albumin  concentration  in  the present study population is 238.7 µg/ml, compared to the 954.5 µg/ml literature concentration quoted  in  Table  17,  and  the  range  is  3.0‐>400  µg/ml.    The  relative  discrepancy  between  the reported literature values and the current study concentrations could be three‐fold. Firstly the Schirmer strip concentrations in the present study only represent the minimum values detected 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in half of the samples and true concentrations could be radically underestimated. Secondly the highest  concentrations  reported  in  the  literature  were  obtained  over  20  years  ago  with  less sophisticated  techniques,  allowing  some  margin  of  error.  Thirdly,  the  present  albumin concentrations  were  collected  through  centrifugation  rather  than  diffusion  extraction,  which could leave albumin residues on the Schirmer strip (Prause, 1979; Denisin et al, 2012).  The majority  of microcapillary‐sampled  concentrations  are  assembled  in  a  cluster  between  5 and  10  µg/ml.  Corresponding  Schirmer  strip  concentrations  however  show  a  much  more significant  range  between  90  and  400  µg/ml  far  exceeding  the  differentiation  between microcapillary levels. Ranking concentrations obtained from subjects by both techniques (Table 30)  showed  that  only  three  subjects  exhibited  a  direct  correlation  in  albumin  concentration. Two of  the  three  subjects  (8  and 3)  represented  the  second  fastest  and  the  slowest  tear  flow rates in the population when sampled by both techniques. The albumin concentrations in these cases are therefore  likely  to be a direct result of  tear  flow i.e.  the most basal  tear  flow has the least diluted albumin and the highest reflex tear flow has the most diluted albumin.   There appears to exist subject‐to‐subject variation in the population that was not related to the separate sampling techniques.   Figures 5.2a‐5.2c attempt to provide some supporting evidence for this hypothesis. The variables have been chosen as variations in Schirmer flow rates rather than variations  in  the already established microcapillary  technique  for  the comparisons made.  Fig 5.2a compares albumin concentration  in  the subject population sampled by Schirmer strip and microcapillary without any discrimination in terms of sampling conditions. Fig 5.2b displays the  same  data  as  in  Fig  5.2a  but  the  subjects  have  been  categorised with  respects  to wetting length  and  time.  The  three  categories  chosen were  the  subjects with  normal wetting  time  (5 min), the subjects with rapid Schirmer wetting (<5 min) and the subjects with slow lacrimation and  a  resultant  wetting  length  of  <20  mm.    Fig  5.2c  shows  the  same  subject  data  with  the addition of circles around the subjects producing reflex tearing upon microcapillary sampling. 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Fig  5.2a.  Microcapillary  albumin  concentration  in  the  ten  subjects  and  the  corresponding Schirmer strip concentration.   
  Fig 5.2b. Albumin microcapillary concentration and corresponding Schirmer strip concentration in subjects divided into three categories according to stimulus response. 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Fig  5.2c.  Duplicate  of  data  presented  in  Fig  5.2b with  the  addition  of  discrimination  of  reflex tearing subjects when sampled by microcapillary. These subject data points are identified with a blue circle.    Figure  5.2a  displays  no  apparent  relationship  between  microcapillary  albumin  concentration and Schirmer strip albumin concentration. When discriminations are made in terms of sampling technique  stimulus  (Fig.  5.2b‐5.2c),  the  normal  wetting  subjects  follow  the  trend  of  no correlation  between  sampling  techniques.  Subjects  experiencing  decreased  lacrimation,  or  a wetting  length  below  20  mm,  both  presented  with  the  highest  measured  Schirmer  strip concentrations  suggesting  some  relationship  between  wetting  length  and  albumin concentration. Increased lacrimation in the two subjects with wetting times below 1 min appear to show a definite negative correlation between microcapillary and Schirmer strip concentration and stimulated tear flow. The third subject with a wetting time closer to the normal 5 minutes (3.26  min)  appears  to  not  support  this  trend  inferring  that  only  extreme  cases  of  induced lacrimation  affect  albumin  concentration  in  a  predictable  way.  Fig.  5.2c  confirms  that  whilst degree of  lacrimation has an effect on albumin concentration it  is  impossible to  infer Schirmer strip  responses  and  concentrations  in  a  subject  from  corresponding microcapillary  responses and  vice  versa.  There  are  however  several  problems  in  assessing  the  data  as  there  were variations in flow rate present both with microcapillary sampling and variation in flow rate with the use of the Schirmer strip. Table 31 examines some of the more unusual subjects in terms of concentration and stimulation. 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Table  31. Albumin  concentration  and  sampling  technique  stimulus  response  in  a  few  selected subjects.   Subject  Schirmer length (mm)  Wetting  time (min)  Schirmer strip µg/ml  Microcapillary µg/ml  Tear  sampling flow 3  13  5  >400  21.5  Basal 5  17  5  >400  7.1  Reflex 10  35  0.66  89.5  7.5  Medium  Subject 3, which had a basal tear sampling flow and the highest microcapillary‐sampled albumin, also had the highest Schirmer strip concentration and the  lowest wetting  length. This  is useful evidence  that  supports  the  view  that  flow  rate  is  undoubtedly  a  factor  in  albumin  sampling. Contrastingly subject 10 had the most rapid wetting time for Schirmer and a medium tear flow with a microcapillary value of 7.5 µg/ml and a Schirmer value of 89.5 µg/ml.  This microcapillary concentration is slightly less than the average of 8.9 µg/ml but by no means at the lowest end.  The Schirmer wetting  rate was  significantly  faster  in  comparison  to all  the other  subjects  and consequently the resultant albumin concentrations would be expected to be much lower if flow rate was  only  a  factor.  Subject  5  complicates  the  results  further  in  having  the  second  lowest Schirmer  wetting  length  but  reflex  tears  when  sampled  by  microcapillary.  The  resultant Schirmer  strip  value  is  among  the  highest  (out  of  range  of  the  assay)  and  the  reflex microcapillary tear value on the other hand is at the lower end of average.   These data presented in Table 31 suggest that whilst degree of lacrimation does have an effect, stimulation by Schirmer strip does not necessarily equate to stimulation by microcapillary. The possible  conclusion  is  the  presence  of  an  individual  enhancement  factor,  able  to  override technique‐induced  stimulation  effects  on  albumin  concentration.  The  step‐by‐step  analysis  of subjects presented above leads to two apparent deductions regarding sampling and stimulus:  
• Tear  flow  rate  was  contributory  to  albumin  concentration  differentiation  between subjects but not an overriding factor. 











 Fig  5.4  Equal  interval  distribution  of  albumin  concentrations  in  38  samples  collected  by Schirmer strip sampling.   The  vast  majority  of  assayed  microcapillary  albumin  concentrations  in  the  present  research were  below  40  µg/ml  (Fig  5.3).  Published  microcapillary  collected  mean  tear  albumin concentrations  range  from  10.3‐200µg/ml  (Table  18).  Of  these,  mean  tear  albumin  levels determined  by  ELISA  were  14.60‐45.1µg/ml.  This  range  correlates  well  with  ELISA‐derived concentrations obtained  in the present research.  Interestingly,  the data gathered from the 457 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individual  sample  determinations  indicates  that  many  previously  reported  albumin concentrations  sampled  by  microcapillary  are  in  fact  significantly  overestimated.  This  is potentially  a  result  of  the  use  of  less  accurate  assay  techniques.  Schirmer  strip  obtained  tear albumin  concentrations  determined  by  ELISA  (Fig  5.4)  were  also  lower  than  the  literature concentrations  (3‐1087  µg/ml  vs.  600‐1830  µg/ml),  although  concentrations  still  represent  a significant  increase  compared  to  the  microcapillary  value.  Importantly,  both  sampling techniques  also  exhibit  a  similar  concentration  distribution,  which  is  different  from  a  typical Gaussian  curve.  There  was  no  apparent  direct  correlation  between  microcapillary  albumin concentrations and Schirmer strip albumin concentrations though, which suggests that the two techniques  cannot be used  interchangeably  of  one  another. The  results  presented  in Table 30 and  Fig  5.4,  however,  show  that  discrimination  in  albumin  concentration  between  subjects sampled by the Schirmer‐strip is still possible.   The  tearing  response  induced  in  subjects  by  each  sampling  technique  was  also  investigated.  This was of interest as the technique specific effects of stimulation of tear flow and of irritation was difficult to disentangle from the literature. Excessive or decreased lacrimation by subjects in the  present  research  appeared  to  affect  albumin  concentrations,  as  would  be  expected  from previous  research  on  total  protein dilution,  but  this was  only  limited  to  extreme  cases  (Table 30).  Instead  there  was  the  suggestion  of  individual  susceptibility  to  stimulus  and  inherent lacrimation enhancement factors when subjected to the two sampling techniques (Table 31). A subject  experiencing  reflex  tearing  upon  microcapillary  sampling  is  consequently  not predestined to experience excess wetting and diluted concentrations when sampled by Schirmer strip. The results do however show that individual albumin concentrations could be compared, if subjects  were  compared with  the  same  sampling  technique  (Table  30,  Fig  5.4).  The  range  of values exhibited in Fig 5.4 also show that clear distinguish between individuals with higher and lower albumin concentrations could be obtained by centrifugation extraction of worn Schirmer strips and  subsequent ELISA analysis. Because differences between albumin concentrations  in subjects  could  be  identified  using  either  sampling  technique,  Schirmer  strip  sampling  and microcapillary  sampling  were  both  deemed  suitable  further  evaluation  with  point‐of‐care analysis.   The difference in albumin concentrations between subjects sampled by Schirmer strip may be of particular interest as it is a reflection of how the individual eye deals with the mild insult of filter paper  insertion.  The  Schirmer  strip  response  could  then  potentially  be  extrapolated  to  how individuals deal with other ocular challenges such as contact lens wear. Subjects with higher or lower albumin therefore represent population subsets, which would be of interest to study. 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6.1. Aim  The aim of this study was to evaluate the viability of using commercially available point‐of‐care testing  equipment  designed  for  urinary  albumin  analysis,  for  tear  albumin  analysis.  Currently there are no point‐of‐care systems in the contact lens clinic that directly assay albumin, or any other protein in the tear film.  
 
6.2. Introduction  The  distribution  profile  of  microcapillary‐sampled  tear  albumin  concentrations  (section  5.7), together with  the  albumin  data  sampled  at  the  designated  baseline  in  chapter  4,  suggest  that subjects have indigenously lower or higher tear albumin levels. Results in chapter 5 also showed that subjects respond differently to sampling stimulus. Collectively, the results presented in the previous  chapters,  highlight  that  larger  data  sets  are  needed  to  better  identify  and  compare population subsets with different  tear albumin concentrations. This  chapter evaluates existing point‐of‐care analysis for the novel use of measuring tear albumin concentration. The reason for this is two‐fold. Firstly, the aim is to identify a suitable protocol for the collection of additional albumin data and secondly the aim is to propose point‐of‐care testing of tear film components as a useful aid to contact lens practitioners.  
 The benefits of point‐of‐care research are discussed in section 6.3 with respect to general  tear protein  analysis  and  the  determination  of  tear  albumin.  Existing  methods  for  tear  film assessment are identified in section 6.4 and placed into context with the only current tear film point‐of‐care analyser ‐ the TearLab®, which measures tear osmolarity. The TearLab® has been effectively  put  into  practice  in  contact  lens  clinics  and  demonstrates  that  there  is  a  clinical interest in point‐of‐care techniques. Importantly, the key features of this system also helped to construct the criteria used for the selection of point‐of‐care kits for albumin analysis.   Ultimately,  two  urinary  albumin  analysers  were  chosen  for  evaluation:  the  HemoCue®  201 Albumin Analyser and the AfinionTM AS100 Analyser. Research presented  in chapter 5 showed that  microcapillary  and  Schirmer  strip  tear  sampling  techniques  individually  provided  good discrimination between subjects and were suitable  for  further evaluation. Furthermore,  it was hypothesised  that  Schirmer  strip‐sampled  albumin  concentrations  demonstrate  the  individual 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subject  response  to a mild  insult  to  the eye. The evaluation and  comparison of  Schirmer  strip albumin concentrations between subjects could therefore be of clinical significance as  it might predict how the eye would react to other challenges, for instance a contact lens. For this reason it was decided to evaluate both microcapillary‐sampled and Schirmer strip‐sampled tears on the point‐of‐care analysers.  
6.3 Benefits of point­of­care analysis  Chapter 5  introduced the notion of using point‐of‐care technology to facilitate the collection of additional  albumin  data.  The  use  of  point‐of‐care  testing  devices  has  long  been  prevalent  in hospitals  and  general  practice  surgeries.  More  importantly,  point‐of‐care  technology  has  the highest annual growth rate within the in vitro diagnostic market (~10%) and use is predicted to become  considerably  more  widespread  in  the  near  future  (Warsinke,  2009).  An  official definition  of  point‐of‐care  testing  is  “  The  provision  of  a  test when  the  result will  be  used  to make a decision and to take appropriate action, which will lead to an improved health outcome “ (Price et al, 2004). In practice, however, point‐of‐care is most often used to denote portable or small handheld automated analysers  for medical analysis or diagnosis. Analysers are generally characterised by simplicity of use, short analysis time and small sample volumes. An example of a  prolific  area  of  point‐of‐care  systems  is  at‐home  disease  management  for  conditions  like diabetes, which require the careful monitoring of blood glucose levels. (Sacks et al, 2002).   Other biological fluids such as saliva and urine are also presently used, or being investigated for use,  as non‐invasive  alternatives  to blood  samples  (Warsinke, 2009).   Although  tears  are only available  in  small  volumes,  they  can  be  obtained  non‐invasively  and  can  provide  valuable information on the tear film composition. Tear film composition affects stability and health, and contains useful biomarkers,  as discussed  in  section 3.6.1. With  this  in mind,  the advantages of utilising  point‐of‐care  technology  in  contact  lens  practices  could  be  two‐fold.  Firstly,  it  is important to realise that contact lens practitioners do not have the benefit of the same resources for clinical analysis that hospitals do. Although some external research departments are able to analyse tear fluid, the logistics of sample transport is an issue. Additionally laboratory resources are  expensive  and  results  would  only  be  available  retrospective  to  the  appointment  and  the ocular  observations  made  at  that  time.  One  potential  benefit  of  automatic  point‐of‐care analysers is therefore the possibility of assessing biomarkers, and more importantly evaluating the results, during the period of a contact lens appointment. In this way, a practitioner trained in the collection of  tear  fluid could obtain  immediate valuable  information regarding  the state of the  tear  film  during  health  and/or  at  the  time  of  a  problematic  contact  lens  wear  period. Secondly,  from  a  research  point  of  view,  point‐of‐care  testing  can  facilitate  the  collection  of 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additional  tear  film data  from  larger  subject populations. With  suitable  technology,  little extra effort would be  required of a practitioner  to  sample and analyse  tear proteins.   Consequently, this  could  simplify  the  implementation  of  larger  scale  clinical  studies.  Equally,  point‐of‐care analysis could bring more exclusive data sets to the specific investigation of the role of albumin in the tear film. The potential benefits are collated in Fig 6.1.   
 Fig.  6.1.  Diagram  of  the  potential  of  point‐of‐care  analysis  (POC)  and  how  it  can  aid  albumin investigation in tears.    There already exist point‐of‐care techniques for the measurement of albumin in urine. These are designed  to  detect  microalbuminuria,  which  is  a  predictor  of  diabetic  complications  such  as diabetic  nephropathy  and  retinopathy.  Microalbuminuria  can  be  diagnosed  in  three  different ways (Rowe et al 1990):   1. Urinary excretion levels of albumin are between 20 and 200 µg/ml in a first morning sample.  2. Urinary excretion levels of albumin are between 20 and 200 µg/ml in a 24‐hour sample or on more than two or three occasions in a month.  3. Urinary excretion levels of albumin are between 20‐200µg/min during an overnight timing. 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The  point‐of‐care  measuring  range  for  urinary  albumin  corresponds  well  with  the  range  of microcapillary‐sampled  albumin  concentration  in  tears  reported  in  the  literature  (10.3‐200 µg/ml)  and determined  in  chapters 4 and 5  (0.75‐153 µg/ml).  For  this  reason,  the automated urinary albumin analysers are of  significant  interest  for potential use  in  the evaluation of  tear albumin.   




 Tear meniscus  Appearance and height of meniscus  Particulate matter  Quantity of mucosal and cellular debris in the tear film Interference  Thickness and appearance of the lipid layer 
Tear film break up: Tear Break Up Time (TBUT)  Integrity of the tear film during prolonged eye opening with the instillation of fluorescein Non‐Invasive Tear Break Up Time (NITBUT)  Integrity of the tear film during prolonged eye opening using a spectral grid pattern projected onto the eye 
Staining Agents: Fluorescein  Stains irregularities in the corneal epithelium  Rose Bengal  Stains cell debris and mucus fibrils 
For suspected dry eye: Schirmer test  Tear flow with filter paper strips Phenol red test  Tear flow with stained cotton thread Tear dilution test  Dilution  of  colour  over  time  in  staining  agents (Fluorescein and Rose bengal) instillated into the eye TearLab®  Tear film osmolarity 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Whilst  the  tests  in  Table  32  can  be  carried  out  during  a  clinical  appointment,  most  of  them cannot be classified as point‐of‐care tests. This is because the tests used are often subjective and rely  on  visual  observations  and  grading  scales  where  interpretation  can  differ  between practitioners. The exception is the TearLab®, which quantifies tear film osmolarity.   6.4.1 Point‐of‐care testing in the contact lens clinic: The Tear Lab® 
 In terms of objective quantitative tests for the diagnosis or assessment of the health of the tear film,  the  TearLab®  system  is  the  only  point‐of‐care  test  currently  on  the  contact  lens market. Recent  advances  in  tear  electrolyte  analysis  by  fibre  optic  sensoring  (Harvey  et  al,  2012)  are however expanding the point‐of‐care possibilities in this area further. 
 6.4.1.1 TearLab® instrument specifications (TearLab® Corporation, 2012) 
 The  TearLab®  system  consists  of  several  different  components:  the  bench‐top  analyser  (Fig 6.2), the system pen (Fig 6.3) and the individual test card. Additional to this are control solutions and control cards.  

























• suitability for microcapillary and/or Schirmer strip sampling  Based  on  these  criteria,  suitable  existing  point‐of‐care  analysers  for  the  measurement  of albumin concentration in urine were identified and are compared below. 
 
6.6 Existing point­of­care technology for the measurement of albumin  With space requirement being  identified as a  limiting  factor,  anything  larger  than a bench‐top analyser  was  discarded  from  comparison.  Available  point‐of‐care  tests  for  human  albumin concentration in urine were compiled and compared with respect to the desired criteria as well as  the  laboratory  gold  standard  –  ELISA.  This  is  shown  in  Table  33.  In  the  comparison  with ELISA, the cost of microplate reader, transit of samples and laboratory personnel has not been included, which would increase this cost significantly. 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Table  33.  Details  of  commercially  available  point‐of‐care  kits  for  albumin  analysis  and  their comparison with ELISA. Effective sensitivity indicates the sensitivity of determining albumin in a 5µl tear sample after necessary dilution factors have been applied.  
Instrument  Price  Price/test  Sensitivity  Volume  Time  Effective 











 The HemoCue® Albumin 201 Analyser  (HemoCue AB) was  introduced  to  the market  in  2005 and was chosen as a primary candidate due to:  
• The relatively small sample volume 
• The short time frame for analysis 






 6.6.2. The AfinionTM AS100 Analyser instrument specification (Kvam et al, 2007)   The AfinionTM AS100 analyser (Fig.6.5) was chosen as a secondary alternative to the HemoCue® Albumin  201  Analyser with  respect  to  the  cost  but  is  a  potentially  superior  kit  in  regards  to volume requirements, range and effective sensitivity. With a volume of only 3 µl this system is able  to analyse single microcapillary samples neat without dilution. Other benefits  include  the choice of entering patient and operator ID to keep sample records easily obtainable.  The range of  the  system  is  5‐200  mg/L  with  an  analysis  time  of  3.5  min.  The  system  consists  of  the AfinionTM  AS100  analyser  and  individually  sealed  test  cartridges  with  a  detachable microcapillary (Fig 6.6).  




  Fig  6.8.  Analysis  method  for  the  detection  of  creatinine  by  the  AfinionTM  AS100  Analyser (adapted  from Kvam et  al,  2007). The  sequential  additions of  enzymes  to  the  test  solution,  as detailed, eventually results in a coloured end product. 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6.6.2.1 Running protocol of the AfinionTM AS100 Analyser  1. 4 µl of tear sample is expelled onto a square of Parafilm®.  2. 3 µl of sample is absorbed by the detachable capillary on the AfinionTM ACR Test Cartridge.  3.  The  capillary  is  replaced  into  the  cartridge,  which  is  then  placed  in  the  AfinionTM  AS100 analyser  4. The sample is analysed for 3.5 minutes  5. The result is given on the digital display in mg/L.   A noteworthy observation of the Afinion cartridge is the capillary design. For the protocol above, the  sample  has  been  previously  taken  with microcapillary  and  expelled  onto  Parafilm®.  The design  of  the  test  cartridge  (Fig,  5.7)  would,  however,  make  direct  sampling  from  the  eye  a potential possibility. For the determination of other analytes, the Afinion analyses whole blood. The  blood  is  collected  by  the  detachable  capillary  directly  from  a  finger  prick,  which demonstrates  that  the  cartridge  material  has  been  evaluated  for  the  risk  of  backwards contamination. However, as bubbles in the capillary will render it useless, direct sampling would only be truly useful for the collection of steady flow tears or reflex tears. Also confirmation of its suitability  and  information about  the materials used  in  the  system would be needed  from  the manufacturer.  
 
6.7 Evaluation of point­of­care technology for the analysis of tear albumin 
 The  HemoCue®  Albumin  201  Analyser  and  the  AfinionTM  AS100  Analyser  were  compared against  the  ICL  ELISA,  which,  as  detailed  in  chapter  2,  is  one  of  the  standard  laboratory techniques used for tear protein analysis and has already been identified as a suitable analysis method for albumin. Disadvantages of the ELISA technique, which makes it unsuitable for use in clinics,  are  that  it  is  expensive,  time  consuming  and  requires  both  laboratory  equipment  and some level of training.  Benefits are that it is sensitive, with very small volume requirements and that  it  is  highly  accurate.  These  are  desirable  qualities  for  a  point‐of‐care  system  and consequently,  ELISA was  used  as  the  gold  standard  against which  the  point‐of‐care  analysers were measured. 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Prior to any tear sample research, albumin standards of known concentrations were evaluated to assess how the point‐of‐care kits compared with ELISA. Both deionised water and phosphate buffered  saline  (PBS)  solutions  were  analysed,  as  PBS  is  closer  to  the  tear  film  in  terms  of characteristics but water might be more practical  for use  in  contact  lens  clinics. Tear  samples collected by microcapillary and Schirmer strip were analysed subsequent to standards analysis. The microcapillary  sample  distribution  profile  achieved  by  the AfinionTM AS100 Analyser was also compared to the larger population profile determined by ELISA, detailed in section 5.7.   6.7.1  Analysis  of  albumin  standards  by  point‐of‐care  techniques:  effect  of  phosphate  buffered saline and deionised water  
 The  aim  of  this  experiment was  to  compare  and  contrast  the  two  point‐of‐care  systems with respect  to  the measurement of  standard albumin concentrations. Consistency between sample readings was also investigated to evaluate the precision of the systems.  
 6.7.1.1 Methods 
 Albumin  standards  with  concentrations:  200,  150,  100,  75,  50,  30,  20,  10  and  5  µg/ml  were prepared by weighing out human serum albumin  (Sigma Aldrich)  in deionised water and PBS (Sigma Aldrich) with a target concentration of 1 mg/ml. Subsequently dilutions were made from this stock solution to reach the final concentrations. The stock solutions were analysed against an existing straight double dilution curve of albumin starting at 1mg/ml. This enabled solutions made  for  different  experiments  to  be  relatable  to  each  other  even  if  the  exact  concentrations differed.  The  prepared  albumin  standards  were  then  tested  on  both  point‐of‐care  kits  in triplicates to assess precision and comparability. Samples were measured neat according to the analyser protocols described previously. 






 Fig 6.11. Comparison of albumin standards in both sample diluents measured by the AfinionTM AS100 Analyser and the HemoCue® Albumin 201 Analyser.   Figure  6.9  demonstrates  that  the  two  point‐of‐care  techniques  correlate  well  for  albumin concentrations  in  deionised  water.  Both  analysers  also  exhibited  high  precision  between  the triplicate measurements. Measurements  by  the Afinion  analyser were  consistently  lower  than the  HemoCue,  which  could  be  a  reflection  of  the  different  systems  or  that  one  system  has  a higher accuracy  than the other. Nevertheless results obtained by both systems  in  this solution displayed sufficient discrimination between samples to be useful for tear sample research.  Results  in  PBS  from  the  Afinion  Analyser  (Fig  6.10)  exhibit  a  significant  range  between measurements  of  the  same  concentration.  Below  50  concentrations  were  very  precise  but samples with higher values showed great disparity. The HemoCue Analyser, on the other hand, exhibited  similar  precision  between  albumin  concentrations  in  PBS  and  in  deionised water.  A possible  reason  for  the  discrepancies  between  sample  readings  is  the  cartridge  temperature; Afinion cartridges are very sensitive to cold temperatures. Samples were read linearly in order of  dilution  i.e.  most  concentrated  samples  first.  Any  temperature  related  issues  would consequently have been skewed towards the higher ranges. Another issue is cartridge stability. The PBS measurements were made a  short  time period after  the  cartridge  lot had  reached  its expiry. Degradation of kit  reagents  could  therefore potentially have affected  the higher end of the measuring range during analysis. 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Collected results in Figure 6.11 show that the point‐of‐care techniques exhibit consistent strong positive  correlation  with  each  other  and  with  standards  in  the  two  sample  diluents.  The exception  is  the  previously  mentioned  poor  results  determined  by  the  Afinion  Analyser  on albumin  standards  in PBS. Measured  albumin  concentrations were  lower  than  the  anticipated target  value  but,  as  confirmed  in  the  subsequent  section  6.7.2  this  is  due  to  human  error  in preparing the solutions. 
 6.7.2 Analysis of albumin standards by point‐of‐care technology and ELISA: effect of phosphate buffered saline and deionised water 
 The aim of this experiment was to assess the accuracy of the point‐of‐care systems against the established  ELISA  technique  and  also  to  re‐assess  the  precision  of  albumin  concentrations  in PBS on the Afinion Analyser.  




 Comparisons  of  albumin  standard  analysis  in  deionised  water  and  PBS  on  the  HemoCue® Albumin  201  Analyser  and  ELISA  are  shown  in  figures  6.12  and  6.13  respectively.  The comparisons between the AfinionTM AS100 Analyser and ELISA for deionised water and PBS are shown in figures 6.15 and 6.16.   
 Fig  6.12  Albumin  standards  in  deionised  water  measured  by  the  HemoCue®  Albumin  201 Analyser and ELISA.  
 Fig  6.13  Albumin  standards  in  PBS  measured  by  the  HemoCue®  Albumin  201  analyser  and ELISA. 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Fig 6.14 Albumin standards in deionised water measured by the AfinionTM AS100 Analyser and ELISA.  
 Fig 6.15 Albumin standards in PBS measured by the AfinionTM AS100 Analyser and ELISA.  The results in figures 6.12‐6.15 show that the point‐of‐care techniques exhibit accuracy similar to the Immunology Consultants Laboratory ELISA. Concentration data provided by the HemoCue Analyser  are  close  to  perfectly  aligned  with  ELISA  concentrations.  The  Afinion  Analyser produced  slightly underestimated  concentrations,  especially  in  the higher  ranges but was  still consistently  accurate.  Precision  of  the  point‐of‐care  techniques,  as  shown  by  the  applied standard deviation between measurements,  is  also overall  very good. The problem previously seen with the precision of the Afinion in the analysis of PBS solutions is no longer present, which 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suggests  that  it  was  related  to  cartridge  expiry  date.  Actual  albumin  concentrations,  as determined  by  the  ELISA  were  less  than  the  target  concentration  value.  These  show  that discrepancies  seen between  target  and measured  concentrations  in  section 6.6.1.2 was due  to human error during standard preparation and not a reflection of inaccuracy in the point‐of‐care instruments.  6.7.3 Analysis of microcapillary‐sampled tears on the AfinionTM AS100 Analyser and ELISA  
 The aim of this experiment was to assess the AfinionTM AS100 Analyser for the determination of albumin  in  tear  fluid  sampled  by  microcapillary.  Preliminary  tear  sample  studies  on  the HemoCue® Albumin 201 Analyser showed that  the 18µl volume requirement was too  large to assess microcapillary samples albumin concentrations efficiently. Microcapillary  tear sampling generates  volumes  between 1‐5  µl  and  the  dilution  factor  required  to  reach  18  µl meant  that most samples ended up below the range of the assay. The point‐of‐care analysis of tears sampled by  microcapillary  was  therefore  only  carried  out  on  the  Afinion  Analyser.  Resultant  albumin concentrations were  correlated  to  the  established  Immunology  Consultants  Laboratory  ELISA technique.  
 6.7.3.1 Methods 
 Tear samples were collected from 8 subjects (3 male, 5 female) at various time points over three days.  Sample  time  points  were  not  limited  to  the  stable  daytime  concentrations  as  it  was important  to  produce  a  range  of  concentrations.  Ultimately  the  aim  of  the  experiment was  to assess  the Afinion Analyser  for  use  in  future  tear  sample  research,  irrespective  of  daytime  or evening. All subjects had been well characterised in terms of their sampling response previous to  the  present  research  and  represented  basal,  medium  and  reflex  tear  flows.  Four  µl  were collected  by microcapillary  from  the  left  eye  of  each  subject,  as  detailed  in  section  2.3.2,  and subjects were  sampled  at  least  three  times during  the  study period.  In  total  29  samples were collected, which were stored at ‐80°C until time of analysis. 




 Creatinine  levels were also recorded but were below the measuring range  for all  tear samples assayed.  Fig  6.16  shows  the  correlation  between  microcapillary‐sampled  tear  albumin concentrations  analysed  by  the  Afinion  Analyser  and  by  the  Immunology  Consultants Laboratory ELISA. Concentrations are displayed in increasing concentration. 
 Fig 6.16. Albumin concentrations sampled by the AfinionTM AS100 Analyser and ELISA.  There is a strong positive correlation between the sample data obtained by the two techniques. Samples  1‐5  reflect  the  inability  of  the  Afinion  analyser  to  quantify  albumin  concentrations below 5 µg/ml. For concentrations above the lower detection limit, the difference between the Afinion and the ELISA is less than 5 µg/ml.  Both techniques are therefore able to provide good discrimination between  samples within  a  very  limited  range of 5‐25 µg/ml. All microcapillary samples  analysed  by  the  Afinion  are  presented  in  Fig  6.17.  Results  are  displayed  as  equal interval data to produce a sample distribution. This distribution is similar to the microcapillary data collated in section 5.7 (Fig 6.18). 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Fig  6.17  Albumin  distribution  in  microcapillary  tear  samples  analysed  by  AfinionTMAS100 Analyser  
 
 Fig  6.18  Albumin  distribution  in  microcapillary  tear  samples  analysed  by  Immunology Consultants Laboratory ELISA.  These results show that the small sample set analysed by the AfinionTM AS100 Analyser is in line with the larger population distribution. 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6.7.4 Analysis of Schirmer strip‐sampled tears on the AfinionTM AS100 Analyser, the HemoCue® Albumin 201 Analyser and ELISA. 
 The aim of this experiment was to assess the validity of analysing Schirmer strip‐sampled tears on  point‐of‐care  instruments.  Tear  samples  collected  by  Schirmer  strips  could  be  assayed  on both  the  AfinionTM  AS100  Analyser  and  the  HemoCue®  Albumin  201  Analyser  as  the  high dilution factor required to bring samples into the measuring range provides enough volume for the  HemoCue.  The  samples  were  also  assayed  by  ELISA  to  provide  a  correlation  between  all three techniques.  6.7.4.1 Methods  Schirmer  strip  samples  were  obtained  from  the  same  clinical  population  that  was  used  in chapter  5  (section  5.3.1).  None  of  the  subjects  wore  contact  lenses  and  no  ocular  disease  or disorders  were  observed  prior  to  sampling.  Schirmer  strips  represented  wetting  lengths between  10mm  and  35mm,  and  were  extracted  whole  by  centrifugation  according  to  the protocol described in section 2.4.3.   Samples for point‐of‐care analysis were diluted 1:9 by adding 2 µl of sample solution to 18 µl of deionised water. Water was  chosen  as  solvent  because  it  showed  the  best  precision  between albumin  standards.  ELISA  sample  dilutions were  determined  by  performing  the  point‐of‐care analysis  first  and using  that  value  to  calculate  a  suitable  dilution  factor.  The  resultant  sample dilutions  ranged  from  1:500–1:3000.  All  sample  analysis  was  performed  according  to instrument instructions, as detailed in chapter 2. In total 18 samples were assayed. 






The  results  in  Fig  6.19  and  Fig  6.20  show  excellent  correlation  in  assayed  Schirmer  strip concentrations  between  the HemoCue  and  the Afinion  instruments  and  the  established ELISA technique.  Concentrations  >600  µg/ml  showed  higher  disparities  between  point‐of‐care techniques and ELISA values. A possible reason for this is the higher dilution factors required by these samples for ELISA analysis, which could affect the results.  Similarly, sample 5 in Fig 6.19 is merely a reflection of the HemoCue Analyser’s lower range cut off value of 5 µg/ml. The actual value,  with  the  applied  1:9  dilution  factor,  could  be  anything  between  0‐45  µg/ml.  The corresponding Afinion results are 76.5 and the ELISA result is 67.3. Consequently, the HemoCue result  could  have  only  just  fallen  below  the measuring  range.  Ultimately,  all  three  techniques managed to provide good discrimination between albumin concentrations sampled by Schirmer strips in the present clinical population. 
 
6.8 Discussion  Point‐of‐care technology in contact lens clinics could provide useful information on the tear film composition  to  contact  lens  practitioners.  Additionally  it  could  facilitate  further  research  into the tear film and long‐term studies on clinical populations. The research presented in this thesis has  aimed  to  provide  a  platform  for  the  investigation  of  the  role  of  albumin  in  tears. Concentrations have been shown to be most stable in early daytime hours and to be affected by sampling and assaying techniques. Existing point‐of‐care techniques for the analysis of urinary albumin  have  a  measuring  range  compatible  with  expected  tear  albumin  concentrations,  as identified  in  chapters 3,4  and 5.  These were  therefore  suitable  for  investigation  and potential implementation into contact lens clinics.  Two  urinary  albumin  analysers were  evaluated  in  this  chapter:  the  HemoCue® Albumin  201 Analyser from HemoCue AB and the AfinionTM AS100 Analyser from Axis‐Shields. Both showed high  precision  between  triplicate measurements  of  albumin  standards  prepared  in  deionised water and in PBS. Initially the Afinion performed badly in PBS but a second investigation using fresh  solutions  and  another  cartridge  lot  produced  good  results  similar  to  the  ones  seen  for standards  prepared  in  deionised water.  Although  temperature was  a  possible  issue,  the most likely  source  of  the  discrepancy  in  the  first  set  of  standard  measurements  is  the  quick degradation  of  the  system  components  after  passing  the  expiry  date.  Consequently  it  is recommended to only use cartridge lots within the expiry and to allow cartridges to reach room temperature well  before  analysis. Because  the  second  standard measurements  exhibited  good precision,  both deionised water  and PBS were  recognised  as  suitable  solvents  for  the present point‐of‐care analysis. 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Correlation of standard samples with the established ELISA technique showed good agreement between the three techniques. Afinion concentrations at the higher end of the measuring range were  disparate  from  ELISA  measured  concentrations  (Fig  6.14  and  Fig  6.15).  This  is  less important  for  clinical use,  as  shown  from  the albumin distribution  in Fig 6.18, microcapillary‐sampled concentrations rarely reach such high levels. Analysis of microcapillary‐sampled tears on the AfinionTM AS100 Analyser supported this statement (levels were <45 µg/ml) and showed good correlation with ELISA (Fig 6.16). The error margin between  the  two  techniques was 5≥ µg/ml  and  both  techniques  would  be  able  to  discriminate  accurately  between  subjects  in  a population.  The  Afinion  also  produced  a  sample  distribution  profile  similar  to  the microcapillary‐sampled albumin profile established by ELISA analysis (Fig 6.17). Consequently the Afinion would be suitable for analysing microcapillary sample data in a contact lens clinic. 
 The  HemoCue  Analyser  could  not  be  used  for  the  determination  of  tear  albumin  sampled  by microcapillary,  as  the  instrument  requires  a  sample  volume  of  18  µl.  Both  the  HemoCue® Albumin 201 analyser and the AfinionTM AS100 analyser were however able to analyse samples collected by  Schirmer  strip. Albumin  samples  (n=18)  extracted  from Schirmer  strips  collected from a clinical population showed excellent correlation between the point‐of‐care  instruments and the ELISA assay (Fig 6.19 and Fig 6.20). Both point‐of‐care analysers were also able to show accurate discrimination between samples from the clinical subject population. The analysis time of  the HemoCue  is  90  seconds  compared  to  the  3.5 minutes  of  the  Afinion.  Individual  cost  of analyser and test cartridges for the HemoCue are also significantly less than the Afinion (Table 21) and  the  cartridges have a  longer expiry date. For  these  reasons,  the HemoCue Analyser  is potentially preferential to the Afinion for the analysis of Schirmer strip‐sampled tear albumin in the contact lens clinic.   The Schirmer strip technique is already established as a routine investigation in the contact lens clinic (Table 32) and is consequently useful for use in point‐of‐care analysis. Chapter 5 identified that microcapillary‐sampled albumin concentrations and Schirmer strip concentrations cannot be used interchangeably as the albumin levels sampled by the Schirmer strip were increased in a non‐predictable manner. Discriminations between albumin concentrations  in subjects sampled by the Schirmer strip were, however, still possible. The insertion of the Schirmer strip subjects the  eye  to  a mild  insult  and  this  results  in  increased  albumin.  The magnitude  of  this  increase appears  to differ between subjects and could provide valuable  information on how population subsets  respond  to  ocular  challenges.  It  would  therefore  be  interesting  to  identify  different population subsets and correlate  the albumin concentrations sampled by Schirmer strips with comfort  scores on  the  sampling experience. Another aim would be  to  correlate Schirmer  strip 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albumin concentrations  in subjects with the effect of contact  lens wear to see  if Schirmer strip albumin could be a predictor for problems with wearing lenses.   The  present  research  also  demonstrates  that,  given  suitable  conditions,  existing  point‐of‐care technology  can  be  utilised  for  determination  and  quantification  of  tear  sample  components. Opportunities  for  the  cross‐use  of  point‐of‐care  analytical  technology  is  likely  to  increase  as more biomarkers are determined and techniques become more sensitive. There already exist a large variety of other analyte tests available in a point‐of‐care format. Examples are: hematocrit, cholesterol,  triglyceride,  glucose,  influenza  A/B,  pH,  hemoglobin  (Nichols,  2003).  A  review  on protein point‐of‐care testing by Warsinke, (2009) identified the invasive sampling techniques as one of the major hurdling blocks to current point‐of‐care. The sampling and analysis of tears is therefore  an  exciting  avenue  and  further  investigations  into  point‐of‐care  technology  for proteins of interest would be beneficial. An issue of using instruments that are designed for the analysis  of  blood  and  urine  for  tear  sample  analysis  is  the  potential  of  contamination  due  to differences  in  fluid  composition.  The  Afinion  AS100  Analyser  has  been  evaluated  for interference with a variety of drugs, their metabolites and common urine components (Kvam et 











7.1 Introduction  Tear albumin is of interest for several reasons. Compared to other tear film proteins present in high concentrations (e.g. lactoferrin, lysozyme, lipocalin) albumin has been largely neglected in research  and  its  role  in  the  tear  film  is  poorly  understood.  In  the  literature,  tear  albumin  is largely utilised as a marker of vascular leakage, although information on mobility and transport of albumin into the ocular environment is incomplete. In plasma however, albumin is known to perform many  vital  functions, which  include:  controlling  oncotic  pressure,  promoting  binding and transport  functions, and providing anti‐oxidant effects (section 1.3.3). A hypothesis  is  that albumin might perform similar functions in tears and consequently may constitute more than a simple marker. As a result,  further  investigations  into both albumin concentrations  in  the  tear film and the consequences of its presence are warranted.   The  purpose  of  the  research  presented  in  this  thesis  was  to  provide  a  strong  foundation  for further studies on albumin in the tear film. There were three main objectives:  
• To  collate  and  evaluate  the  literature  to  identify  factors  of  variation  for  tear  albumin concentrations. 
• To  investigate albumin concentrations  in  the  tear  film with regard  to both diurnal and subject‐to‐subject variations. 
• To perform a parallel  investigation  into  the use  of  point‐of  care  technology  to  analyse albumin concentration in tears in contact lens clinics.  The summary and conclusions of this research are described in sections 7.2‐7.4.   
7.2 The determination of factors affecting albumin in tears  The disparities  in  published  tear  albumin  concentrations were  investigated by  addressing  the previously neglected literature and performing a systematic investigation of collected reported human albumin concentrations in tear fluid. Factors for variation were conveniently divided into external  (sampling  technique and stimulation, method of  analysis,  time of day, open or  closed eye  tears)  and  internal  (ocular  disease  or  disorder,  and  subject‐to‐subject  variation).  Three major factors for variation were identified: sampling technique, ocular disorder or disease, and assay methodology. 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Sampling technique was found to be the most  influential  factor of variation in measured mean albumin  concentrations.  Harsher  filter  paper  techniques  produced  an  increase  in  albumin concentration  compared  to  microcapillary  sampling.  The  magnitude  of  this  increase  differed between  studies  but  an  average  of  50  times  the microcapillary  value was  noted.  Significantly, increased albumin concentrations were observed with harsher sampling techniques (compared to microcapillary) even with the additional factors of ocular disease and disorder. Ocular disease and  disorders,  as  individual  factors  of  variation,  exhibited  increased  albumin  concentrations compared to asymptomatic controls. This increase was however non‐specific and high albumin concentrations, as a  factor, were not directly  linked  to any specific disease or disorder.   Assay technique  has  been  an  issue  in  interpreting  the  significance  of  the  early  tear  albumin determinations  (ca  pre  1990).  Semi‐quantitative  techniques  such  as  immunodiffusion  are  less sensitive  than modern  techniques  and  provide  higher  values.  More  recent  advances  in  assay techniques  have  lead  to  increased  sensitivity.  This  has meant  that,  although  assay  techniques carry a small degree of variation, this is negligible compared to the other factors described here. The  careful  understanding  of  these  factors  is  therefore  vital  in  the  design  of  further  research studies  into  albumin  in  the  tear  film.    This  is  particularly  true when  investigating  subject‐to‐subject variation, which, as shown in chapter 3 and 4, is elusive, and of a magnitude that could easily be masked by inflicted additional albumin influx.  
  
7.3 The investigation of diurnal variation in tear albumin concentrations  The assembled tear albumin literature displayed a consistent lack of description or comment on the  time  period  during  which  tear  sampling  took  place.  Published  data  on  when  albumin concentrations  were  measured  were  insufficient  to  be  able  to  draw  any  conclusions  on  this factor  from  the  literature.  Data  from  the  overnight  tear  film  and  diurnal  variations  in  other biological  fluids  did  however  suggest  the  possibility  of  time‐related  variation  in  albumin concentration.    Consequently,  albumin  concentrations  were  sampled  throughout  the  day  to investigate  this  further.  A  population  of  thirteen  subjects  was  recruited  and  subjects  were divided  into  two  study  groups,  Group  1  and  Group  2.  Group  1  (n=13)  had  tears  collected  by microcapillary every two hours during normal office hours for a period of 2‐6 days, depending on subject availability. Group 2 (n=5) comprised a subset of subjects trained to collect their own tear samples using microcapillary.   For group 2, albumin concentrations were measured every two hours: post‐waking up to and including pre‐retiring to bed over a number of days (9‐11).   The collected data revealed previously unrecognised albumin variations, both between subjects and  within  some  subjects  during  the  course  of  the  day.    An  apparent  stable  period  between 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7.4 The evaluation of point­of­care technology for analysis of tear albumin  The  identification of  time periods during  the day where albumin concentrations are  relatively stable has provided valuable  information  for  the design of studies  involving  the assessment of tear  albumin  concentrations between different populations. The  identified  time points,  during which  tear  albumin  concentrations  vary  insignificantly  within  subjects,  correlate  well  with expected  opening  hours  of  contact  lens  clinics  and  research  facilities.  Contact  lens  clinics  are ideal  institutions  for  the  recruitment  of  study  populations  for  tear  protein  analysis,  because subjects  attend  these  on  a  regular  basis  for  eye  examinations.  Disadvantages  of  sampling  in commercial  premises  include  the  lack  of  laboratory  space  and  trained  personnel  to  conduct protein analysis. Time and cost of analyses are also  important  issues. Point‐of‐care  technology was therefore evaluated to facilitate the collection of additional tear albumin data in contact lens clinics. The benefits of  the automated point‐of‐care assays are  that  they are portable,  fast, and simple to use and have a high accuracy.   Experimental  investigation  of  point‐of‐care  analysis  was  performed  in  two  parts.  Firstly  the effect  of  tear  collection  technique  on  tear  albumin  concentrations  was  evaluated  to  choose  a suitable sampling protocol. Secondly, point‐of‐care instruments were chosen and compared with the established ELISA technique for the determination of albumin in tear fluid.  Microcapillary  sampling  and  Schirmer  strip  sampling  were  evaluated  for  tear  collection  and future  use  by  point‐of‐care  analysis.  Tear  albumin  concentrations  and  technique‐induced stimulation of tear flow was assessed in a population of 10 subjects sampled by both Schirmer strip and microcapillary. Schirmer strip samples were extracted by centrifugation of the whole strip. This protocol was suitable for clinical use as it was simple, required no buffers and results had  previously  been  shown  to  produce  an  electrophoretic  protein  profile  similar  to microcapillary‐collected  samples  (section  5.2.2).  Furthermore,  investigations  of  extraction protocols showed that only assaying sections of the strip only would produce an incomplete and potentially erroneous picture of the albumin concentrations present.   Subject‐to‐subject variation was evident, in terms of tearing response, to both the Schirmer strip and  the  microcapillary  sampling  technique  in  the  population  (n=10).  However,  the  results showed  no  direct  correlation  between  the  induced  stimulation  of  tear  flow  by  the  two techniques. Similarly, the albumin concentrations sampled with one technique could not be used to  predict  albumin  concentrations  sampled with  the  other.  Schirmer  strip  sampling  exhibited increased  albumin  concentrations  compared  to  microcapillary  sampling  (3.0‐>400  µg/ml  vs. 
  161 
0.75‐21.5  µg/ml)  and  created  a  far  greater  range  of  values  between  subjects.  Both  sampling techniques were  however  able  to  provide  good  discrepancy  between  albumin  concentrations sampled by different  subjects. The Schirmer strip  is already widespread  in use  in contact  lens clinics  and  would  be  easier  to  implement  for  albumin  tear  collection  in  clinical  studies. Microcapillary sampling on the other hand requires more training but provides a non‐invasive sample of the tear film. Both techniques were therefore selected for evaluation on point‐of‐care technology.  A review of available information identified two suitable point‐of‐care instruments for albumin determination:  the HemoCue® Albumin  201 Analyser  and  the AfinionTM AS100 Analyser.  The analytical ranges of the point‐of‐care systems (5–150, 5‐200 µg/ml) and the analysis times (1.5 min, 3 min) make both instruments compatible for use in contact lens clinics. Evaluation of the instruments using albumin standards in deionised water and PBS showed that both techniques exhibited  precision  and  accuracy  similar  to  the  established  sandwich  human  serum  albumin ELISA  from  Immunology  Consultants  Laboratory  Inc  (ICL).  Results  for  the  AfinionTM  AS100 Analyser  in  PBS,  however,  implied  that  reagents  used  below  room  temperature  and  after  the expiry date affected both accuracy and precision negatively.   Microcapillary‐sampled  tears  were  considered  for  use  on  both  instruments  but  the  volume requirement of the HemoCue® Albumin 201 Analyser was too large (18µl) to make analysis on this  instrument  viable. The AfinionTM AS100 analyser has  a  volume  requirement of 3µl, which enabled the measurement of neat microcapillary collected tear samples without dilution.   Tear albumin concentrations from 8 subjects, were determined by the AfinionTM AS100 Analyser and showed strong positive correlation with ELISA derived results.   A  subsequent  sample  distribution  of  albumin  concentrations  analysed  by  the  Afinion  showed that results exhibited a similar range and distribution profile to samples analysed on the ELISA. Schirmer strip‐sampled tears were analysed on both point‐of‐care techniques, as dilution of the collected  samples  was  necessary  to  produce  albumin  concentrations  within  the  measuring ranges of the instruments (5‐200 µg/ml).  Samples were diluted one in nine (2µl + 18 µl), which generated enough sample volume  to enable analysis by  the HemoCue Analyser. Both point‐of‐care  instruments  showed  excellent  correlation  with  ELISA‐derived  results  for  albumin concentrations  determined  from  clinically  obtained  Schirmer  strips  (n=18).  Results  also exhibited good discrimination between albumin concentrations from different subjects.   Collectively these results show that point‐of‐care analysis of tear albumin, using the HemoCue® Albumin 201 Analyser or the AfinionTM AS100 Analyser is viable and instruments demonstrate 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assayed concentrations similar to the ELISA technique. Precision between standard replicates is also excellent.  In terms of practicality, the HemoCue Analyser is preferential to use, as  it  is has smaller  dimensions,  and  is  cheaper  and  faster  to  run.  Sample  volume  is  however  a  limiting factor. The Afinion Analyser is therefore suitable for the assessment of microcapillary‐sampled tears  whereas  both  instruments  are  able  to  accurately  determine  albumin  concentrations  in Schirmer strip‐sampled tears.   There are several benefits of point‐of‐care analysis of tear albumin.  The simplicity of the point‐of‐care analytical procedure, and the lack of sample transit between clinic and laboratory, make tear albumin determination  faster and more cost effective  than ELISA analysis. This  facilitates the analysis of study populations  that visit  contact  lens clinics and may make  the collection of additional  data  sets  more  accessible.  There  is  also  an  opportunity  to  correlate  albumin  tear concentrations with  results  of  eye  examinations,  which may  provide more  information  about albumin as a biomarker. The consistent increase of albumin concentrations in the evening tear film, identified in the research presented in this thesis, indicates that albumin might be actively recruited  into  the  tear  film  as  part  of  the  ocular  defence  system.  The  measurement  of  tear albumin  levels  in subjects could  therefore have potential clinical  significance, although  further research is needed.  
 
7.5 Conclusion  The research presented in this thesis has provided several new insights into the parameters that dictate  the measurement of  albumin  in  tears.  It  has  also provided new areas  for  investigation and facilitated the collection of additional data.  In summary, the contributions are:  
• The unique collation of the available tear albumin literature and the evaluation of factors affecting albumin in tears. 
• The  identification  of  a  previously  unrecognised  asymmetric  shift  in  albumin concentrations in the evening. 
• The further evaluation of tear sampling techniques with respect to effect on tear albumin concentration. 









 Diurnal  variation,  with  a  progressive  increase  in  albumin  concentrations  in  the  evening  was evident in the sampling population. There were however differences between subjects in terms of the starting point and extent of the evening increase in albumin. The present study measuring tear albumin concentrations throughout the waking day was conducted using 5 subjects and it would be beneficial  to  repeat  the  study with  a  larger  population.  This would partially  help  to confirm the present results but also to investigate whether the individual subject responses are subject  specific  anomalies  or  representations  of  population  subsets  with  different  coping mechanisms  to  the  ocular  environment  pre‐retiring  to  bed.  It  is  recognised  in  the  present research that other unknown factors for albumin variation may exist. A study of this magnitude would  thus also benefit  from the  inclusion of a questionnaire assessing  the  individual’s ocular comfort score and lifestyle to investigate other possible influencing factors.  
 7.6.2 Point‐of‐care technology in the contact lens clinic 
 The  results  presented  in  this  thesis  show  that  albumin  is  a  protein  that  has  been  neglected compared  to  its  fellow major  tear  proteins  in  the  tear  film.      It would  be  valuable  to  analyse albumin  variations  between  subjects  at  the  defined  stable  time  points  to  identify  eventual population  subsets with  differing  albumin mechanisms.    The  research  presented  in  chapter  6 identified  existing  point‐of‐care  technology,  which  could  be  utilised  to  accurately  determine albumin concentrations in tears. This laboratory‐based investigation should be extended with a trial  incorporating  point‐of‐care  into  the  contact  lens  clinic.  This  would  enable  the  quick assessment  of  albumin  levels  in  a  larger  population  and  also  the  correlation  of  albumin concentrations  with  a  wide  range  of  other  factors  determined  during  a  contact  lens appointment.   The  aim  would  be  to  use  the  instruments  to  perform  two  separate  investigations. Microcapillary‐sampled albumin concentrations are  collected non‐invasively and consequently denote the baseline tear film environment. Baseline albumin concentrations could be assessed in contact  lens  clinics  using  the  AfinionTM  AS100  Analyser  and  gather  more  data  on  albumin 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distributions  in  populations.  The  insertion  of  the  Schirmer  strip  represents  a  small  physical insult  to  the  eye  and  produces  an  increase  in  albumin  concentrations  compared  to microcapillary  sampling.  The  extent  of  the  resultant  increase  in  albumin  concentration differs between  subjects  and  it  would  be  interesting  to  characterise  this  response.  Potentially,  the albumin  concentration  increase  by  Schirmer  strip  sampling  signifies  how  the  eye  of  an individual  subject  reacts  to  insults  and  deviations  from  normal  ocular  conditions.  This information could be of clinical significance as it might be able to identify subjects with better or worse  abilities  to  withstand  ocular  challenges  such  as  contact  lens  wear.  The  HemoCue® Albumin  201  Analyser  would  be  suitable  for  the  investigation  of  Schirmer  strip‐sampled albumin concentrations in contact lens clinics.  7.6.3 Albumin extraction from sampling materials  There were clear inconsistencies in lacrimation responses and albumin concentrations between subjects sampled with different tear collection techniques. What confounds the issue further and have not  been dealt with  fully  in  this  thesis  is  the  relative  absorptive  and  extraction qualities between the different sampling materials. Schirmer strip was used as an absorptive material in the  present  research  but  there  are  other  materials  available  (e.g.  polyester  wicks,  cellulose acetate sponges,) (section 3.5.1). There is currently no extraction protocol that has been proven to have 100% efficiency on Schirmer strips or other absorptive materials. Comparative analyses of  albumin  extraction  from  sampling materials  such  as  Schirmer  strip  and  polyester  sponges would  provide  further  detail  on  material  factors  and  lead  to  a  more  informed  choice  when considering sampling methodology.   Furthermore it would be of interest to evaluate contact lenses for use as tear sampling tools for the determination of  tear albumin concentration. The placement of a  contact  lens  into  the eye partitions the tear film into the pre‐lens tear film and the post‐lens tear film. When the contact lens is removed, the liquid adhered to the front and back surface of the contact lens is consistent with  a  sample  of  the  tear  film.  This  sample  has  been  named  the  tear  envelope  as  the  fluid “envelopes”  the  lens  (Mann  and  Tighe,  2007).  By  centrifuging  the  lens  immediately  after removal from the eye, in a similar fashion to Schirmer strip extraction described in section 2.4.3, the sample can be collected. The volume can be up scaled by the addition of deionised water to the  lens  prior  to  centrifugation  and  in  general,  the  process  can  yield  sample  volumes  ranging between 4 and 25 µl. These volume ranges would enable the tear envelope to be analysed by one or  both  of  the  point‐of‐care  instruments.  The  composition  of  the  tear  envelope  sample  is dependent  upon  the  subject  and  the  qualities  of  the  lens  material.  Assaying  albumin concentrations  might  therefore  identify  subject‐lens  combinations  with  higher  or  lower 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albumin. Factors such as: loss of protein by lens deposition of albumin and extraction efficiency of the lens, would be important to evaluate prior to such a study. 
 7.6.4 Diurnal variation and contact lens wear  The observed progressive late day increase in tear albumin concentration identified in chapter 4 may have  relevance  to  contact  lens wear; potentially  in  relationship  to end of day discomfort, which  is  a well  recognised  but  poorly  understood  phenomenon.  A  questionnaire  based  study conducted by Chalmers and Begley (2006) showed that intense symptoms of dry eye discomfort in  contact  lens  wearers  significantly  increased  later  in  the  day  compared  to  two  hours  after waking.  It would be valuable to  investigate tear albumin concentrations throughout the day  in contact lens wearers to see if the same effect of increase in the evening is detectable.    Similarly  it  may  be  of  value  to  investigate  extracted  worn  lenses.    The  comparison  of  tear albumin  concentration  extracted  from  contact  lenses  worn  all  day  (including  evening)  to concentrations extracted from contact lenses worn during the daytime only, may be of value for the  further  investigation  of  the  evening  tear  film.  Albumin  concentrations  on  lenses  could potentially  be  correlated  to  tear  film  concentrations.  Alternatively,  deposited  albumin concentrations might plateau after a few hours of wear and no correlation with day vs. evening wear is evident. Nevertheless, the differentiation between the evening tear film and the daytime tear film suggests that there is potential value in investigating the link between serum albumin leakage  and  end  of  day  discomfort.  Akin  to  the  study mentioned  in  section  7.6.3,  this  would require a thorough assessment of contact lens extraction protocols.   7.6.5 Albumin ligands in the tear film  
  Albumin  in  plasma  is  able  to  bind  a  variety  of  ligands  and  therefore  also  executes  ligand‐mediated effects. Although this thesis has focused on albumin as a single entity, it is likely to be a simplified model  and  albumin  should be  researched  further with  respect  to  its  ligand binding qualities. As detailed in the introduction, fatty acids are partly responsible for the stability of the tear  film  lipid  layer and are extensively  transported by albumin  in plasma.  Similarly,  steroids, vitamins,  and metals  such  as  copper, magnesium,  chloride  and  calcium  have  high  association constants (> 6.5 x102) to albumin and are potentially brought across the blood‐tear barrier with albumin during transport. The measurement of tear concentrations of any of these components alongside tear albumin would be useful  to reveal any association between the two entities. An example would be to differentiate between delipidated albumin and the fatty acid bearing form in plasma. These results could then be used to analyse tear albumin and identify to which extent 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each form is present. Statistically, albumin in plasma carries 1‐2 long chain fatty acid molecules at  any  one  time, whilst  in  circulation  (Reed et  al,  1975)  but  the  actual  distribution  in  tears  is undetermined.   7.6.6 Albumin as a marker for other plasma products 
 Finally  it  is worth noting  that  albumin could be a marker  for  the  recruitment of other plasma products able to pass through the blood‐tear barrier.  It would therefore be of  interest to focus further  research on  the  identification of plasma components  that may  leak alongside albumin. The  tear  concentration  of  these  could  then  be  correlated  with  albumin  to  investigate  any potential relationships. 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The  research presented  in  this  appendix details  the  attempt  to develop an  in‐house  sandwich ELISA  for  the measurement  of  human  serum  albumin.  As  discussed  in  chapter  2,  commercial ELISA kits are comparatively expensive and the purpose of the laboratory constructed assay was to lower the cost of analysis of tear albumin concentrations. Chapter 2 provides an overview of the working  components  of  the  sandwich  ELISA  and  a  typical  running  protocol,  which  is  not included in this appendix. The sections presented here focus on the development and evaluation of a sandwich ELISA protocol for the measurement of albumin.    
A.2 Development of a sandwich ELISA for the determination of human serum albumin  A.2.1 Introduction  This  section  describes  the  development  and  evaluation  of  a  sandwich  ELISA  targeting  human serum  albumin.  Several  criteria were  determined  for  the  production  of  a  successful  protocol. These were modelled on commercial ELISA specifications and were:  
• Accurate measurements of albumin concentrations 
• A  blank  OD  similar  to  commercial  products  (0.1‐0.01  OD).  This  was  to  enable  good distinction between low‐level albumin samples and to produce a highly sensitive assay 
• Coefficient of variation < 15% between sample duplicates.  
• Inter  and  Intra‐assay  coefficient  of  variation  <  15%  confirming  even  capture  antibody coating and blocking.  
• Repeatability of results  A.2.2 Initial running protocol  The  Initial  ELISA protocol  described  below was  the  starting  point  for  the  development  of  the laboratory  based  ELISA  assay.  Three  antibodies  were  used  in  this  first  set  of  experiments, adopting  a  sandwich  complex  formation with  a  capture  antibody,  a  detection  antibody  and  a conjugated antibody (Fig A.1). 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 Fig A.1. Initial antibody setup  Human  albumin  specific  conjugated  antibodies  are  significantly  more  expensive  that  goat  or rabbit  conjugated  antibodies  and  were  considered  only  as  a  second  alternative  to  the  initial setup in Fig A.1.  Initial ELISA protocol (Protocol 1):   1.  A Corning‐half area plate was coated with goat‐antihuman albumin antibody in sodium carbonate/sodium  bicarbonate  coating  buffer  at  100µl  per  well  using  a  multichannel pipettor.  Checkerboard  titrations  were  made  of  the  capture  antibody  to  establish  the most suitable working range (Fig A.2). Plates were then incubated in a moist box at 8˚C for 24 hours.                  Fig A.2. Checker board titrations for assay protocol 1. Concentrations are in µg/ml. 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2. The  coating  solution was  emptied  down  a  sink  and  the  plate was  banged  dry  against paper  towels  until  no more wet  spots  appeared.  200µl  of  3%  skim milk  PBS  blocking solution was pipetted into each well. The plate was then incubated in a moist box at 8 °C overnight (minimum of 17 hours blocking time).   3. Blocking solution was then emptied down a sink and the plate was banged dry on paper towels until no more wet spots were visible. Human serum albumin was diluted in TBS at  varying  concentrations  and  pipetted  into  wells  at  100µl/well.    The  human  serum albumin  represents  the  antigen  and  actual  dilutions  are  described  in  Figure  A.2.  The plate was then incubated at room temperature for one hour.   4. After 1 hour, the plate was emptied and banged dry as mentioned previously in steps 2 and 3.  200µl  of  0.1% PBS  tween 20 washing  solution was pipetted  into  each well  and then plates were emptied and banged dry. This was repeated for a total of three washes, after which the plate was banged dry again before moving onto step 5.    5. Rabbit  anti‐human  serum  albumin  detection  antibody  diluted  in  TBS  0.05%  tween solution was pipetted into each well at 100µl/well according to the protocol  in Fig A.2. The plate was then incubated at room temperature for one hour.   6. A  second washing  step  as  described  in  step  4  was  performed  to  remove  all  unbound material.    7. Goat anti‐rabbit  IgG Enzyme conjugated antibody diluted  in TBS 0.05% tween solution was added to each well at 100µl/well according to Figure A.2. The plate was incubated at room temperature for one hour.    8. A third washing step was performed as described in step 4.  9. 100 µl of TMB was then pipetted into each well and the plate was left to develop in the dark for ten minutes.    10. 100µl of 1M phosphoric acid was then pipetted into each well to stop the reaction. The plate was read on the spectramax M2 at a wavelength of 450 nm. 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A.2.3. Modifications to initial protocol  Further modifications to the initial running protocol during development were made as detailed in  the assay protocols  in  tables 35, 37 and 38. The  first 5 protocols are described  in Table 35. The  protocols  detail  the  plates  used  and  the  respective  concentrations  of  capture  antibody (Cab), antigen (Ag), detection antibody (Dab) and conjugate (Conj) for each experimental assay run. Concentrations described as numbers  linked with a dash (e.g. 10‐0.0098) signify a double dilution  curve  from  the  first  to  the  last  value.  Incubation  times,  washing  buffer  and  volumes remained the same between all protocols.  Table 35.  Assay protocols 1‐5. 





















Corning half area  20‐0.625  3% milk  0.5, 0.1, 0.05  1, 0.25  1:2000, 1:10.000  NO 
2 
Sero‐wel   1‐0.0313  3% milk  1‐0.0313  0.5, 0.25  1: 10.000  NO 
3 
Sero‐wel   x Direct ELISA  3% milk  10‐0.0098  0.25  1: 10.000  YES, high 
4 
Sero‐wel   1‐0.00098  3% milk  0.1‐0.00153  0.25  1: 10.000  NO 
5 
Sero‐wel   0.039  3%, 10%, 20%,  milk 3%BSA  10‐0.0098  0.25  1: 10.000  NO 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Fig  A.3.  Recorded  OD  of  Assay  1.  The  higher  dilution  factor  of  1:10,000  produced  ODs  in  the measuring  range  of  the  Spectramax  M2  (columns  7‐12).  Path?  refers  to  samples  too concentrated to be analysed using the specified 450nm wavelength.  Subsequent  assay  protocols  (2‐5)  (Table  35)  were  designed  to  further  optimise  the  capture antibody and antigen concentrations. Optimal dilution for the secondary antibody (the detection antibody)  was  found  to  be  0.25  µg/ml.  The  initial  plate  selection  was  also  rectified  and  the Corning  plate,  which  had  insufficient  well  volume,  was  replaced  with  a  Sero‐wel  plate.  A consistent issue was the lack of a true blank OD that was discernibly different from lower levels of antigen present. Assay protocol 3 substituted the sandwich ELISA for a direct ELISA (coating the  antigen  directly  onto  the  solid  phase,  bypassing  the  need  for  a  capture  antibody).  This protocol identified a possible cross‐reaction between the capture antibody and the other assay components, as the exclusion of the capture antibody resulted in a blank OD. The achieved blank was  still  elevated  compared  to  commercial  blank  ODs  and  doubling  dilution  of  the  antigen resulted  in  a  fairly  uniform  absorbance  value  suggesting  a  possible  antigen  plateau.  Higher antigen dilutions were employed in assay protocol 4 but double dilutions still exhibited uniform colour  development.  Assay  protocol  5  attempted  to  improve  blank  OD  by  increasing  block concentration and the inclusion of BSA as an alternative blocking agent but this did not resolve the  high  background.  The  results  of  assay  protocols  1‐5  suggested  a  possible  cross‐reaction between  assay  components  and  this  factor was  evaluated  using  double  immunodiffusion  and single radial immunodiffusion. 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A.2.4 Principle of double immunodiffusion  Double immunodiffusion is better known as the Ouchterlony method and is based on the specific interaction between antibodies and  their antigens. Antigen and antibody samples are pipetted into individual wells that have been punched out into agarose gel (Fig A.4).  




















• Antibodies and analytes  All reagent components for immunodiffusion were obtained from Sigma Aldrich. The Comassie Blue  stain  solution  was  prepared  by  adding  1.2g  of  Brilliant  Comassie  Blue  to  90ml  ethanol, 90ml deionised water and 10ml glacial acetic acid. Destain was prepared by combining 150 ml ethanol, 400ml of deionised water and 50ml of glacial acetic acid.  A.2.4.3 Gel preparation  0.6g Agarose  and 1.5g PEG 8000 was weighed out  and added  to 50 ml Tris‐Borate‐EDTA  in  a conical  flask.  The  solution  was  stirred  over  heat  until  all  the  particulate  matter  was  visibly dissolved. The solution was then poured into a pre‐warmed 100 ml screw top bottle in a 56 °C water bath. This ensured that the agarose mixture remained liquid.   A.2.4.4 Gel pouring  Melinex® sheets were  fixed to slightly  larger  thick, clear plastic rectangles by dabbing a bit of water on the backside of the sheet. A small triangular cut was made in the top right corner of the Melinex® sheet to differentiate it from the bottom and avoid confusion during analysis. 10 ml of the agarose solution were then poured into a 12 ml centrifuge tube kept in the water bath and then  immediately poured onto a Melinex® sheet, attempting  to  form a uniform  layer covering the sheet. It was important to place the Melinex® sheet on a level surface to ensure even flow of the gel. Gels were then left for 15 minutes to solidify. 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A.2.4.5 Gel diffusion and analysis  A  5  mm  immunodiffusion  cutter  was  used  to  punch  holes  into  the  gel.  The  cut  wells  were removed by means of a glass pipette and discarded. Two different configurations were used: five holes in a “flower” formation with equal distance to a central well (Fig A.4.), and columns of two holes next to each other. The flower formation allows the comparison of several entities at the same time whereas the two holes on their own are used for single comparisons.   Neat samples were then pipetted into the holes, with 5µl / well, and the sheet was placed in a moistbox  for  24  hours,  allowing  the  samples  to  diffuse  in  the  gel.  The  Gel  sheet  was subsequently immersed in a 0.9% saline solution overnight to stop the diffusion reaction.  Filter paper was then placed onto the sheet and subsequently heavy books to flatten it into a thin film and expel excess liquid for approximately 24 hours. The flattening step was performed next to a window to achieve favourable drying conditions. Results were sometimes visible upon diffusion completion but all gels were stained to improve precipitation contrast. The sheet was removed from the plastic support for the staining procedure and completely immersed in Comassie Blue stain for 2 hours. The sheet was then transferred into a container with destain solution until all background stain was removed. Generally more than one fresh destain solution was needed to achieve this. Precipitation results were analysed visually and are described in section A.2.6.   A.2.5 Principle of single radial immunodiffusion  Single  radial  immunodiffusion  was  first  described  in  1965  by  Mancini  et  al.  and  is  more commonly referred to as the Mancini method. An agarose gel is prepared containing an antibody specific  to  the  protein  of  analysis.  Antigen  added  to wells made  in  the  gel  is  then  allowed  to diffuse  radially  over  time  to  bind  with  the  antibodies  present  in  the  gel.  As  the  antigen encounters the antibody the resultant complexes will precipitate out of solution and form visible aggregates. The expansion of the precipitation circle continues until the antigen has passed the zone of equivalence, where concentration is optimal to the antibody and the most precipitation occurs  (Fig A.5).  After  this,  the  antibody  is  in  sufficient  excess  to  limit  precipitation  reactions until the process is halted completely. 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Fig  A.5.  Diagram  of  the  relationship  between  concentrations  of  antigen  and  antibody  and  the resultant precipitation.   The  diameters  of  precipitin  complexes  surrounding  samples  of  antigen  are  directly proportionate to the antigen concentration in the sample. By introducing set concentrations of the protein, diameters provided can be used as a standard curve to calculate unknown sample concentrations from (Fig A.6). The lower limit of albumin detection using this system has been found  to  be  an  antigen  concentration  of  1.25  µg/ml with  a  standard  deviation  of  <2%  of  the mean (Mancini et al.1965).  
 Fig  A.6.  Example  of  a Mancini  immunodiffusion  assay with  a  standard  curve,  control  and  test samples (1‐4). In this example, 1 and 4 contain antigen at various concentrations and 2 and 3 are negative. 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A.2.5.1 Materials and method for preparation  The materials and gel preparation of Manicini gels are identical to the Ouchterlony method with two notable differences.   During the storing of the agarose gel solution in the 56°C water bath, 50µl of the desired antibody is added to the gel and gently mixed until evenly distributed. The pouring  of  the  individual  gel  into  the  12 ml  centrifuge  tubes  is  then done.  The hole  punching design also differs and was equal to the one exemplified in Fig A.6. As with the Ouchterlony gels, samples were assessed visually.  A.2.6 Immunodiffusion results for assay development  As a result of the possible cross‐reaction between antibodies, Ouchterlony (Fig A.7) and Mancini gels (Fig A.8.) were run. The Ouctherlony gel was devised to detect whether there was any cross‐reaction  between  the  different  antibodies  used  and  other  assay  components  such  as  coat  and block buffer  constituents. BSA was also  included and deionised water was added as a  control. The Mancini gel provided a closer assessment of the capture antibody as it had been identified as a possible source of concern in protocol 3 (Table 35).  
 Fig A.7.  Ouchterlony 1 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Fig A.8.  Mancini 1.  Ouchterlony 1 confirmed  that capture and detection antibodies were able  to correctly  identify human serum albumin. Antibodies  in coating buffer also elicited a response eliminating buffer component  interference  as  a  source  for  concern.  The  reactions  between  goat  anti‐human albumin  (spot  14)  and  the  surrounding  components  were  more  difficult  to  discern  and  the possibility of cross‐reactions still required further investigation. Mancini 1 assessed interactions between  the  capture  antibody  and  other  components.  As  expected,  HSA  in  varying concentrations  were  compatible  and  BSA  showed  no  interaction  with  the  antibody.  Spot  7, which  represents  the  rabbit‐anti  human  albumin  antibody,  exhibited  some  levels  of  complex formation although this could equally be attributed to excess of concentration and was treated as  an  anomaly.  Consequently,  questions  still  existed  regarding  the  suitability  of  the  antibody setup.  A.2.7 Further assay development  It was established that further assay development should continue with two parallel paths:   
• The  repetition  and  extension  of  immunodiffusion  analysis  to  characterise  antibody reactivity.  
• The continued modification of the assay protocols. This involved:  confirming the antigen dilutions, investigating insufficient blocking and washing as a cause for lack of blank OD and investigating the effect of restructuring the antibody complex.   A.2.7.1 Immunodiffusion analysis  Parallel  to  the  investigation of block buffer  and washing  conditions,  immunodiffusion analysis was carried out to further evaluate assay component interactions and also possible interactions 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with BSA (Fig A.9). Ouchterlony A investigated the cross‐reactions between the antibodies in the existing setup (Fig A.1) and reactivity towards BSA. Ouchterlony B investigated cross‐reactions between the capture antibody and the detection antibody in varying concentrations to eliminate reaction due to the prozone effect. Human serum albumin was included as a control.            A                                           B      Fig A9. Ouchtherlony gels showing possible  interactions between assay components as well as BSA.  The Ouchtelony gels provided little definitive evidence about potential cross‐reactions. Assay A confirmed that BSA does elicit a similar response to HSA with rabbit anti‐human albumin (spots 9‐12) suggesting a less specific paratope and a potential for concern. Assay B showed a definite reaction between goat anti‐human albumin and HSA (spot 15‐16) and suggested the possibility of  a  less  clearly  defined  reaction  between  goat  anti‐human  and  rabbit  anti‐human  antibodies (spots 1‐2, 9‐10). 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A.2.7.2 Protocol modification  A commercial ELISA (Immunology Consultants Laboratory section 2.7) was run to confirm that the  antigen  dilutions  used  in  the  development  protocols were made  accurately  and  created  a sensible curve. Results are shown in Table 36.  Table 36. Comparison between target antigen concentration and measured result.   Target antigen concentration (ng/ml)  Commercial Assay result (ng/ml) 15.7  12.1 31.3  25 62.5  59 125  120 250  >Range 500  > Range  The antigen dilutions were close to the target concentration and thus the antigenic plateau and high blank OD could not be attributed to error in dilution. A subsequent factor to evaluate was block  efficiency,  as  poor  blocking  could  lead  to  non‐specific  binding.    A  commercial  blocking agent was purchased (Stabilguard) and compared to the original 3% skim milk blocking buffer to evaluate the block efficiency. A new plate was also introduced (Costar) to evaluate the effects of block‐plate combination.    In  addition  to  block  and  plate  variables,  it  was  decided  to  re‐design  the  sandwich  antibody complex.  The  immunodiffusion  results  had  not  been  able  to  conclusively  establish  that  there were  no  antibody  cross‐reactions  taking  place.  A  new monoclonal mouse‐antihuman  albumin capture antibody was purchased to replace the polyclonal capture antibody and the system was re‐arranged.  This  was  an  attempt  to  increase  specificity  and  remove  any  possible  previous interactions  with  the  capture  antibody  and  the  other  assay  components.  The  available antibodies  enabled  two  possible  setups,  which  are  described  in  Fig  A.10.  These  were  both evaluated in case one proved to be superior. 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Fig A.10. New antibody setups for the human serum albumin sandwich ELISA  A.2.7.3 Outcome of protocol modification  Table 37 details the protocols used to assess the effect of block buffer and plate combination (6‐9) and the protocols used to assess the new antibody complexes (8‐9).   Table 37. Assay protocols 6‐9. 




















Sero‐wel   0.5‐0.0157  Stabilguard  10‐0.157  0.1  1:15.000  NO 
7 
Sero‐wel   0.5‐0.0157  3% milk  10‐0.157  0.1  1:15.000  NO 
8 
Costar   10‐0.157 new Cab  3% milk  0.5‐0.0098  0.2 Gt dab  1: 10.000  NO 
9 
Costar   1 new Cab  Stabilguard  0.5‐0.0039  0.2 Rb dab  1:12.000  NO 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blank  OD.  It  became  apparent  in  this  study  that  the  current  protocol  was  not  functioning  as intended  and  that  too  many  individual  variables  were  assessed  in  each  experimental  setup. Ultimately  it  was  decided  to  purchase  an  enzyme‐conjugated  detection  antibody  to  limit  the assay components and reduce the opportunities for cross‐reaction between antibodies.  A.2.7.4 Effect of albumin specific enzyme‐conjugated antibody  The detection antibody and the existing conjugate antibody were removed from the system and replaced with a polyclonal sheep anti‐human albumin HRP conjugated antibody. Table 38 details the subsequent assay protocols used to characterise this new setup.   Table 38.  Assay protocols 10‐15. 






















Sero‐wel   0.5‐0.0157  3%  10‐0.157  /  1:7500  YES, high 
11 
Sero‐wel   0.25  6% milk  3‐0.000625  /  1:8000. 1:16000  YES, high 
12 
Sero‐wel   0.25  3% milk  0.6‐0.00225 + tear samples  /  1:5000, 1:7500, 1:15000  YES, high 
13 
Sero‐wel  0.25  3% milk  0.6‐0.00225 + tear samples  /  1:7000  YES, high 
14 
Nunc Maxisorp  0.25  3% milk  0.6‐0.00225+ 0.3  /  1:7000  YES, high 
15 
Sero‐wel   0.25  3% milk  0.6‐0.00225+ 0.3  /  1:7000  YES, high 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A.2.8 Investigating assay precision and suitability for tear albumin analysis  Three duplicates of the standard curve, along with two control samples (500 µg/ml, 12.5 µg/ml) and  five  tear  samples were  assayed  under  different  conjugate  dilutions  in  protocol  12  (Table 38). The majority of the tear samples produced ODs below the curve due to the elevated blank OD.  Tear  albumin  concentrations  could  not  be  obtained  for  the  tear  fluid  of  those  subjects. Duplicate  precisions  on  standards  were  overall  within  the  15%  CV  limit  (determined  in  the introduction)  but  this  was  not  consistent  across  the  assay,  particularly  with  the  lower  level samples and controls. Assay protocol 13 adopted a similar layout to assay protocol 12, but with set  conjugate  dilution,  to  assess  intra‐assay  precision  and  the  importance  of  standard  curve placement.  Three  standards  curves  were  placed  on  different  sections  of  the  assay  and  the resultant ODs and curve shapes were compared. This is shown in Figure A.11.  




A.3 Discussion of ELISA assay development   Assay  protocol  15  (Table  38)  represents  the  current  protocol  and  its  limitations  as  discussed above.  These  limitations  lead  to  the  laboratory‐developed  assay  having  no  part  in  albumin analysis  for  the  research  presented  in  this  thesis.    It  was  decided  that  the  current  blocking protocol along with washing or coating protocols were potentially sub‐standard.  Pipetting error was  considered  as  an  alternative  cause  for  the precision difficulties with  the  laboratory  assay although  this  was  discarded,  as  no  transferred  problems  were  observed  when  using  the commercial  alternative.  Disregarding  the  precision  issues,  the  running  time  of  the  laboratory assay was  48  hours  compared  to  2.5  for  the  ICL  ELISA  (section  2.7.3).  This makes  the  latter significantly  more  time  efficient  as  well  as  more  sensitive  and  more  precise.  Whilst  more experiments could have been undertaken to further improve the laboratory‐constructed assay, the  ultimate  aim  was  to  limit  cost.  The  time  spent  on  assay  development  was  extensive  so offsetting costs against time constraints made the choice of a commercial assay more appealing.  
 
A.4 Conclusion  Even  though  the  laboratory‐developed  assay  did  show  promise  and  ability  to  differentiate between some levels of higher tear samples, the consistent lack of an acceptable blank OD and the precision desired  lead  to  the  conclusion  it would  to be  too  time‐consuming  to  rely on  the laboratory  assay  for  the  duration  of  the  project.  Nevertheless  it  provided  the  sought  after valuable insight into the components and their interactions in the ELISA method. 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APPENDIX B 
ADDITIONAL DATA FOR CHAPTER 6  Table 39.  Albumin concentrations in deionised water measured by the HemoCue ®Albumin 201 Analyser.    1  2  3  Mean  SD  % CV 
200  >R  >R  >R      
150  147  139  145  143  4.16  2.90 
100  101  99  97  99  2  2.02 
75  83  76  78  79  3.61  4.56 
50  52  62  52  55  5.77  10.43 
30  33  27  35  31  4.16  13.14 
20  31  20  19  23  6.66  28.54 
10  8  12  8  9  2.31  24.74 
5  5  5  10  6  2.89  43.30         Mean: 
3.95  16.21  Table  40.  Albumin  concentrations  in  deionised  water  measured  by  the  AfinionTM  AS100 Analyser.    1  2  3  Mean  SD  % CV 
200  154.4  155.0  148.7  152.7  3.48 2.28 
150  108.9  101.1  111.9  107.3  5.57 5.20 
100  70.6  76.9  67.6  71.7  4.75 6.62 
75  57.9  68.5  66.9  64.4  5.71 8.87 
50  40.9  44.4  38.0  41.1  3.21 5.53 
30  24.6  25.7  22.8  24.4  1.46 6.00 
20  16.8  17.4  15.9  16.7  0.75 4.52 
10  8.2  8.9  7.9  8.33  0.51 6.160 
5  <R  <R  <R               Mean:  3.18  5.65 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Table  41.  Albumin  concentrations  in  phosphate  buffered  saline  measured  by  the  HemoCue® Albumin 201 Analyser.    1  2  3  Mean  SD  % CV 
200  >R  >R  >R  /  /  / 
150  >R  >R  >R  /  /  / 
100  142 126 137 135 8.19 6.06 
75  111 113 112 112 1 0.89 
50  64 60 59 61 2.64 4.33 
30  36 41 35 37 3.21 8.61 
20  21 23 16 20 3.61 18.02 
10  <R  <R  6  6  /  / 
5  <R  <R  <R  /  /  /         Mean:  3.73  7.58  Table  42.  Albumin  concentrations  in  phosphate  buffered  saline  measured  by  the  AfinionTM AS100 Analyser.    1  2  3  Mean  SD  % CV 
200  157.4 >R 170.0 163.7 8.91 5.44 
150  132.6 144.0 181.9 152.8 25.81 16.89 
100  66.0 90.5 100.5 85.6 17.75 20.72 
75  51.6 75.4 68.5 65.1 12.25 18.79 
50  48.5 46.3 47.4 47.4 1.10 2.32 
30  28.2 26.1 32.1 28.8 3.04 10.57 
20  18.3 18.5 18.0 18.2 0.25 1.38 
10  <R  <R  <R  /  /  / 
5  <R  <R  <R  /  /  /         Mean:  9.87  10.87 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